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Prediction of risk of recurrence of venous thromboembolism
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thromboembolism: systematic review, prognostic model and
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Kym IE Snell,1 Susan Bayliss,1 David Moore1 and David Fitzmaurice4
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3Health Economics, School of Health and Population Sciences, University of Birmingham,
Birmingham, UK
4Primary Care Clinical Sciences, School of Health and Population Sciences,
University of Birmingham, Birmingham, UK
*Corresponding author j.ensor@keele.ac.uk
Background: Unprovoked first venous thromboembolism (VTE) is defined as VTE in the absence of a
temporary provoking factor such as surgery, immobility and other temporary factors. Recurrent VTE in
unprovoked patients is highly prevalent, but easily preventable with oral anticoagulant (OAC) therapy.
The unprovoked population is highly heterogeneous in terms of risk of recurrent VTE.
Objectives: The first aim of the project is to review existing prognostic models which stratify individuals by
their recurrence risk, therefore potentially allowing tailored treatment strategies. The second aim is to
enhance the existing research in this field, by developing and externally validating a new prognostic model
for individual risk prediction, using a pooled database containing individual patient data (IPD) from several
studies. The final aim is to assess the economic cost-effectiveness of the proposed prognostic model if it is
used as a decision rule for resuming OAC therapy, compared with current standard treatment strategies.
Methods: Standard systematic review methodology was used to identify relevant prognostic model
development, validation and cost-effectiveness studies. Bibliographic databases (including MEDLINE,
EMBASE and The Cochrane Library) were searched using terms relating to the clinical area and prognosis.
Reviewing was undertaken by two reviewers independently using pre-defined criteria. Included full-text
articles were data extracted and quality assessed. Critical appraisal of included full texts was undertaken
and comparisons made of model performance. A prognostic model was developed using IPD from the
pooled database of seven trials. A novel internal–external cross-validation (IECV) approach was used to
develop and validate a prognostic model, with external validation undertaken in each of the trials
iteratively. Given good performance in the IECV approach, a final model was developed using all trials
data. A Markov patient-level simulation was used to consider the economic cost-effectiveness of using a
decision rule (based on the prognostic model) to decide on resumption of OAC therapy (or not).
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Results: Three full-text articles were identified by the systematic review. Critical appraisal identified
methodological and applicability issues; in particular, all three existing models did not have external
validation. To address this, new prognostic models were sought with external validation. Two potential
models were considered: one for use at cessation of therapy (pre D-dimer), and one for use after cessation
of therapy (post D-dimer). Model performance measured in the external validation trials showed strong
calibration performance for both models. The post D-dimer model performed substantially better in terms
of discrimination (c= 0.69), better separating high- and low-risk patients. The economic evaluation
identified that a decision rule based on the final post D-dimer model may be cost-effective for patients
with predicted risk of recurrence of over 8% annually; this suggests continued therapy for patients with
predicted risks ≥ 8% and cessation of therapy otherwise.
Conclusions: The post D-dimer model performed strongly and could be useful to predict individuals’ risk
of recurrence at any time up to 2–3 years, thereby aiding patient counselling and treatment decisions.
A decision rule using this model may be cost-effective for informing clinical judgement and patient opinion
in treatment decisions. Further research may investigate new predictors to enhance model performance
and aim to further externally validate to confirm performance in new, non-trial populations. Finally, it is
essential that further research is conducted to develop a model predicting bleeding risk on therapy, to
manage the balance between the risks of recurrence and bleeding.
Study registration: This study is registered as PROSPERO CRD42013003494.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Calibration A measure of agreement between the observed probability of recurrence-free survival and the
expected (predicted) probability of recurrence-free survival at a specified time point.
c-statistic A measure of discrimination, where a value of one represents perfect discrimination and a
value of 0.5 represents poor discrimination.
Discrimination A measure of a model’s ability to separate between two patients of differing risk.
For example, for any two patients, one at high risk of outcome and one at low risk, the discrimination
is the probability that the high-risk patient will be assigned a higher probability of outcome than the
low-risk patient.
Expected/observed A measure of calibration, where expected (E) represents the expected probability of
recurrence-free survival, and observed (O) represents the observed probability of survival at a specified
time point.
Incremental cost-effectiveness ratio A measure of cost-effectiveness defined as the change in costs
divided by the incremental benefits of an intervention.
Predictor Within this report ‘predictor’ is used to refer to any clinical, laboratory or demographic
characteristic. The term ‘predictor’ encompasses other similar terms such as prognostic factor, covariate,
variable, dependent variable, etc.
Prognostic model Other terms also related to prognostic model may include prediction models, clinical
decision rules, or clinical prediction guides. The term ‘prognostic model’ is used within this report to
encompass all of these terms, therefore all are considered to refer to the same thing. Within this report a
prognostic model is defined as a combination of at least two predictors within a statistical model, used to
predict an individual’s risk of outcome.
Quality-adjusted life-year A measure of disease burden, including both the quality and the quantity of
life lived. It is used in assessing the value for money/cost-effectiveness of a medical intervention.
S(t) – Sˆ(t) A measure of calibration. Where S(t) represents the observed probability of recurrence-free
survival and Sˆ(t) represents the expected (predicted) probability of recurrence.
Unprovoked/idiopathic Defined within this report as a first venous thromboembolism in a patient with
no history in the previous 3 months of major surgery, significant immobility, pregnancy, use of combined
oral contraceptive pill or hormone replacement therapy, or active cancer. These factors can all be
characterised as transient or temporary, meaning that where one of these factors was associated with
initial VTE, the risk of a recurrent VTE after removing the transient risk factor is low. Patients with a
transient risk factor are defined as provoked. Conversely to unprovoked, the term idiopathic is often used
to refer to a first venous thromboembolism for which there is no known cause. Under this definition it is
often considered that thrombophilia is a provoked factor, and so these patients are not defined as
idiopathic. However, under the definition of unprovoked first venous thromboembolism, thrombophilia
would be considered unprovoked, as it is not a transient risk factor, rather a constant, hereditary risk factor
which cannot be removed. As such, those with hereditary thrombophilia are considered as unprovoked
within this report.
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ACCP American College of Chest
Physicians
AIC Akaike information criterion
AUC area under the curve
BCSH British Committee for Standards
in Haematology
BIC Bayesian information criterion
BMI body mass index
CI confidence interval
DASH D-dimer, Age, Sex, Hormone
therapy




HER DOO 2 Hyperpigmentation, Edema,
Redness/D-dimer, Obese (body
mass index > 30 km/m2), Old
(age > 65 years)/2 or more factors
should indicate for patients to
continue therapy
HR hazard ratio
HRT hormone replacement therapy
ICER incremental cost-effectiveness ratio
IECV internal–external cross-validation
INR international normalised ratio
IPD individual patient data
MAR missing at random
MC Monte Carlo
MEGA Multiple Environmental and
Genetic Assessment of risk factors
for venous thrombosis study
MFP multivariable fractional polynomial
NICE National Institute for Health and
Care Excellence




PROBAST Prediction study Risk Of Bias
Assessment Tool
PSA probabilistic sensitivity analysis
PTS post-thrombotic syndrome
QALY quality-adjusted life-year
RCT randomised controlled trial
RIETE Registro Informatizado de
Enfermedad TromboEmbólica
RVTEC Recurrent VTE Collaborative
SD standard deviation
VTE venous thromboembolism
DOI: 10.3310/hta20120 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 12
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Ensor et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR





Venous thromboembolism (VTE) refers to a blood clot within either the leg or the lung. Typical treatmentfor a VTE involves blood thinners for at least 3 months. Some patients may require longer treatment if
they are considered to be at high risk of a second clot.
This project aimed to identify, develop and evaluate methods for deciding whether or not a patient with
VTE is at high risk of a second clot, and should therefore continue with treatment for longer periods
of time.
In order to identify a patient’s risk of a second clot, several patient characteristics such as sex and age were
combined in a clinical prediction tool. For example, the tool predicts that a 60-year-old male with a first
clot in the lung has a high risk of a second clot, and therefore may be considered for extended treatment
to prevent a second clot. The tool showed good reliability when examined in new data and therefore
improves on existing research.
Additionally, we evaluated the value for money of using the prediction tool in clinical care to decide how
long to treat for.
The evidence presented here suggests the prediction tool may help to make decisions about how long to
treat individual patients for, in order to reduce the chance of a second clot, improve quality of life and
reduce costs involved in treatment and patient care.
Further research is needed to develop a similar tool for predicting the effect of continued treatment on a
patient’s risk of bleeding.
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Venous thromboembolism (VTE) is a chronic disease which may present in two ways: either a clot in the
leg (deep-vein thrombosis) or a clot in the lung (pulmonary embolism). An initial VTE may be termed as
either provoked, where a transient risk factor is present (such as prolonged immobility), or unprovoked, in
the absence of any known risk factor. Due to the temporary nature of provoking factors, those with a first
unprovoked VTE are at much higher risk of recurrent VTE (approaching 30% at 5 years after cessation of
therapy) as there is no known cause.
Initial treatment for VTE comprises heparin followed by oral anticoagulation, usually for at least 3 months.
However, ideal treatment duration is unclear, particularly for the unprovoked VTE population, as
individuals’ risk of recurrent VTE is highly heterogeneous. Although anticoagulation effectively prevents
recurrent VTE, the patient is at increased risk of bleeding while on therapy. There is therefore a decision
problem in balancing the risks between recurrence (off therapy), and bleeding (on therapy). It would
therefore be beneficial if therapy decisions could be tailored to patients’ risk so that, for example, a patient
at higher risk of recurrence off therapy, than their risk of bleeding on therapy, could be recommended to
continue anticoagulant therapy.
Prognostic models can be used to predict individuals’ risk of recurrence based on clinical, laboratory and
demographic patient characteristics. The identification of potentially important predictors which may be
associated with recurrence risk is important in the development of such a prognostic model.
Aims
This project primarily aimed to develop and validate a prognostic model for the prediction of individual
recurrence risk following cessation of therapy for a first unprovoked VTE. Individual patient data (IPD) were
utilised from one large prospective database in order to develop a new prognostic model based on
multiple predictors, and to externally validate the developed model. The final developed prognostic model
allows individualised recurrence risk prediction, which may help to inform patient care as part of an
evidence based approach.
To inform the development of a new prognostic model, the project also aimed to undertake a systematic
review of all the evidence on existing prognostic models for VTE recurrence and adverse outcome
following cessation of therapy for a first unprovoked VTE. The findings could inform clinical practice and
patient care by summarising the current prognostic models and their predictive performance.
Finally, to assess the potential value of the developed model in practice, an economic evaluation was
undertaken to assess the cost-effectiveness of a decision rule based on the developed model compared
with current practice. Various risk thresholds were assessed, such that if a patient’s predicted risk was
above the threshold, the patient would be recommended to continue therapy indefinitely, and if predicted
risk was below the threshold, therapy could be discontinued. The conclusions of the cost-effectiveness
analysis identified an optimum risk threshold at which such a decision rule is cost-effective in
various situations.
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Systematic review of prognostic models: methods
Bibliographic databases (including MEDLINE, EMBASE, The Cochrane Library and clinical trials registers)
were searched using index terms relating to the clinical area and prognosis. Title and abstract reviewing
was undertaken by two reviewers independently using pre-defined inclusion/exclusion criteria. Two
reviewers further assessed eligible full texts using pre-defined criteria. Included full-text articles were data
extracted independently by two reviewers, using piloted data extraction forms. Quality assessment and
critical appraisal of included full texts was undertaken using an early version of the Prediction study Risk Of
Bias Assessment Tool for risk of bias and applicability in prognostic model studies.
Systematic review of prognostic models: results
The systematic review of existing prognostic models for recurrent VTE in the unprovoked population
identified three full-text articles, along with seven abstracts related to these three full-text articles and a
further two unique abstracts. The three included studies developed three unique prognostic models: HER
DOO 2 [Hyperpigmentation, Edema, Redness/D-dimer, Obese (body mass index > 30 km/m2), Old
(age > 65 years)/2 or more factors should indicate for patients to continue therapy], Vienna and D-dimer,
Age, Sex, Hormone therapy models. Quality assessment and critical appraisal highlighted several
methodological issues with the development of the models (especially for the HER DOO 2 model), and the
applicability of the models to the proposed population. For example, varying definitions of unprovoked VTE
were used in the data for model development, making the performance of the model unreliable within a
new population in which some patients may be classified as unprovoked using a different definition to the
development study.
All three models were classed as at least moderate risk of bias, as none had received external validation.
This motivated the current research to ensure any new model developed was externally validated. The
review also identified potentially important predictors included consistently in the existing models, which
could be investigated within the new prognostic model developed.
Prognostic model development: methods
Individual patient data for three databases were acquired from project collaborators, and the Recurrent
VTE Collaborative database (containing seven trial populations) was identified as most appropriate for
model development, with the remaining databases planned for external validation of the model if possible.
Exploratory and univariable analyses were performed to prepare the data and identify potential predictors
of interest, as well as to investigate the effect of predictors of importance indicated within the review.
The set of candidate predictors included age, sex, treatment duration, site of index event, D-dimer and
lag time. Sample size exceeded 10 events per candidate predictor. Given the available predictors of
importance, two potential models were identified based on the point at which the models could be
applied. First, a model which could be used at the cessation of therapy to predict recurrence risk (the pre
D-dimer model), and second a model which could only be used after a set ‘lag time’ (the post D-dimer
model). The second model could only be used at some point after cessation of therapy because it
included D-dimer as a predictor, which is measured at some ‘lag time’ after stopping therapy because
anticoagulation therapy affects its value.
A flexible parametric survival model was used to model the recurrence outcome and to allow investigation
of the baseline hazard within trials. A multivariable fractional polynomial algorithm was used for predictor
selection, to consider non-linear associations between continuous predictors and recurrence. Differences in
the baseline hazard due to the trial populations were accounted for using a random-effects intercept
within the model, producing a weighted mean baseline hazard and an estimate of between-study
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variability around this mean. Sensitivity analyses investigated the inclusion of interaction effects of interest,
time-dependent effects, and the impact of missing data on the analysis using multiple imputation. Model
assumptions were checked.
A novel internal–external cross-validation (IECV) approach was used to utilise the seven distinct trial
populations. The IECV approach iteratively selects N-1 studies from the N total studies available, and the
prognostic model is developed within this subset of studies, leaving the remaining study for external
validation of the model. A total of N different models are derived (one for each set of included studies,
though one larger study was retained in all cycles due to sample size issues) and each is validated in the
omitted study. Model performance can then be summarised across the omitted studies using random-effects
meta-analysis. Model performance was measured in terms of both calibration and discrimination.
Prognostic model development: results
Predictor selection identified sex and site of index event as important within the pre D-dimer model, while
patient age, D-dimer and lag time were additionally included within the post D-dimer model. Model
performance through the IECV approach showed that the post D-dimer model had superior performance
in terms of discrimination, with the average c-statistic 0.69 in the external validation of this model
compared with 0.56 in the external validation of the pre D-dimer model. This suggests that D-dimer and its
associated lag time are important and strong predictors, which add significantly to the discriminatory ability
of the model.
For both the post D-dimer model and the pre D-dimer models, on average the calibration across all
external validation trials was consistently strong with close agreement between observed and predicted
risk of recurrence up to at least 2 years. Interrogation of the model fit in regard to multiple imputation of
missing data, interaction terms, non-linear trends, outliers and other advanced aspects did not suggest the
final models produced should be modified.
Overall the pre D-dimer model was shown to be inadequate in terms of discrimination, which may be
expected given that only sex and site of index event were shown to be statistically significant. Conversely
the post D-dimer model showed good performance across the validations trials, for both discrimination
and calibration, and may be useful in clinical practice to predict individuals’ risk and thereby inform
treatment decisions, alongside clinical judgement and patient preference.
Systematic review of cost-effectiveness: methods and results
Similar methods as for the systematic review of existing prognostic models were employed in the
systematic review of cost-effectiveness studies. Economic models, trial-based economic evaluations and
costing studies were eligible for inclusion. Relevant outcomes were cost-effectiveness, cost estimates,
resource utilisation estimates and quality of life/utility estimates. Included studies were assessed using
relevant economic checklists.
The review did not identify any studies for inclusion, highlighting the current lack of evidence on the
cost-effectiveness of using a prognostic model-based decision rule in patients with a first unprovoked VTE.
The conclusions of the review therefore indicated that the development of an economic model and
cost-effectiveness analysis needed to be undertaken.
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A Markov patient-level simulation was used to consider the economic cost-effectiveness of using a decision
rule (based on the prognostic model) to decide on resumption of oral anticoagulant (OAC) therapy (or not).
Individual patient characteristics were drawn from distributions based on IPD used in the development of
the prognostic model; clinical parameters within the model were obtained from two of the collaborators
databases, with remaining parameters informed by the literature, or clinical consensus. Incremental
cost-effectiveness ratios were calculated based on an average of the costs and quality-adjusted life-years
(QALYs) gained from 50,000 simulated patients.
Economic modelling: results
Results from the economic modelling suggested that a base-case threshold risk of 8% or higher for
therapy with warfarin would be cost-effective if decision-makers were willing to pay up to £20,000 per
QALY gained, when compared with treat no-one. This indicates that it may be cost-effective to treat all
patients with predicted annual risk of recurrence > 8%, and to cease therapy for patients with lower than
8% predicted risk, as opposed to treating no patients.
The model was sensitive to changes in utility and mortality estimates that either solely favoured the no
therapy comparator or the decision rule strategy. In order to better assess economic value of such a
decision rule further information is required in relation to the long-term bleeding risks on therapy in the
unprovoked patient population.
Conclusions
This project has developed a prognostic model which can be used in clinical practice to aid decision-making
with regards to the duration of OAC therapy for patients suffering a first unprovoked VTE. The prognostic
model was developed using robust methodology and a novel IECV approach allowing external validation in
multiple trials. A systematic review of existing prognostic models in this area identified methodological
issues to be addressed when developing any new model. In particular, the three existing models had not
been externally validated to date, which is an essential step to confirm the performance of the model in a
new population. The developed post D-dimer model showed good calibration and discrimination on
average across all external validation data sets within the IECV approach. An economic evaluation was
undertaken suggesting that a decision rule based on the post D-dimer model would be cost-effective for
patients with predicted risk of recurrence of over 8% annually, suggesting continued therapy for risks above
8% and cessation of therapy for risks below 8%. Although the health economic model relies on many
assumptions due to lack of routinely collected data, it provides a platform for evaluating further prognostic
models once these data are available, particularly in regard to bleeding risks on therapy. This will be useful
also for evaluating cost-effectiveness of treatment strategies based on the new generation of OACs. Further
work is required to confirm the performance of the model within routine clinical practice (further external
validation in non-trials data), and in improving our ability to predict severe bleeding events for patients
taking long-term OACs.
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Future research recommendations
Further research could build on the pre D-dimer model by seeking additional predictors that may improve
discrimination further. Another option is to adapt the model to be used at the exact time of cessation of
therapy. This would be beneficial in order to predict patients’ recurrence risk at the time of stopping
therapy, and thereby negate the need for a lag time period in which the patient is not on therapy (and so
is at unnecessarily higher risk of recurrence in this period). Such a model should include predictors for sex
and site of index event as these were found to have important associations with recurrence risk in the pre
D-dimer model. Future research should aim to incorporate the effect of D-dimer either at the time of
cessation of therapy, or on therapy, as D-dimer was shown to be a strong predictor within the post
D-dimer model. There is ongoing research investigating the predictive ability of D-dimer levels measured
on therapy.
It is also important that further external validation of the post D-dimer model be performed, especially
within non-trial populations. Trial populations available within the development database may have been a
select group of individuals, and therefore the post D-dimer model requires validation in other populations
(e.g. from cohort studies or large databases). Such data sets may not currently be available that contain
D-dimer values, and so further observational studies are needed that enrol new patients, measure their
predictors following cessation of therapy (including D-dimer and lag time), and record recurrent VTE and
adverse outcomes.
Finally there is an essential need for further research to develop and validate a prognostic model for
bleeding events on therapy. The current research developed a model which can predict individuals’
recurrence risk at some time after cessation of therapy, but this does not account for the subsequent risk
of bleeding for patients put on therapy based on their predicted risk. The economic evaluation
incorporates the risk of bleeding on therapy, but this could not be individualised as no bleeding event
model appropriate to the population exists. There is a need for patient data on both recurrence and
subsequent bleeding events which may allow prognostic models to be built and/or validated for both these
outcomes simultaneously.
Study registration
This study is registered as PROSPERO CRD42013003494.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research Health.
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Venous thromboembolism aetiology and outcomes
The term venous thrombosis describes the development of a clot, usually within the veins of the legs
(deep-vein thrombosis; DVT) and lungs (pulmonary embolism; PE). It is a chronic disease with DVT and PE
considered as different presentations of the same disease. Patients with DVT may present with a clot
confined either to the calf (distal DVT) or above the knee (proximal DVT), with proximal DVT often
conveying a greater risk of recurrent venous thromboembolism (VTE). Upper limb thrombosis is a rare
event usually associated with either anatomical anomalies of underlying thrombophilia. This report focuses
on DVT and PE.
There are several recognised pre-disposing risk factors for an initial VTE, including hormone intake, surgery,
trauma, pregnancy and prolonged immobility. Where these factors have contributed to the development
of a first VTE, this is termed ‘provoked’. These factors can be considered as transient or removable risk
factors, because although they increase the risk of an initial VTE, they are temporary and when the
provoking factor is removed the patient is at a low risk of recurrent VTE (e.g. post surgery). In contrast, an
initial VTE is termed ‘unprovoked’ if it occurs in the absence of a known provoking factor. This distinction
is important because recurrence of VTE (following appropriate therapy with anticoagulation) is largely
driven by whether the initial episode was provoked rather than unprovoked. Due to the temporary nature
of provoking factors, those with a first unprovoked VTE are at much higher risk of recurrent VTE
(approaching 30% at 5 years after cessation of therapy) as there is no known cause.
For the purposes of this report an initial VTE will be defined as unprovoked where there is no history in the
previous 3 months of any of the following risk factors:
l major surgery
l lower limb trauma




Therapy for venous thromboembolism
The aim of therapy for VTE is twofold, initially to prevent extension of the acute thrombosis and secondarily
to prevent both recurrence and long term sequelae such as post-thrombotic syndrome (PTS) and pulmonary
hypertension. Current treatment comprise initial management with heparin, usually low-molecular weight
heparin for a minimum of 5 days, overlapping with oral anticoagulant (OAC) therapy (usually warfarin in the
UK) until the international normalised ratio (INR) is above two. It is usual to treat an initial VTE for a
minimum of 3 months; however, the optimum duration of therapy beyond this is unclear, particularly in the
unprovoked population where individuals risk is heterogeneous. Alternative treatments to heparin and
warfarin are now available with rivaroxaban (Xarelto®, Janssen Pharmaceuticals, Inc.) now licensed for
treatment of VTE in the UK, with other new agents in the pipeline. The decision problem with regard to
length of therapy still remains with these newer treatments.
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Prevention of recurrent VTE poses a difficult clinical decision problem; a balance must be struck between
the risks of recurrent thrombosis if anticoagulant treatment is stopped versus the risks of bleeding
associated with continued anticoagulation therapy.
This has been highlighted in recommendations from the 9th American College of Chest Physicians (ACCP)
antithrombotic guidelines,1 which particularly highlighted this issue of balancing the risks of recurrence and
bleeding in unprovoked population. The guidelines suggested that those suffering an initial unprovoked
DVT should be treated with different lengths of anticoagulation therapy dependent on their bleeding risk.1
Those at low to moderate risk of bleeding are suggested to have extended treatment over 3 months of
therapy, whereas those at high risk are recommended to have a further 3 months of therapy beyond this.1
Previously the emphasis from a clinical perspective has been to identify those patients at sufficiently high
risk of recurrence to justify continuing therapy. More recently the emphasis has shifted to identifying those
patients at sufficiently low risk of recurrence to justify cessation of therapy. This reflects an appreciation of
the importance of risk of recurrence, with recurrent events being fatal in approximately 5–9% of patients.2
The current UK guidelines from the British Committee for Standards in Haematology (BCSH)3 state that all
patients with a proximal DVT or PE should be treated for at least 3 months, in line with ACCP guidance.
In terms of extending treatment beyond 3 months it is stated that therapy should be continued if the risk
from recurrence on stopping treatment is greater than the risk from anticoagulant-related bleeding.
However, these opposing risks are not easily predicted in an individual. In a patient with an average risk of
warfarin-related bleeding the annual risk of recurrent VTE that would favour continued anticoagulant
therapy has been estimated to be between 3% and 9%.3
In terms of identifying those patients who may require longer duration of therapy, the BCSH guidelines
identify that patients with unprovoked venous thrombosis have an annual risk of recurrence of more than
9% in the first year after stopping treatment.3 As this risk exceeds the risk of warfarin-related bleeding, the
BCSH recommend that patients with a first unprovoked or recurrent episode of proximal DVT or PE should
be considered for long-term anticoagulation.3 The issue is not straightforward, however, as although the
cohort risk for patients with a history of unprovoked venous thrombosis may be > 9% as suggested by the
BCSH, individual patients risk of recurrence is highly heterogeneous.
The BCSH guidelines illustrate this through identification of a lower annual risk in patients with a normal
D-dimer result after completion of initial warfarin therapy compared with those with an elevated D-dimer
(3.5% vs. 9%).3 D-dimer is a breakdown product of fibrin, the principal constituent of a venous clot, and
has been mainly used within the context of diagnosis of VTE. Within the diagnostic context a normal
D-dimer result, defined usually by the laboratory, effectively rules out an acute VTE when used in
combination with a clinical risk score.4 Risk of recurrence has also been related to the presence of PTS and
male sex.5–7
A further consideration is the consequence of recurrent VTE. Patients with an initial unprovoked PE are
three to four times more likely to suffer recurrence as PE rather than DVT. This may be significant given
that the risk of fatal PE is two to four times more likely in patients with symptomatic PE as compared with
patients with symptomatic DVT alone.3
It remains uncertain if recurrence is more likely after a second or subsequent episode of unprovoked VTE
than after a first event. However, given that risk of recurrence is sufficiently high after a first event to
justify consideration of continued treatment, unprovoked recurrence is at least confirmation that the
recurrence risk is high in that individual patient and recurrent events are fatal in approximately 5–9%
of patients.2
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Prognostic factors
As most recurrences are easily preventable using anticoagulant therapy, it is of great importance that
patient characteristics associated with risk of recurrence are identified, so that patient therapy can be
stratified. Stratification of patients with unprovoked VTE according to their recurrence risk might be
achieved on the basis of clinical predictors such as sex, comorbidities or weight, or by measuring laboratory
markers of thrombophilia such as factor V Leiden, the prothrombin 20210A mutation, natural coagulation
inhibitor deficiencies, elevated coagulation factors and antiphospholipid antibodies.2,6,8,9 More recently
efforts have been made to utilise global coagulation markers, including D-dimer, as prognostic tools.2,9
Prognostic factors provide a wealth of potential uses.10 For example, they identify groups of patients at
highest risk of recurrence and thus inform prevention therapy, patient counselling and policies: they allow
clinicians to monitor potential changes in treatment response and outcome risk; they may reveal the causal
pathway between onset and recurrence of VTE; they are potential adjustment and confounding factors in
randomised trial and observational analyses; they inform sample size and randomisation strategies in future
trials; and they can be combined within a prognostic model to predict outcome risk for individuals.10
Prognostic models
Prognostic models, prediction models, clinical decision rules, or clinical prediction guides are some of the
terms used to describe statistical models which allow individual prediction of an outcome of interest.
Prognostic models are useful tools in the area of VTE recurrence because the population is highly
heterogeneous and therefore it is useful to have a mechanism to predict individuals risk rather than
arbitrarily categorise patients when deciding on treatment strategies.2,9 A prognostic model combines
multiple predictors to predict the risk of a patient with particular characteristics having an event within a
specified time. Individual risk predictions can help to inform clinical and patient decision-making with
regard to treatment strategies, in this scenario whether or not to extend treatment with OACs to prevent
recurrent VTE.
Aims of the project
The three main aims of the project are broadly outlined below, with specific project aims detailed further
in Chapter 2.
Systematic review of prognostic models The first aim of the project is to systematically review all the
evidence on existing prognostic models for VTE recurrence and adverse outcome following cessation of
therapy for a first unprovoked VTE. The findings should inform clinical practice and patient care by
summarising the current prognostic models and their predictive performance. The conclusions of the
review will also help to inform the development of a new model within the context of existing research.
Development and validation of prognostic model The second and main aim of the project is to develop a
prognostic model for the prediction of individual recurrence risk following cessation of therapy for a
first unprovoked VTE. Individual patient data (IPD) will be utilised from one large prospective database in
order to develop a new prognostic model based on multiple predictors and to externally validate the
developed model. The results of this aim will provide a final prognostic model which allows individualised
recurrence risk prediction, which could be used to inform patient care as part of an evidence-based approach.
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Economic evaluation The third aim of the project is to undertake a cost-effectiveness analysis of a decision
rule based on the developed prognostic model. A Markov patient-level simulation will be used to compare
standard treatment strategy to a treatment strategy based on the proposed decision rule. Various risk
thresholds will be assessed, where if patients predicted risk falls above the threshold the patient would be
recommended to continue therapy, and where patients risk falls below the threshold, therapy may be
discontinued. The conclusions of the cost-effectiveness analysis will identify an optimum risk threshold at
which such a decision rule is cost-effective.
The primary database for use in developing the prognostic model is the Recurrent VTE Collaborative
(RVTEC) database which contains seven trials investigating an association between D-dimer, measured
after anticoagulation was stopped, and VTE recurrence.11 It includes a total of 1634 patients with a first
VTE (given the working definition of unprovoked VTE); of these, there was no missing follow-up
information post treatment and 230 had a recurrence post treatment. The median follow-up time post
treatment is 22 months.
The two additional databases for external validation of the developed model include the Registro
Informatizado de Enfermedad TromboEmbólica (RIETE) and Multiple Environmental and Genetic Assessment
of risk factors for venous thrombosis study (MEGA) databases. The RIETE database (www.riete.org) is
primarily a Spanish registry which has recruited 40,000 consecutive patients with confirmed VTE, 30,000
of which are a first episode. The database contains 6291 patients with a median of 6 months’ follow-up
data post treatment. The total number of recurrent episodes of VTE within this population is 742.
The MEGA database consists of the cases from a case–control study including 5961 patients with a first
VTE consecutively enrolled from two anticoagulation clinics in the Netherlands which was compiled
between 1999 and 2004. Within the database there are 1218 patients with a first episode of unprovoked
VTE with 278 patients sustaining a recurrence: the median follow-up post treatment is 67 months.
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Chapter 2 Research aims
As discussed above the main aim of the project is to develop and validate a prognostic model forpredicting VTE recurrence post cessation of therapy for a first unprovoked VTE. A systematic review of
existing prognostic models in the area will help to inform the development of the new model within the
context of existing research. In addition, an economic evaluation will identify an optimal decision rule
based on the prognostic model, giving an indication of the potential performance of such a rule within
clinical practice. Detailed project aims are listed below.
1. To undertake a systematic review to identify and summarise studies of any design examining prognostic
models (and clinical decision rules based on such models) that utilise multiple prognostic factors in
combination to predict the risk of VTE recurrence and/or adverse outcome in patients that have ceased
therapy for a first unprovoked VTE. The patients examined must, before cessation of therapy, have
received at least 3 months’ treatment with an OAC therapy.
2. To undertake univariate (unadjusted) analyses within each of the three IPD databases to identify
prognostic factors associated with VTE recurrence.
3. To undertake multivariate (adjusted) analyses within the three databases to identify those factors that
have independent prognostic value for the risk of VTE recurrence (i.e. to examine if the prognostic
ability of factors identified in part 2 remains even when adjusting for other variables).
4. To use the seven trials within the RVTEC database (including 1863 patients and 290 recurrences) to
develop and validate (using internal–external cross-validation; IECV) a prognostic model that predicts
individual risk of VTE recurrence after cessation of therapy, based on the most important prognostic
factors identified in parts 1, 2 and 3. The most parsimonious model (with fewest prognostic factors
included), which results in high predictive accuracy will be sought.
5. To use the prognostic model from part 4 and health economic modelling to develop and evaluate a
clinical decision rule for stopping anticoagulation therapy for patients with unprovoked VTE being
considered for cessation of routine anticoagulation therapy.
6. To externally validate the prognostic model from part 4 and the decision rule from part 5 in different
study populations than those used to generate the model: first, the RIETE database (6291 suitable
patients and 742 recurrences post treatment); then second, the MEGA database (containing
1218 patients with follow-up information post treatment). Then, if necessary, to refine the prognostic
model and decision rule as appropriate.
7. To compare, if possible, the performance of existing published prognostic models (and clinical decision
rules) found through the systematic review in part 1 with the new rule.
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Chapter 3 Systematic review of existing
prognostic models for the recurrence of venous
thromboembolism following treatment for a first
unprovoked venous thromboembolism
Introduction
The aim of this chapter was to undertake a systematic review of studies developing or validating a
prognostic model for individual recurrence risk prediction following cessation of therapy for a first
unprovoked VTE. The review identified current prognostic models and critically appraised the development
and validation of these models. This systematic review highlights the current work in this area and
informed the development of a new prognostic model (see Chapter 4) within the context of the
existing models.
It is common in areas where prognostic models are useful, for several models to be developed, due to the
myriad ways of developing a model and differences between the underlying populations used to develop
these models. As such, it can be difficult for practitioners to identify which model is the most appropriate
to their problem and to understand the shortcomings of the model.12 A definitive review and critique of
the existing models could help clinicians and other practitioners to better understand the strengths and
weaknesses of each model, allowing informed decisions to be made on which (if any) models to use
in practice.
The systematic review could also help to identify predictors for which evidence towards their prognostic
effect was strong or weak, highlighting predictors for consideration within the model development
(see Chapter 4). Further issues found within the development of existing models could also be considered
within the development of a prognostic model for this project (e.g. related to model development
methodology). Finally, as detailed in the research aims (see Chapter 2), the performance of existing models
found in the review could be compared with the newly developed prognostic model (see Chapter 4),
where the included predictors are similar.
A protocol for this systematic review was submitted to the National Institute for Health Research, outlining
the methods which follow, published in BioMed Central Systematic Reviews journal13 and was registered
on PROSPERO (CRD42013003494).
Methods
Aims of the review
The primary aim for the review was to identify studies that had developed or validated a prognostic model
utilising multiple (at least two) predictors to predict the risk of recurrent VTE or adverse outcome (mortality
or bleeding) following cessation of therapy for a first unprovoked VTE. Then to critique and summarise the
development and validation (internal and external performance) of the identified prognostic models, with a
view to identifying issues which may be considered in the development of a new prognostic model (see
Chapter 4). For all models a summary of their context was described qualitatively including the predictors
modelled, the development population and the setting of the model.
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The following bibliographic databases were searched: The Cochrane Library (Wiley) (including the Cochrane
Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Health Technology Assessment
databases and the Cochrane Central Register of Controlled Trials), MEDLINE (Ovid) 1950–2014, MEDLINE
In-Process & Other Non-Indexed Citations (Ovid) to date and EMBASE (Ovid) 1980–2014. Searches used
index terms and text words that encompassed the patient group supplemented by terms relating to
recurrence or adverse outcome and prognostic factors (see sample MEDLINE search in Appendix 1).
Publicly available trials registers were also searched, such as ClinicalTrials.gov, UK Clinical Research
Network Study Portfolio Database, World Health Organization International Clinical Trials Registry Platform
and the metaRegister of Current Controlled Trials. Reference lists of all included papers were checked and
subject experts were contacted. No restrictions on publication language were applied.
In addition, abstracts from the following national and international conferences from 2005 onwards were
hand-searched in order to capture studies that were not yet fully published:
l haematology conferences: International Society of Thrombosis and Haemostasis, American Society of
Hematology, European Hematology Association, British Society of Haematology
l cardiology conferences: British Cardiac Society, American College of Cardiology, European Society of




Studies of any design [e.g. cohorts, randomised controlled trials (RCTs)] or systematic reviews that
developed, compared or validated a prognostic model (or clinical prediction rule based on a model)
utilising multiple (at least two) predictors to predict the risk of recurrent VTE or adverse outcome (mortality
or bleeding) following cessation of therapy for a first unprovoked VTE.
Patient group
Patients aged ≥ 18 years with a first unprovoked VTE where the patient has received at least 3 months
treatment with an OAC therapy. Studies with mixed populations (including those outside the remit), were
included provided that appropriate data for the defined group of patients were extractable.
Setting
Studies in any setting were included.
Potential prognostic models
Studies must have reported a prognostic model utilising multiple prognostic factors to predict the risk of
recurrent VTE or adverse outcome following cessation of therapy for a first unprovoked VTE. A prognostic
model was defined as a combination of at least two predictors within a statistical model, used to predict
an individual’s risk of outcome (e.g. VTE recurrence).
Study selection
Study selection followed a two-step process. Titles (and abstracts where available) were initially screened
by two reviewers independently, using predefined screening criteria (see Appendix 2). These were broadly
based on whether or not studies (1) included patients with a first unprovoked VTE, who received a
minimum of 3 months OAC therapy, and (2) developed or examined prognostic models in relation to
individual prediction of VTE recurrence or other clinical outcomes. Full texts of any potentially relevant
articles were then obtained and two reviewers independently applied the full inclusion criteria (see
Appendix 2). Any discrepancies between reviewers were resolved by discussion or by referral to a third
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reviewer. Portions of non-English-language studies were translated where necessary to facilitate study
selection and subsequent data extraction. The study selection process was documented using the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.14 Any relevant
systematic reviews identified were screened for further primary studies. Reference management software
was used to record reviewer decisions, including reasons for exclusion.
Data extraction
Data extraction was conducted independently by two reviewers using an in-depth piloted data extraction
form. Disagreements were resolved through discussion or referral to a third reviewer.
Data extraction included the following elements:
l study characteristics (e.g. sample size, country, year)
l study design characteristics (e.g. RCT, prospective, length of follow-up)
l patient characteristics (e.g. summaries of age, sex, family history, treatment details in the sample)
l candidate prognostic factors considered (e.g. any thresholds used for continuous predictors, methods
of measurement, timing of measurement post cessation of therapy)
l outcome measures (e.g. recurrence of VTE, mortality, bleeding)
l statistical methods employed and how prognostic factors included in the analysis were handled
(e.g. continuous, dichotomised)
l prognostic models {e.g. the final model (its specification and included factors), how it was developed
and an individual risk probability was produced, and any internal and external validation performance
statistics for discrimination [such as the c-statistic (area under the curve; AUC)] and for calibration
[such as the E/O ratio (expected/observed events)], together with their confidence intervals (CIs)}.
Assessment of study quality
The quality (risk of bias) of any studies developing or evaluating a prognostic model was assessed by
piloting Prediction study Risk Of Bias Assessment Tool (PROBAST), a tool for assessing risk of bias and
applicability of prognostic model studies that was nearing completion and ready for piloting when this
review was undertaken.15
Particular elements were considered in the following domains:
l Patient selection (such as whether or not it was a prospective design, what study design was used,
if appropriate inclusions and exclusions were used, and whether or not patients had similar disease
presentation, or if this was accounted for in analyses).
l Outcomes (such as whether or not the outcome definition was pre specified, predictors were excluded
from the definition, the same definition and assessment was used for all patients and whether or not
the outcome was determined blind to predictor information).
l Predictors (such as whether or not the same predictor definitions were used for all patients, predictors
were measured blinded to outcome data, all predictor information was available at the time the model
was intended for use and whether or not non-linear associations for continuous predictors were
considered and categorisation was not data driven).
l Sample size (such as whether or not there was a pre-specified sample size consideration accounting for
numbers of events and multiple comparisons in selection of factors, whether or not all enrolled patients
were included in analyses and how many data were available for external validation).
l Missing data (such as adequate reporting on completeness of data and whether or not imputation
was investigated).
l Statistical analysis (such as handling of continuous variables, selection of possible predictors irrespective
of univariable analyses, whether or not overfitting and optimism was accounted for using bootstrapping
or shrinkage and whether or not weights assigned to predictors related to regression coefficients).
l Internal and external model validation (such as whether or not model validations are reported and how
these were carried out).
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Details on the methodology of model development and findings from studies reporting a prognostic model
were summarised narratively, and in the context of any potential risk of bias identified. Key components
were the predictors included in the final model; how the included predictors were coded; what the
specification of the model was, and how it produces an individual outcome probability or risk score; the
reported predictive accuracy of the model; and whether or not the model was validated internally and
externally and, if so, how.
The consistency of development methods used and main findings was examined to identify if studies at
higher risk of bias produced different results and conclusions to those considered to be at low risk of bias.
If multiple studies were found that validated the same prognostic model, then it was planned to synthesise
calibration statistics (such as E/O events) and discriminatory statistics (such as the c-statistic, AUC), using
the random-effects meta-analysis of DerSimonian and Laird,16,17 to summarise the model’s average
performance across different settings and its predicted performance in a future setting.18,19
Amendments to protocol
The original protocol for this review stated that a systematic review of all potential prognostic factors
would be undertaken, which would include any individual factor shown to be associated with risk of
recurrence or adverse outcome. Due to the large wealth of information on potential prognostic factors and
high levels of heterogeneity in the evidence, a review of all prognostic factors would require significant
resource for limited conclusions. Due to the large heterogeneity between studies it was thought to be
unwise to attempt to synthesise such evidence as no firm conclusions could be drawn from such a review.
It is widely accepted within the prognostic research community that individual risk prediction requires the
use of a combination of factors.18 Therefore summarising the prognostic ability of individual factors in
isolation would also not meet the primary aim of this project. As a result, a protocol amendment was
submitted to undertake a systematic review of only prognostic models, including any study utilising a
combination of multiple factors in a model to predict individual risk of recurrence or adverse outcome after
cessation of therapy in patients with a first unprovoked VTE. Thus studies only considering the prognostic
ability of a candidate prognostic factor were no longer included or synthesised, unless they also reported
the development and/or validation of a multivariable prognostic model.
These amendments were discussed with, and agreed by, the National Institute for Health Research and a
revised protocol submitted.
Results
Quantity of research available
Searching of bibliographic databases as described in Search strategy resulted in 13,516 records identified
after automatic removal of 1879 duplicate records. A further 2747 records were manually removed as
duplicates, leaving 10,769 records to be screened for inclusion. Screening of titles and abstracts identified
that 10,485 were not relevant to the review question. Full-text articles were sought for eligibility
assessment, three articles were unobtainable,20–22 and while 16 non-English-language articles were
translated, a further three articles could not be translated into English despite extensive efforts to obtain
translations23–25 (see Appendix 3). This resulted in a total of 278 full-text articles sourced for assessment.
Of the 278 full-text articles assessed for inclusion, 258 articles were excluded (see Appendix 3), with
91 articles excluded as discussion or review articles not developing or updating a prognostic model,
150 articles were excluded based on issues related to the model (e.g. not developed for individual
prediction, adjusted a single predictor, etc.), three articles were excluded based on the study population,
and 14 were excluded based on both study population and issues around the model used (Figure 1).
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As a result of the screening process a total of 20 articles met the inclusion criteria, including seven ongoing
studies8,26–35 (see Ongoing studies), eight conference abstracts relating to studies which appeared to meet
the inclusion criteria,30–40 one record of this Health Technology Assessment report29 and four full-text
peer-reviewed articles,2,9,41,42 one of which appeared to be an update to one of the other three articles.42
The authors of the 15 included conference abstracts and ongoing studies were contacted to seek
additional information, such as a subsequent publication. Based on author responses, 13 of the 15 articles
were associated with the four full-text articles included. The authors of the remaining two articles did not
respond to further enquiry and so no further publications could be found to supplement the available
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FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram.
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and aimed to identify a subgroup of patients at high and low risk of recurrent VTE. The analyses
investigated patient characteristics including age (dichotomised), sex, body mass index (BMI)
(dichotomised), idiopathic presentation, site of index event, malignancy, creatinine clearance, known
thrombophilia, immobilisation, and comorbid cardiac and pulmonary disorders; it was unclear from the
abstract if analyses were univariable or multivariable. Further information regarding the study was
unavailable from the included abstract, therefore it was unclear whether or not a prognostic model was
developed and if individual recurrence risk could be predicted from such a model. The second abstract
relates to the ongoing VISTA study,26 which is further discussed in Ongoing studies.
The four full-text articles included in the review (and 13 associated abstracts) will be discussed in further
detail throughout the remaining sections of this chapter: Main study and patient characteristics,
Description, critique and main findings of model studies, Comparison of included studies quality (which
compare and contrast the three main articles and discuss common strengths and weaknesses), and
Discussion (which provides an overall discussion on the issues found which may help to inform the
development of a new prognostic model). The ongoing studies identified will be discussed in Ongoing
studies. Three of the articles developed three independent prognostic models or rules (whereas the fourth
is an update to one of the models), outlined briefly below.
HER DOO 2: Rodger et al.9
Rodger et al.9 used a conditional logistic regression model to develop a clinical decision rule which
suggested that a female patient with less than two predictors (post-thrombotic signs, D-dimer level
≥ 250 µg/l, BMI ≥ 30 kg/m2 or aged ≥ 65 years) could potentially safely discontinue OAC therapy after
5–7 months of initial OAC therapy for an unprovoked VTE. A low risk (< 3% annual recurrence risk) group
of males could not be identified in the study and therefore Rodger et al.9 recommended that all male
patients continue OAC therapy.9
Vienna prediction model: Eichinger et al.2,42
Eichinger et al.2,42 used a Cox proportional hazards model to develop a prognostic model including sex, site
of index event and D-dimer as predictors. A nomogram based on the prognostic model was derived to
allow easy implementation of the model and can be used to calculate patient’s cumulative recurrence rate
at 12 and 60 months from cessation of therapy, with estimated 95% CIs.2 An extension to the Vienna
model has been proposed which aimed to utilise D-dimer measurements over time to allow prediction
using the Vienna model from time points at 3, 9 and 15 months after cessation of therapy.42
DASH score: Tosetto et al.41
Tosetto et al.41 used a Cox proportional hazards model to develop a clinical prediction guide including
predictors for abnormal D-dimer levels (+2 score), age ≤ 50 years (+1 score), male sex (+1 score) and
hormone use (–2 score). This proposed score can be used to calculate patients’ cumulative recurrence rate
at 1, 2 and 5 years from cessation of therapy, with estimated 95% CIs. Tosetto et al.41 suggest that a
combined D-dimer, Age, Sex, Hormone therapy (DASH) score of ≤ 1 would indicate an annual recurrence
risk < 5% and therefore indicate that a patient could potentially stop OAC therapy, conversely a DASH
score of ≥ 2 would indicate annual recurrence risk > 5% and thus suggest patients should potentially
continue OAC therapy.41
Throughout this chapter these articles will be referred to using their author’s name, while the
corresponding models will be referred to using their given name as above.
Main study and patient characteristics
In this section study and patient characteristics will be compared across the three included articles where
possible. Due to the large heterogeneity in the methods used for model development and the presentation of
the final models, a detailed assessment and discussion of the methods used and proposed models will follow
in a critical appraisal of the included articles (see Description, critique and main findings of model studies).
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The study characteristics of included articles are described in Table 1. Two of the articles, Rodger et al.9
and Eichinger et al.,2,42 conducted prospective cohort studies to develop their prognostic models. Tosetto
et al.41 collected IPD from seven prospective cohort studies with which to build their prognostic model. All
studies included recurrent VTE as their outcome of interest, and each included patients from several
different centres across a range of countries creating the opportunity for heterogeneity in overall results
and making it difficult to define the population in which the developed models can be applied. Table 2
shows the variable inclusion and exclusion criteria used across the three studies, with different criteria
applied for treatment duration; for example, Rodger et al. including those treated for 5–7 months with
OAC therapy, and Eichinger et al. including any patient treated for greater than 3 months OAC therapy.
Importantly, there were some differences across the studies in terms of the definition of unprovoked VTE
used. Although surgery, trauma, immobility, pregnancy and cancer all appear as provoking factors across
the studies, only the Vienna study2,42 excludes hormone therapy as a provoking factor. Hormone therapy is
considered to be a weak risk factor for recurrent VTE and as such is often included in the definition of
unprovoked VTE. However, hormone therapy is a transient risk factor and unprovoked VTE is defined as an
absence of transient risk factors, making its inclusion concerning. The patient population may differ in
terms of recurrence risk due to including patients with a lower risk of recurrence than the unprovoked VTE
population, which will impact on the estimated predictor effects in any developed model (see Description,
critique and main findings of model studies).
TABLE 1 Study characteristics for the included articles
Model HER DOO 2 Vienna DASH
Author Rodger et al.9 Eichinger et al.2,42 Tosetto et al.41
Year of publication 2008 2010 2012
Country Four countries (unspecified) Austria Austria, Canada, Italy,
Switzerland, UK, USA
Study setting Twelve tertiary care centres,
patients enrolled between
October 2001 and March 2006
Recruited from four thrombosis
centres in Vienna between
July 1992 and August 2008
Patient-level meta-analysis of
previously published studies11
Study design Multicentre prospective cohort
study
Prospective cohort study IPD from seven prospective
studies
Clinical outcome Recurrent VTE Recurrent VTE Recurrent VTE
Total sample size, n 646 929 1818
Events, n 91 176 239
HER DOO 2, Hyperpigmentation, Edema, Redness/D-dimer, Obese (body mass index > 30 km/m2), Old (age > 65 years)/2 or
more factors should indicate for patients to continue therapy.
DOI: 10.3310/hta20120 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 12
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Ensor et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
13
The study populations differed in various ways across the three included studies, and differing patient
characteristics and predictors were recorded. Those characteristics which were commonly reported across the
studies are presented in Table 3, including patient age, sex, site of index VTE, BMI, D-dimer level, presence of
factor V Leiden, duration of OAC therapy, duration of follow-up and definition of unprovoked VTE.
There were differences in the presentation of results across the studies, with the Vienna2,42 and DASH41
studies presenting the median of continuous characteristics and frequency of categorical characteristics,
whereas the HER DOO 2 [Hyperpigmentation, Edema, Redness/D-dimer, Obese (body mass index
> 30 km/m2), Old (age > 65 years)/2 or more factors should indicate for patients to continue therapy]9
study presented means for continuous characteristics (see Table 3). Both the HER DOO 29 and DASH41
studies split characteristic data by event status (recurrent VTE/no recurrence), whereas the Vienna2,42 study
presented overall population characteristics, making comparisons across the studies difficult.
There were distinct differences in the number of observed events across the included studies, with 176,
239 and 91 events for the Vienna,2,42 DASH41 and HER DOO 29 studies respectively (see Table 3). The small
number of events seen in the Vienna2,42 and HER DOO 29 studies may lead to insufficient statistical power,
which will be discussed within the critical appraisal (see Description, critique and main findings of model
studies). The DASH41 study combined IPD from seven source studies providing greater sample size and
statistical power; the same IPD database was utilised in the development of a prognostic model in
Chapter 4.11
TABLE 2 Study inclusion/exclusion criteria and definitions of unprovoked for the included articles
Model HER DOO 2 Vienna DASH
Author Rodger et al.9 Eichinger et al.2,42 Tosetto et al.41
Inclusion criteria Patients with first unprovoked
thromboembolism (proximal DVT or
segmental or greater PE), received
heparin for 5+ days and received
oral anticoagulation therapy for
5–7 months
Includes patients that had recurrent
VTE during treatment period
Aged > 18 years with a first
VTE, treated with OACs for at
least 3 months
Initial unprovoked VTE event
VTE in association with oral
hormonal therapy or
thrombophilic blood
abnormality and no other
VTE risks were included
Exclusion criteria Aged ≤ 17 years, already
discontinued OAC, required
ongoing OAC for reasons other
than VTE, geographically
inaccessible for follow-up, treated
for recurrent unprovoked VTE, or
known high-risk thrombophilia
(deficiency of protein S, protein C
or antithrombin, persistently
positive lupus anticoagulant,
or 2+ thrombophilic defects)
Initial provoked VTE event Patients with known
antiphospholipid antibodies
or anti-thrombin deficiency
Excluded if not proximal DVT
or PE index event
Definition of
unprovoked
Not provoked by leg fracture or
plaster cast, immobility for
> 3 days, surgery in 3 months prior
to index event, diagnosis of cancer
in last 5 years




protein S; presence of lupus
anticoagulant; or cancer
Not provoked by surgery,
trauma, pregnancy and the
puerperium, immobility, or
cancer
HER DOO 2, Hyperpigmentation, Edema, Redness/D-dimer, Obese (body mass index > 30 km/m2), Old (age > 65 years)/2 or
more factors should indicate for patients to continue therapy.
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Other characteristics, such as patient age, proportion of males, BMI and duration of OAC therapy,
appeared to be somewhat consistent in terms of reporting across the studies (see Table 3). D-dimer levels
were consistent across the Vienna2,42 and HER DOO 29 models, where both measured the median D-dimer
level. Comparison to the DASH41 study was not possible as D-dimer was dichotomised (normal vs.
abnormal) within the study. The proportion of patients with factor V Leiden appears to be greater in the
Vienna2,42 study than the comparable HER DOO 29 study, though this may be explained by greater chance
discrepancies in the prevalence of factor V Leiden likely to occur in smaller studies.
Description, critique and main findings of model studies
Quality assessment of the three included articles was undertaken using an early version of the PROBAST
for assessing risk of bias and applicability of prognostic model studies.15 The results of this assessment
formed the structure and content of this critical appraisal covering areas including patient selection,
outcomes, predictors, sample size and analysis methods of the three included studies (see Assessment of
study quality).
Key similarities and differences between the models are then summarised, focussing on the implications
for the robustness of the respective findings. The findings from the PROBAST assessment, in terms of areas
of potential risk of bias in the included studies, are summarised in Table 4, and presented validation
statistics for the studies are summarised in Table 5.
HER DOO 29
Rodger et al.9 aimed to develop and internally validated a clinical decision rule to identify a subgroup of
patients at low risk of recurrent VTE, in whom OAC therapy could be stopped after 6 months.
TABLE 4 Quality issues for the included articles
Model HER DOO 29 Vienna2,42 DASH41
Use of a selection procedure? Yes Yes Yes
Adjustment for optimism in selection procedure? No Yes Yes
Events per predictor > 10? No Yes Yes
Appropriate type of model? No Yes Yes
Modelled continuous predictors as linear/non-linear? No Yes No
Considered multiple imputation to handle missing
data?
No No No
Internal validation? No Yes Yes
External validation? No Yesa No
Adjustment for optimism in internal validation? Yes Yes Yes
Reported discrimination? No Yesa Yes
Reported calibration? No Yesa Yesa
Were final model predictor weightings related to
regression coefficients?
Yes Yes Yes
Risk of bias? High Moderate Moderate






a Not for the nomogram/score used in practice.
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Patient selection
Rodger et al.9 used a prospective cohort study with consecutive unselected patients from 12 tertiary care
centres in four countries. The prospective cohort design ensures that predictor information can be collected
blinded of patient outcome. Inclusion criteria were patients treated with low-molecular-weight heparin for
at least 5 days, OAC therapy for between 5 and 7 months with an INR between 2 and 3, and with no
recurrence during therapy. Patients were excluded if they would not provide consent, were aged
< 17 years, had already ceased therapy, required therapy for another reason, were inaccessible for
follow-up, were being treated for unprovoked recurrence or known thrombophilia. Thrombophilia testing
was not performed as part of the study, but any patients with known thrombophilia prior to the start point
were excluded.
The definition of unprovoked VTE used by Rodger et al.9 was based on an absence of the following
provoking factors:
l leg fracture or plaster cast
l immobility for > 3 days
l surgery using general anaesthetic (in the 3 months prior to the index event)
l diagnosis of cancer (in the past 5 years).
This definition of unprovoked VTE therefore includes women who have currently, or previously, used OCs
or HRT. Hormone therapy should be considered as a provoking factor for recurrent VTE; though some
argue that because the effect of hormone therapy is weak it may be included within the definition.41,44
Strictly, the definition of unprovoked VTE refers to a VTE in the absence of any transient risk factors, hence
why hereditary thrombophilia can be considered unprovoked VTE.45 As hormone therapy is a transient risk
factor patients with a history of hormone therapy could be considered provoked. As a result there may be
patients included in the model development who are at potentially lower risk than other unprovoked
patients. This could lead to biased estimation of effect sizes within analyses, particularly for the effect of
sex, which could lead to poor validation in external populations which may not include patients with
hormone-related index events.
TABLE 5 Model performance statistics for internal validation of proposed models presented for the
included articles




Model for use (score) – – –
Development model (Beta terms) – – –
Vienna2,42
Model for use (nomogram) – – –
Development model (Beta terms) 0.88 0.651 60 months= 0.646
DASH41
Model for use (score) – 0.71 –
Development model (Beta terms) 0.974 0.72 –
a Bootstrap calibration slope.
b c-statistic based on development data.
c c-statistic based on bootstrap internal validation.
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The primary outcome of the study was recurrent VTE, with associated deaths also recorded. Suspected
DVT was confirmed by compression ultrasound, whereas suspected PE was confirmed by high-probability
ventilation/perfusion scanning and/or spiral computed tomography. All events were adjudicated by
independent physicians who were blinded to predictor information. As such, outcomes were pre-specified
with the same definition and assessment used for all patients reducing the risk of detection bias, where
there are differences in the determination of outcomes. The outcome definition excluded any candidate
predictors again reducing the risk of detection bias and overall providing a low risk of bias with regard to
outcome assessment.
Predictors
Rodger et al.9 report that information was collected on 69 potential predictors based on evidence from a
pre-specified systematic review. Summary information was provided for 21 candidate predictors (with







l abnormal baseline imaging




l heterozygous for prothrombin gene mutation
l factor VIII (U/ml)
l factor V Leiden
l ventilation/perfusion scan or pulmonary vascular obstruction result < 95%
l post-thrombotic signs
l history of chronic obstructive pulmonary disease or emphysema
l family history of VTE
l previous secondary VTE
l use of OC in year before event
l HRT in year before the event.
All predictors were measured before outcomes occurred, with laboratory predictors measured from
samples taken while still on OAC therapy, and predictor definitions were consistent for all patients.
Therefore the risk of selection bias due to differences in the characteristics of patients, and also the risk
of reporting bias through differences in the reporting of predictors based on outcomes, could be
considered low.
The use of a systematic review to identify potential predictors, the consistent updating of the systematic
review and the assessment of all identified predictors provides confidence that there is a low risk of
selection bias where patients are selected based on their characteristics, and attrition bias based on
exclusions from analyses.
Rodger et al.9 categorised all continuous predictors that had a p-value < 0.2 at univariable analysis, by
dichotomising at various thresholds and identifying ‘optimal’ thresholds as those with the highest chi-
squared value. The process of categorisation was therefore completely data driven which often leads to
reporting bias, where the most significant results are presented.46 Rodger et al.9 indicate that dichotomised
predictors were used to enhance the applicability and acceptance of the proposed clinical decision rule.
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Although it is a valid reasoning, with researchers and clinicians looking for parsimony in any decision rule,12
the dichotomisation of continuous predictors leads to a loss of information. Dichotomisation splits patient’s
risks into two groups treating patients on either side of a threshold as distinctly different, when in reality
they may be very similar on the original scale.47 Best practice recommends that continuous predictors
remain continuous in any analysis and to investigate non-linear associations.47–50
Sample size and patient flow
A total of 646 patients had at least one follow-up visit and were included within the analysis. Only 600 of
these patients completed follow-up, with 14 lost to follow-up, 10 patients dying after their first follow-up,
nine patients withdrawn and 13 patients restarting OAC therapy for another reason. There were 91 events
recorded out of the 646 patients included in the analysis, which could be considered insufficient power to
investigate the 36 predictors described within the article. As a rough guide at least 10 events are required
for each candidate predictor being investigated to give enough power for the analysis to yield valid
conclusions.51 Therefore, to investigate 36 predictors would require roughly 360 events. It is unclear from
the article whether or not model building included the 36 predictors summarised within the article, or the
96 predictors for which information was recorded: roughly 960 events would be required to adequately
power such an analysis.51 As the study was substantially underpowered (with a maximum of 2.5 events per
predictor), the results of model building and conclusions drawn must be carefully interpreted. Predictor
effects could be substantially biased, with overestimation or underestimation of both the effect size and its
associated uncertainty.51
Rodger et al.9 conducted a complete-case analysis, excluding patients with any missing predictor
information. There was missing predictor information quantified for five predictors included in the
predictor selection procedure:
l abnormal baseline compression ultrasound (events= 14/non-events= 180)
l factor V Leiden (events= 0/non-events= 1)
l ventilation/perfusion scan or pulmonary vascular obstruction result < 95% (events= 53/
non-events= 283)
l post-thrombotic signs (hyperpigmentation, edema or redness in either leg)= (events= 18/
non-events= 83)
l family history of VTE (events= 0/non-events= 1).
The use of a complete-case analysis for the final model may introduce attrition bias by excluding patients
who have outcome data but are missing information from one or more candidate predictors. The drop in
the number of events is also a cause for concern; a potential total of 85 events were missing across the five
predictors, enhancing the possibility of spurious relationships being seen or important prognostic effects
being missed during the predictor selection procedure. In terms of the final model, only post-thrombotic
signs were included and so the complete-case analysis sample size was reduced by 101 patients, of whom
18 were events. Overall the sample size and handling of missing data within the study indicate a potentially
high risk of bias within the model development.
Analysis
Rodger et al.9 used a conditional logistic regression model and selected predictors using a stepwise forward
selection process. As the outcome of interest was time to recurrent VTE, a time-to-event analysis may have
been more appropriate here as logistic regression does not account for the censoring of patients over time
and variable lengths of follow-up. The analysis also did not consider the potential heterogeneity across the
three tertiary centres from four different countries, stratification by centre or country would take into
account any heterogeneity in the baseline risk of recurrence within these potentially different populations.52
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Predictors were only included in multivariable analysis if univariable analysis yielded a p-value < 0.2, though
univariable results were not presented in the article. This exclusion of candidate predictors from
multivariable analysis was therefore completely data driven based on univariable results, which could lead
to potential bias in results because predictors which may be important in combination (e.g. in a
multivariable model) were not considered for multivariable analysis. Univariable analyses are not
recommended for decisions about inclusion criteria in a multivariable model.53
The use of a forward selection procedure in model development can lead to overoptimism in regression
coefficients (betas) and therefore a method such as shrinkage or bootstrapping should be used to account for
this optimism. Rodger et al.9 did not use methods to account for optimism in their analyses and as such there
is a risk that the performance of their proposed model could be weaker when applied to a new population.
Rodger et al.9 decided to split patients into two groups based on sex in a post-hoc analysis because a
specified low-risk group (< 3% annual risk of recurrence) could not be identified. Post-hoc subgroup
analyses such as this are often not considered in any assessment of study power. Stratifying by sex reduced
the number of events for females and males to 28 and 63 events, respectively, creating similar issues to
those discussed above in the estimation of regression coefficients within the model.51
Five clinical decision rules were developed for women and two for men, the final decision rule was
selected based on criteria including the classification of performance; the proportion of patients identified
as low risk; the face validity of the model; ease of use of the model; and more parsimonious models. The
performance of decision rules for men was considered poor, particularly in identifying a low-risk group of
men which could be considered for cessation of therapy, as such the study recommended that men




¢ redness in either leg
l D-dimer level ≥ 250 µg/l
l BMI ≥ 30 kg/m2
l aged ≥ 65 years.
Rodger et al.9 suggested that any female patient with fewer than two of these predictors could potentially
safely cease OAC therapy after 5–7 months of initial OAC therapy for an unprovoked VTE. The specification
of the model is not described in full, with regression coefficients presented for the final model only, but
without any measurement of variability such as a standard error or 95% CI for the coefficients. It is unclear
if or how the decision rule is related to the regression coefficients, though it may be that a rounding of the
coefficients to the nearest integer was used. There is no indication of the level of risk associated with a
particular score using the proposed decision rule; for example, what the risk of recurrence at 1 year post
cessation of therapy is for a female with three of the included factors.
The decision rules developed were internally validated using split-sample cross-validation. Five hundred
subsamples, half the size of the study sample, consisting of randomly selected patients from the
population were used to assess rule performance. The mean annual recurrence risk predicted by the
clinical decision rule was recorded within each subsample and showed that for all subsamples the decision
rule identified a low-risk group of women with mean annual risk of recurrence between 0% and 3%,
suggesting that the rule performed well in internal validation. No measure of performance in terms of
calibration or discrimination was presented, and no external validation of the rule was conducted. An
external validation of the clinical decision rule is currently being undertaken comparing use of the decision
rule to decide on cessation of therapy versus standard therapy.27,28
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Summary
Overall there are significant concerns over the robustness of the proposed clinical decision rule. The testing
of many more predictors than the study was powered for could lead to potentially spurious predictor
effects. The data-driven dichotomisation of continuous predictors does not allow for non-linear effects,
and instead suggests a constant effect in patients at either side of the chosen threshold.48 The effects of
missing predictor information were not assessed which could have resulted in different conclusions had
there been more data available. Potentially inappropriate analyses were performed, without accounting for
heterogeneity in baseline risk across differing populations and performing post-hoc subgroup analysis.
The decision rule was poorly presented, with a lack of explanation linking regression coefficients with the
decision rule. Furthermore, there was no reporting of uncertainty surrounding coefficients and no
description of calibration or discrimination given. Therefore, there is substantial concern that the proposed
decision rule would not perform as presented when applied in a new population and examined in new
data independent to that used to develop the model.
Vienna prediction model2,42
Eichinger et al.2,42 aimed to develop and internally validate a prognostic model to improve VTE recurrence
risk prediction for patients following a first unprovoked VTE.
Patient selection
Eichinger et al.2,42 also used a prospective cohort design with consecutive unselected patients recruited
from four thrombosis centres in Vienna, between July 1992 and August 2008. Similar to Rodger et al.,9 a
prospective cohort design ensures that predictor information can be collected blinded of patient outcome.
Patients were included if they were at least 18 years old and had been treated with OAC therapy for at
least 3 months for a first unprovoked VTE.






l deficiency in antithrombin, protein C, protein S
l presence of lupus anticoagulant, or
l cancer.
This definition of unprovoked VTE therefore follows a standard definition based on an absence of any
transient risk factors. As a result the study population should be representative of the unprovoked VTE
population and therefore provides a low risk of bias in the model development.
Outcomes
The main outcome of the study was recurrent VTE, with suspected DVT confirmed by venography or
colour duplex ultrasonography. Suspected PE was confirmed by ventilation/perfusion scan and/or spiral
computed tomography. All events were adjudicated by a committee of independent radiologists. Detection
bias was limited by pre-specification of outcome definitions, with the same definition and assessment
used for all patients, meaning systematic differences in the determination of outcomes were avoided.
Outcomes were pre-specified with the same definition and assessment used for all patients reducing the
risk of differences in the diagnosis and reporting of outcomes. The outcome definition excluded any
candidate predictors and was also determined blind to any predictor information, again, reducing the risk
of detection bias and overall resulting in a low risk of bias based on the study outcomes.
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Eichinger et al.2,42 pre-specified a selection of clinical and laboratory predictors based on criteria including
independent confirmation of the association with risk of recurrence (literature), simplicity of assessment
and reproducibility. Using pre-specified candidate predictors reduces the risk of bias through unnecessary
investigations, limiting the number of hypothesis tests and therefore reducing the chance of multiple




l site of index event (distal DVT, proximal DVT, PE)
l D-dimer (µg/l)
l factor V Leiden
l factor II mutation
l peak thrombin.
All predictors were measured blinded to outcome data (with laboratory predictors measured at cessation
of OAC therapy), and predictor definitions were consistent for all patients. These methods reduce the risk
of selection bias due to differences in the patient characteristics and also the risk of bias in the reporting of
predictors based on outcomes.
Eichinger et al.2,42 investigated linear forms of all continuous predictors including age, BMI and D-dimer
level. The study authors also investigated a dichotomisation of BMI based on the standard threshold for
obesity (BMI > 30 kg/m2) used in clinical practice. The study therefore avoided introducing bias from
data-driven methods of categorising continuous predictors, but this approach can still lead to a loss of
information by splitting patients risk into distinct groups.47
Sample size and flow
A total of 929 patients were included within the analysis with 176 recurrent events being recorded. Given
that Eichinger et al.2,42 investigated a total of eight predictors (15 predictors including categorisations of
predictors), the number of events seen could be considered sufficient given the rule of thumb of 10 events
per predictor.51 As the study could be considered suitably powered (with a maximum of 12 events per
predictor), the inclusion of predictors and their effects are likely to be at low risk of bias, with effect sizes
and associated uncertainty likely to be reliably estimated.51
Eichinger et al.2,42 conducted a complete-case analysis, excluding patients with any missing predictor
information. There was missing predictor information quantified for five predictors included in predictor
selection, but no indication of the number of associated events:
l BMI= 20
l D-dimer= 97
l peak thrombin= 300
l factor V Leiden= 13, and
l factor II G20210A mutation= 14.
Complete-case analysis introduces attrition bias through excluding patients with outcome data because
they have missing information related to one or more candidate predictors. The drop in the number of
events could have an impact on the regression coefficients and selection of predictors for inclusion within
the final model, particularly for peak thrombin with a third of patients missing predictor information.
Any analyses including peak thrombin would exclude a third of the study population, markedly reducing
sample size and causing issues with the estimation of predictor effects. As D-dimer is the only predictor
included in the final model, the complete-case analysis would have reduced the sample size by 97, though
it is unclear how many events this represents and therefore could present a high risk of bias in the results
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presented. Overall the sample size and handling of missing data within the study indicate a potentially high
risk of bias within the model development.
Analysis
Eichinger et al.2,42 used a Cox proportional hazards model and selected predictors using a forwards
stepwise selection process. A Cox regression model accounts for the censoring of patients over time and
variable length of follow-up in a time-to-event analysis, making it an appropriate choice for the recurrent
VTE outcome. No stratification by centre was performed as part of the analysis, which did not account for
potential heterogeneity in the baseline risk of recurrence for patients from the four different thrombosis
centres. Failing to account for differences in baseline risk (or at least to investigate whether or not
stratification is necessary), could lead to biased predictor effects which may not be replicated when the
model is applied in a new population.52
Eichinger et al.2,42 first fitted a saturated model using all clinical predictors and then performed forward
selection to investigate laboratory predictors (using an inclusion threshold of p-value < 0.5). To account for
optimism associated with the stepwise selection procedure, Eichinger et al.2,42 evaluated the statistical
significance of included predictors using bootstrap zero-corrected 95% CIs. From 1000 bootstrap
resamples of the population, only factors for which the 95% CI did not overlap zero were included in the
model. Further to this, Eichinger et al.2,42 applied a shrinkage factor (calculated by bootstrap resampling), to
the final beta coefficients to adjust for optimism which may affect the models performance in new study
populations. The extensive use of methods to account for optimism in their analyses suggests that
performance of the model is unlikely to be affected when applied to a new population.
Two prognostic models were presented within the study including the following predictors:
l sex (female as the reference category)
l site of index event (distal DVT as the reference category)
l peak thrombin (included in the first model)
l D-dimer (included in the second model).
Both models included sex and site of index event as predictors, but during initial predictor selection peak
thrombin was identified as significantly prognostic and D-dimer did not enter the model [hazard ratio (HR)
1.21, 95% CI 0.87 to 1.53; p= 0.622]. The authors then decided to evaluate a model including D-dimer
without peak thrombin, and in this model D-dimer was a significant predictor of recurrent VTE. Eichinger
et al.2,42 chose to take forward the model including D-dimer levels as a final model because ‘D-dimer is a
well-standardised and widely established parameter’. The ad hoc selection of predictors may be a cause for
concern as it was not pre-specified that D-dimer was to be included and there was strong evidence against
the prognostic value of D-dimer compared with peak thrombin levels. However, as discussed by the
authors, the inclusion of D-dimer within the model could potentially improve the implementation of the
model, as D-dimer is an established predictor more readily measured in practice. Prognostic models should
aim to include predictors with standard definitions, which are easily available at the time the model is
intended for use; however, the performance of the model may have been significantly improved by the
inclusion of peak thrombin as a predictor (which showed strong evidence of prognostic value). However,
it is also worth noting the substantial number of missing data for peak thrombin (300/929 patients missing
peak thrombin data), which could have influenced the estimated effect of peak thrombin within the
complete-case analysis performed.
Eichinger et al.2,42 proposed a nomogram based on the final model including sex, site of index event and
D-dimer as predictors. The nomogram can be used to calculate patient’s cumulative recurrence rate at
12 and 60 months from cessation of therapy, with estimated 95% CIs. The relationship between the
regression coefficients of the model and the simplified nomogram is not explicitly stated, though it is
suggested that the coefficients are first multiplied by the estimated shrinkage factor. No estimate of
baseline risk is provided and therefore it is only possible to estimate patients predicted risk of recurrence at
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the specified time points within the study (1 and 5 years). The use of estimated recurrence risk at specific
time points (with associated uncertainty), improves on the HER DOO 2 model9 by allowing practitioners to
apply their own judgement based on the predicted risk, using current guidelines and patient consultation,
to make an informed decision on treatment strategy for the individual patient.
Internal validation of the model was performed using bootstrap cross-validated risk scores. Patients were
randomly drawn with replacement from the original sample, to make a new bootstrap sample of 929
patients. Eichinger et al.2,42 re-evaluated their model within this new bootstrap sample and validated their
model in the sample of patients that were not selected from the original study data. The process was
repeated 1000 times and an average risk score for each patient was calculated from the 1000 replications.
Using these averaged risk scores the performance of the model (within the validation subsets) was
assessed using the AUC, which is a measure of model discrimination. For recurrence risk at 12 and
60 months from cessation of therapy the optimism adjusted (bootstrapped) AUC was estimated at 0.674
and 0.646, respectively, indicating moderate discrimination, which suggests moderate ability of the model
to separate groups of patients such as high- and low-risk patients (where AUC= 1 represents perfect
discrimination). The study also reported an apparent c-statistic (assessing discrimination across all time
points, and without adjustment for optimism) of 0.651 for the developed model as a measure of
discrimination (where c-statistic= 1 represents perfect discrimination), which suggests a small reduction in
model performance after accounting for optimism. The Vienna model also calculated a bootstrap
optimism-adjusted calibration slope (or uniform shrinkage factor), which showed moderate calibration
performance of 0.88 (with 1 indicating perfect calibration). This shrinkage factor was also used to adjust
the predictor effect values in their final model, to adjust for the overoptimism. However, the performance
of a model measured in the same data set used to develop the model will always be biased, showing
greater performance than can be expected in an external setting.
An external validation of the Vienna prediction model is currently being undertaken, which should provide
a more reliable indication of model performance in a new patient population. It should also be noted that
the internal validation of the Vienna prediction model relates to the multivariable Cox regression model
developed, and it is unclear whether or not internal validation of the simplified nomogram was conducted.
Summary
In summary, there was a moderate risk of bias associated with the Vienna predication model, mainly
because no external validation has yet been performed. Model development itself was undertaken well.
Patient selection avoided inappropriate exclusions and outcomes were defined consistently for all patients
and blinded to predictor information. Continuous predictors were assessed in their linear form as opposed
to categorising, therefore avoiding a loss of information. Overoptimism in the estimated regression
coefficients was accounted for by using bootstrapping methods to adjust these coefficients.
However, there were also some areas for concern which could have introduced bias into the model
development. The analysis did not investigate potential heterogeneity in the baseline risk of recurrence in
the different populations from the four thrombosis centres used, potentially affecting the models
applicability to a new population. The study authors made an ad hoc decision to include D-dimer as a
predictor in the model, despite its lack of prognostic value during predictor selection. There was strong
evidence of an important effect for peak thrombin, which meant D-dimer was originally excluded. The
decision to include D-dimer was based on practical implications for model use, as it is a more established
predictor. There were also some issues with missing predictor information, with marked reductions in data
for both D-dimer and peak thrombin, and no information on the number of events excluded from
complete case analyses investigating these predictors. Furthermore, it was not clear how the nomogram
was created and whether or not the internal validation of the nomogram was examined.
Overall the Vienna prediction rule was presented well and classed as low risk of bias in terms of model
development. External validation is, however, now essential for the proposed nomogram. If performance
was found to be acceptable, the model would allow individual prediction of recurrence risk limited to the
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two specified time points. The model was presented in a nomogram which may facilitate uptake of the
model in practice, though this format limits the precision available (e.g. in specifying a patient’s exact
D-dimer level). The predicted recurrence rate is provided with associated uncertainty (95% CI), which
allows both clinician and patient to make an informed decision regarding treatment.
Finally, the extension to the Vienna model aimed to allow prediction of recurrence risk at further time
points post cessation of therapy by measuring D-dimer over time.42 Measurements were made at 3, 9 and
15 months post cessation of therapy, and three more nomograms were developed to allow risk prediction
using the Vienna model at these time points. D-dimer levels did not vary over the observation time and the
associated HRs remained very similar (only the point estimate slightly decreased over time).42 A web-based
calculator allows users to predict recurrence risk at any time between baseline (3 weeks) and 15 months
post cessation of therapy.42 The model was adjusted for optimism using leave-one-out resampling to
calculate shrinkage factors for 3, 9 and 15 months of 0.79, 0.81 and 0.7, indicating moderate calibration
of the model at all time points but reduced performance compared with the original Vienna model
(optimism-adjusted calibration slope= 0.88). In terms of discrimination performance (for 5-year predictions)
at each time point, optimism adjusted AUC values were 0.61, 0.61 and 0.58, representing a small
reduction in performance compared with the original model (AUC= 0.646).2,42 However, although the
earlier Vienna model has recently been externally validated, this model has not been externally validated
to date.
DASH score41
Tosetto et al.41 aimed to develop and internally validate a clinical prediction guide to stratify unprovoked
VTE patients by their risk of recurrence and identify those suitable for long-term OAC therapy. The study
performed a meta-analysis of IPD from seven prospective studies (see Main study and patient
characteristics), so as to alleviate issues of statistical power often encountered in single prospective study.
Patient selection
Tosetto et al.41 used IPD from seven prospective cohort studies with consecutive unselected patients
described by Douketis et al.11 previously. The prospective cohort design as used in the previous studies
ensures that predictor information can be collected blinded of patient outcome. Patients were included if
they were at least 18 years old and had been treated with OAC therapy for at least 3 months for a first
unprovoked VTE. Patients were excluded if follow-up ended before D-dimer measurement, or if they had a
distal DVT; only proximal DVT and PE were included as valid index sites.




l pregnancy and the puerperium
l immobility
l cancer.
This definition of unprovoked VTE therefore includes women who have currently, or previously, used OCs
or HRT. As described for the Rodger et al.9 study, hormone therapy is sometimes included in the definition
of unprovoked VTE because the effect of hormone therapy is weak;41,44 however, hormone therapy should
be considered as a provoking factor. The definition of unprovoked VTE refers to a VTE in the absence of
any transient risk factors, hence why hereditary thrombophilia can be considered unprovoked VTE.45 As
hormone therapy is a transient risk factor patients with a history of hormone therapy could be considered
provoked. This could lead to effect sizes within the analyses being incorrectly estimated, particularly the
effect of sex, because there may be subgroups of patients included in the model development who are at
potentially lower risk than other unprovoked patients.
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The primary outcome of the study was recurrent VTE, with associated deaths also recorded. All suspected
outcomes were objectively confirmed and independently adjudicated.11 Outcomes were pre-specified with
the same definition and assessment used for all patients, therefore reducing the risk of differences in the
determination of outcomes. The outcome definition excluded any candidate predictors and outcomes were
also determined blind to any predictor information again reducing the risk of detection bias.
Predictors




l site of index event (DVT alone, or DVT and PE)
l D-dimer (ng/ml)
l hormone use at time of VTE (women)
l previous history of cancer.
All predictors were measured blinded to outcome data (with D-dimer measured 3–5 weeks after cessation
of OAC therapy), and predictor definitions were consistent for all patients. These methods reduce the risk
of selection bias due to differences in the patient characteristics and also the risk of bias in the reporting of
predictors based on outcomes.
Tosetto et al.41 also stratified their analyses by source study to allow for potential heterogeneity in the
baseline risk of recurrence within these seven different populations. The adjustment for underlying
differences in the source study populations may make the final model more robust when applied within a
new population, not used in the development process.
Tosetto et al.41 categorised all continuous predictors, creating a dichotomisation of D-dimer (normal vs.
abnormal), while categorising age into quartiles. Quartiles of age were used to control for a non-linear
relationship between patient age and recurrence risk. The study may have therefore introduced bias from
categorisation of continuous predictors, which can lead to a loss of information by separating patients risk
into distinct groups.47 Categorisation of age appeared to be data driven, whereas dichotomisation of D-dimer
was likely based on the instrument used (though it was not stated), both inducing the risk of reporting biases.
Sample size and flow
A total of 1818 patients were included within the analysis with 239 recurrent events being recorded. Given
that Tosetto et al.41 investigated a total of six predictors (14 predictors including categorisations of predictors),
the number of events seen could be considered sufficient given the rule of thumb of 10 events per predictor.51
As the study could be considered suitably powered (with a maximum of 17 events per predictor), the inclusion
of predictors and their effect estimates may be considered to be at low risk of bias. Predictor effects are likely
to be at low risk of bias, with effect sizes and associated uncertainty likely to be reliably estimated.51
There was no missing predictor information in the analyses performed by Tosetto et al.41 and therefore it
was not necessary to allow for the effects of potential attrition bias. The previous two studies have both
suffered with missing predictor information and conducted complete case analyses, potentially introducing
attrition bias into their analyses. Tosetto et al.41 were therefore able to use all patient data in their analyses
and thus statistical power remained appropriate to assess all predictors for inclusion. However, the study
also used a selection procedure meaning more predictors were considered, resulting in a proportion of
missing predictor data. The DASH model considered predictors including BMI, for which only 802 out of
1818 patients had complete predictor information, which may have effected the ability to detect a BMI
effect. Overall the sample size and handling of missing data within the study resulted in a low risk of bias
associated with the model development.
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Analysis
Tosetto et al.41 used a Cox proportional hazards model and selected predictors using a backwards
elimination process. A Cox regression model accounts for variable lengths of follow-up and the censoring
of patients over time and in a time-to-event analysis, making it an appropriate choice for the time to
recurrent VTE outcome. The analyses were stratified by source study to allow for the differences in the
baseline risk across the seven different study populations, therefore avoiding biased predictor effects which
may improve the external performance of the model.52
Tosetto et al.41 first fitted a saturated model using all clinical predictors, and then performed backward
elimination to investigate candidate predictors (using an exclusion threshold of p-value > 0.1). To account
for excessive optimism associated with the backward selection procedure, Tosetto et al.41 evaluated this
using a heuristic formula and linear shrinkage by bootstrapping. A correction factor was calculated and
applied to the final beta coefficients to adjust for optimism which may affect the models performance in
new study populations. The use of shrinkage methods to account for overoptimism in their selection
process and analyses provides a low risk that the performance of their proposed model could differ when
applied to a new population.
The final DASH score was developed by multiplying the regression coefficients by the calculated correction
factor, doubling these coefficients and rounding them to the nearest integer. Giving a final model included
the following predictors:
l abnormal D-dimer (post therapy), score=+2
l age (≤ 50 years), score=+1
l sex (male), score=+1
l hormone use (at time of index event, in women), score= –2.
The proposed score can be used to calculate patients’ cumulative recurrence rate at 1, 2 and 5 years from
cessation of therapy, with estimated 95% CIs. Despite stratification for source study in the analysis, there is
no reported estimate of baseline risk and therefore patients’ predicted risk of recurrence can only be
estimated at the specified time points presented. The use of estimated recurrence risk at specific time
points (with associated uncertainty) is similar to that presented for the Vienna prediction model.2,42 This is a
substantial improvement compared with the HER DOO 2 model9 as it allows physicians and patients to
make an informed decision on treatment duration for the individual patient.
Internal validation of the model was performed using a bootstrap procedure similar to that described for
the Eichinger et al. study.2,42 Patients were randomly drawn with replacement from the original sample, to
make a new bootstrap sample of 1818 patients. Tosetto et al.41 then re-estimated the DASH score within
this new bootstrap sample, to confirm the recurrence rate and associated CI for DASH score of < 1 (identified
as having an annual recurrence risk < 5%). The process was repeated 500 times and an average risk of
recurrence was calculated to be less than the agreed 5% annual recurrence risk. Apparent c-statistics (which
represent the discriminatory performance within the development data without adjustment for optimism
using, for example, bootstrapping) were between 0.71 and 0.72 for the score and model (beta terms),
respectively, indicating moderate discrimination ability even for the simplified score for use in practice;
however, apparent performance is likely to be optimistic. The DASH model also provided a bootstrap
optimism-adjusted calibration slope (or uniform shrinkage factor) as the Vienna model did, which also
showed strong calibration performance of 0.97 for the DASH model (with 1 indicating perfect calibration).
The shrinkage factor was then used to adjust the predictor effect values for overoptimism in the final model.
However, the performance of a model measured within the development data set is likely to be biased,
indicating stronger performance than could be expected in a new population. The use of IPD meta-analysis
in the derivation of the model and stratification for source studies may make the DASH score more robust to
departures from the development population’s characteristics, but external validation should be sought to
identify the true performance of the model in a new patient population.
DOI: 10.3310/hta20120 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 12
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Ensor et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR




In summary the DASH score proposed by Tosetto et al.41 could be considered at moderate risk of bias,
mainly due to the lack of external validation and the categorisation of continuous predictors in the model
development. Many aspects of model development were done well. Patient selection avoided inappropriate
exclusions and outcomes were defined consistently for all patients and blinded to predictor information.
Stratification was used in analyses to account for heterogeneity in the baseline risk of recurrence across the
source studies. Missing predictor information was not an issue in the model development, avoiding attrition
bias and preserving statistical power. Overoptimism in the selection of predictors and estimated effects was
accounted for by a correction factor calculated by bootstrapping. Reporting of the final score was clear with
recurrence risks associated with particular scores presented including uncertainty.
However, there were also some areas for concern which could have introduced bias into development of
the DASH score. There were issues with categorisation of continuous predictors, which could lead to a loss
of important prognostic information. Furthermore, and most importantly, there was no external validation.
External validation is therefore now essential. The DASH score provides individual recurrence risk prediction
at specific time points post cessation of therapy. If externally validated and found to perform well, then the
score could be useful in practice as the included predictors are well defined and readily available at the
time the decision rule would be applied. However, the true performance of the DASH score within a new
patient population is unclear given the lack of internal and external validation statistics. Any physician or
patient using the DASH score should therefore interpret the predicted recurrence risk with care, and the
included 95% CIs are importantly presented within the study, allowing informed decision-making
regarding treatment.
Comparison of included studies quality
All studies performed suitable patient selection avoiding inappropriate exclusions, used appropriate study
designs, pre-specified outcomes and assessed outcomes blinded to predictor information, giving low risk of
bias across all studies. All studies recruited patients from different centres or countries; however, only one
(Tosetto et al.41) stratified by source in their analyses. Stratification accounts for heterogeneity in the
baseline recurrence risk in different patient groups. Ignoring the clustering of patients within centres or
countries could lead to poor model calibration,52 where model predictions do not closely fit observed
recurrence rates, and could diminish performance in a new setting.
The three studies investigated a wide variety of candidate predictors, including clinical and laboratory
predictors. Eichinger et al.2,42 avoided the categorisation of continuous candidate predictors (see Table 4),
Tosetto et al.41 investigated patient age in quartiles, but pre-specified the analysis to allow for non-linear
associations between age and recurrence risk. Rodger et al.,9 in contrast, performed chi-squared testing to
identify the optimal threshold to dichotomise every continuous predictor under consideration. The
data-driven nature of the analysis incites reporting biases where the optimal thresholds are reported
without any clinical meaning. Dichotomisation of continuous predictors is also methodologically poor, as it
seeks to separate patients risk into two categories treating those above and below the threshold as having
different constant risks, which is unrealistic in practice.48
The HER DOO 2 model development by Rodger et al.9 was markedly underpowered, having collected
information on 69 predictors and assessed at least 36 candidate predictors, with only 91 recurrent events.
Given a rule of thumb based on at least 10 events per candidate predictor to be investigated,51 Rodger
et al.9 only had 2.5 events per predictor, indicating a lack of power that could lead to biased estimates of
predictor effects. Following the same rule, the other two studies had sufficient numbers of events to assess
the predictors of interest with appropriate statistical power (see Table 4).
All included studies suffered from some degree of missing predictor information (either in predictor
selection or final model predictors) and used a complete-case analysis to overcome this issue within the
final models (see Table 4). No methods to assess the impact of this missing predictor information were
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used (i.e. an imputation procedure), and in the study by Eichinger et al.2,42 the number of missing recurrent
events was not reported, so no assessment of the statistical power could be made accurately. Attrition
bias can lead to unbalanced groups of patients and exclusion of patients reduces sample size making
estimation of predictor effects biased and performance of the model specific to a subgroup of the
population for whom information was not missing (there may be a risk of bias due to the nature of the
missing data).
Two studies used bootstrapping and shrinkage methods to adjust predictor coefficients for over-optimism
(see Table 4),2,41,42 whereas the HER DOO 2 development did not account for optimism in predictor
estimates.9 The use of optimism correction methods provides a lower risk of biased, unrealistic predictor
effects, and should ensure the model performance is more consistent in a new patient population.
Another methodological issue relating to model performance is validation; internal validation was
performed across all of the studies, but only one has since been external validated (see Table 4).2,42 Internal
validation was reported in terms of both calibration and discrimination within the DASH41 and Vienna
models2,42 (though not for the simplified nomogram), whereas Rodger et al.9 presented neither (see Table 5):
both calibration and discrimination are vitally important performance statistics for any prognostic
model. External validation is the true indication of model performance, as a model validated within its
development data set will always give optimistic performance statistics.18 The Vienna model has now
externally validated (see Relevant studies identified after the search cut-off dates),2,42 but issues remain
because (i) validation was shown to be lower than expected and uncertainty was high;54 (ii) a new Weibull
model component was added, which itself requires additional validation; (iii) the nomogram version of
Vienna, which is the most used, was not validated; and (iv) validation was not made by independent
authors to the original model development. Thus, until further external validation is undertaken, the true
performance in new populations cannot be ascertained. Further external validation studies are currently
being undertaken to validate both the HER DOO 2 decision rule8,27,28 and the Vienna prediction model,
which will provide a true indication as to the overall performance (in terms of calibration and
discrimination) of these models in new patient populations where they are intended for use.
Finally, the application of the proposed models was described in various ways across the studies. Both the
Vienna prediction model2,42 and the DASH score41 were presented well, with an indication of how the
predictors are combined to calculate a patient’s recurrence risk at a specific time point (see Table 4). Both
provided cumulative recurrence rates at specific time points after cessation of therapy including an
estimate of the uncertainty surrounding these estimates (95% CIs). This information could be used to
direct the decision-making process, informing clinicians and patients of the individual’s level of risk and
therefore allowing individualised treatment strategies. Conversely, the HER DOO 2 model9 derived a clinical
decision rule splitting patients into those with less than two predictors (from their model) and those
greater than two predictors, suggesting that one group could continue OAC therapy, while the other
could safely stop. Rodger et al.9 did not report individuals risk at specific time points, only that fewer than
two predictors would indicate a < 3% annual risk of recurrence. This therefore does not allow clinicians or
patients to make decisions based on their preference of recurrence risk threshold, limiting the applicability
of the decision rule.
Ongoing studies
There were two ongoing studies identified through the literature searches: the REVERSE II study (Recurrent
Venous thromboembolism Risk Stratification Evaluation II)27,28 related to the HER DOO 2 rule, and the
VISTA study26 related to the Vienna prediction model.
The first was an external validation trial of the HER DOO 2 rule proposed by Rodger et al.9 which was
internally validated within the original study. This ongoing randomised trial aims to compare the use of the
proposed decision rule to decide on cessation of OAC therapy, compared with standard practice.27,28
The second is an ongoing randomised trial comparing the use of the Vienna prediction model to decide on
treatment duration, compared with usual care where treatment duration is based on physician judgement.26
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Relevant studies identified after the search cut-off dates
Subsequent to the completion of our review searches, one additional highly relevant study was identified
related to one of the ongoing studies found through the systematic review.34,54 This was an external
validation of the Vienna prediction model using IPD from five studies, which aimed to assess the
performance of the Vienna model in terms of both discrimination and calibration in a new population.11,54
The study reported that the derivation and validation populations were homogeneous after removal of
patients with provoked VTE and those with missing predictor information.54 Discrimination was calculated
using the c-statistic for comparison with the original Vienna model, with a c-statistic in the validation
cohort of 0.626 compared with 0.646 (the optimism adjusted discrimination – see Table 5) for the
derivation data, indicating a reduction in the discriminatory performance of the model in a new setting.
The true calibration of the model in the validation data could not be assessed without the baseline hazard
function.55 As the original Vienna model was developed using a Cox model which does not parameterise
the baseline hazard function, this meant that assumptions about the shape of the baseline hazard function
had to be made.54,56 The authors recalibrated the Vienna model assuming a Weibull distribution; however,
because this new component of the model was developed, this new model would itself require further
external validation.56 As the authors could not use the Cox model directly to predict survival probabilities
(due to the lack of baseline hazard function), they could only assess calibration using the prognostic
index to make predictions within the validation data.55 Comparison of observed and expected survival
probabilities in five risk groups showed a general trend for the Vienna model to underpredict the risk of
VTE recurrence at 12 months post cessation of therapy.54
Discussion
The systematic review of prognostic models for recurrence risk identified three full-text articles developing
three independent prognostic models, or clinical decision tools,2,9,41 from 257 eligible full texts which met the
full inclusion criteria. Data extraction of the three included articles showed that study characteristics and
patient populations differed in some respects, particularly in terms of the definition of unprovoked VTE and in
the number of patients and events included within their analyses (seeMain study and patient characteristics).
A critique of the included studies described and identified the strengths and weaknesses of the studies with a
particular focus on methods of patient selection, outcome reporting, predictor selection, sample size, model
development and validation (see Description, critique and main findings of model studies).
Data extraction highlighted the variable definitions of unprovoked VTE across the included studies
(see Table 2). Eichinger et al.2,42 excluded patients provoked by use of female hormones, such as the OC
pill or HRT, whereas Rodger et al.9 and Tosetto et al.41 defined patients taking hormones as unprovoked.
Risk factors consistently defined as provoking across the studies included surgery, trauma, immobility and
pregnancy. The use of varying definitions to describe the unprovoked population creates confusion as to
what population the proposed models apply to. Tosetto et al.41 justify including hormone intake as
unprovoked because evidence suggests hormone therapy is a weak risk factor for VTE.41,44 However,
hormone intake should be considered as a transient risk factor, provoking initial VTE but an easily
removable risk factor, whereas unprovoked VTE is not categorised by removable risk factors. Further
research in developing prognostic models to predict recurrence risk in an unprovoked population should
use a standard, consistent definition, excluding transient/removable risk factors to ensure that model
predictions are reliable for intended patients. Given the definition of unprovoked VTE used by Tosetto
et al.,41 the proposed DASH score is not applicable within an unprovoked population as it is defined in this
report (see Chapter 1).
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Across the included studies various predictors were included within the proposed final models, with sex,
age and D-dimer level being included consistently within all three models, indicating strong evidence of an
association with recurrence risk. As such, any future model development should investigate the effect of
these predictors (along with other important predictors) in multivariable modelling due to their repeatable
association with recurrence.
Quality assessment based on an early version of the PROBAST showed that there was evidence throughout
the included studies of a moderate to high risk of bias, predominantly because of a lack of external
validation (see Tables 4 and 5). The HER DOO 2 model9 development suffered high risk of bias, and some
marked methodological issues, including the choice of analysis model, substantially underpowered
analyses, data-driven categorisation of predictors, lack of adjustment for optimism and the presentation of
the model for use. The Vienna prediction model2,42 and DASH score41 were more methodologically sound
than the HER DOO 2 model,9 but had moderate risk of bias due to a lack of external validation. Both had
statistical power to investigate their candidate predictors, accounted for optimism in their selection
procedures and Eichinger et al.2,42 assessed continuous predictors without categorisation and loss of
information (though Tosetto et al.41 did categorise continuous predictors). Both studies presented their
proposed models more clearly than the HER DOO 2 model;9 indicating the recurrence rate associated with
predictor values and the uncertainty around those estimates. However, predictions are only provided for
particular, discretised values of risk; for example, both models provide predictions for only a small selection
of time points (Vienna model for 12 and 60 months post therapy, DASH score for 1, 2 and 5 years from
cessation of therapy), and both models only provide 95% CIs for a small selection of predicted annual
recurrence rates. However, until further external validation is undertaken, the true performance in new
populations cannot be ascertained. Further research should aim to consider some of the issues discussed
here with regard to study quality to improve the performance of any proposed models within practice,
provide transparent reporting of model development and finally to improve statistical analyses to ensure
model predictions are more robust.
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Chapter 4 Development and validation of a
prognostic model and clinical decision rule
Introduction
The aim of this chapter is to describe the development and validation of a prognostic model for the risk of
recurrent VTE on cessation of therapy following a first unprovoked VTE. Seven RCTs57–63 from the RVTEC
database (see Chapter 1) were used to develop the model and externally validate it using IECV; further
external validation was then sought in the RIETE and MEGA databases (see Chapter 1).
Evidence from the systematic review of existing prognostic models to predict recurrence risk highlighted
several applicability and methodological issues in existing models (see Chapter 3). There was a lack of
consistent and appropriate definitions for a first unprovoked VTE, with some studies, for example, not
considering hormone intake to be a provoking risk factor.9,41 Several methodological issues were also
identified, including mishandling of continuous predictors in analyses, underpowered analyses and poor
presentation of final models for use in practice. Existing models identified by the systematic review
(see Chapter 3) had not been externally validated (to date), and though internal validation had often been
performed, external validation is essential to indicate true performance of the model in practice.
The prognostic model will be used in subsequent chapters to inform a clinical decision rule for treatment
cessation following initial therapy for a first unprovoked VTE and subsequent cost-effectiveness analysis
(see Chapter 5).
Methods
The aims and methods for data collection, patient inclusion, model development and model validation are
now described.
Identifying, obtaining and cleaning individual patient data
Individual patient data were identified for the project through external collaborators in Spain, the
Netherlands and Canada. Agreement on the sharing of this data was made with each database holder,
clearly stating the intended use of the data for this project and agreeing appropriate recognition for those
that originally collected the data to be used.
Three IPD databases were provided by the external collaborators:
1. RIETE database (Spanish registry data)
2. MEGA database (Dutch)
3. RVTEC database (Canadian).
The RIETE database (www.riete.org) is primarily a Spanish registry which has recorded 40,000 consecutive
patients with confirmed VTE, 30,000 of which are a first episode. There are 15,041 patients who have had
a first episode of unprovoked VTE with at least 3 months’ follow-up. The database contains 6291 patient
records with a median of 6 months’ follow-up data post treatment. The total number of recurrent episodes
of VTE within this population is 742.
The MEGA database is a population-based prospective cohort study including 5961 patients consecutively
enrolled from two centres in the Netherlands which was compiled between 1999 and 2004. Within the
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database there are 1218 patients with a first episode of unprovoked VTE with 278 patients sustaining a
recurrence; the median follow-up post treatment is 67 months.
The primary database for use in developing the model is the RVTEC database which contains seven trials
investigating an association between D-dimer, measured after anticoagulation was stopped and VTE
recurrence. It includes a total of 1634 patients with a first unprovoked VTE; the median follow-up time
post-treatment is 22 months and there are 230 recurrent events post treatment. This database was
prioritised because of (i) the availability of D-dimer values, which clinical members of the team thought
might add considerable predictive value, and (ii) the seven trials in the database allowed IECV,64,65 a novel
way to develop a model while also examining its performance in external data.
Population at baseline and outcome of interest
What defined a relevant population?
Unprovoked patients were selected from the RVTEC database by excluding those patients with a history of
provoking risk factors within the last 3 months, based on the definition of unprovoked VTE as discussed in
Chapter 1, where provoking risk factors included:
l major surgery
l lower limb trauma
l pregnancy
l combined OC pill/HRT
l significant immobility
l active cancer.
Baseline characteristics of the Recurrent VTE Collaborative databases
The characteristics of the population of the seven trials in the RVTEC database at baseline were
summarised using means and standard deviations (SDs) for continuous variables, and using counts and
percentages for categorical variables. Variables available in the database to be considered for inclusion in
the model included patient’s age, sex, D-dimer post treatment, time from treatment cessation to D-dimer
testing (lag time), treatment duration, BMI and site of index event.
Baseline patient characteristics were summarised first for the whole database and second by individual
trial. A summary of the number of recurrent events, total patients, as well as the median and longest
follow-up for each of the seven trials was also presented to describe the recurrent events within the RVTEC
database. The percentage of missing data within the whole database was also presented by each
candidate prognostic variable.
Outcome of interest
The outcome of interest was the recurrence of a VTE following cessation of therapy for a first
unprovoked VTE.
Available candidate predictors
Seven candidate predictors were available within the RVTEC database and all were considered for inclusion




l site of index event (distal DVT/proximal DVT/PE)
l treatment duration before cessation of therapy (months)
l D-dimer level post cessation of therapy (ng/ml)
l lag time between cessation of therapy and measurement of D-dimer (days).
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All candidate factors were continuous except for sex and site of index event which were categorical, with
sex being dichotomous (male/female) and site of index event having three categories (proximal DVT, distal
DVT, PE). Patient age and BMI were measured at cessation of therapy.11
Aims: develop and validate two models, based on different start points
Given the available candidate predictors two models were consider for development based on the timing
of predictor measurement. Most predictors were available at the cessation of therapy. However, D-dimer
was measured after some lag time from cessation of therapy, to allow for the effects of therapy on
D-dimer to diminish. The average lag time was around 37 days post therapy within the RVTEC database,
whereas the standard lag time is around 30 days post therapy.66 Thus two models were considered: pre
D-dimer (start point at cessation of therapy) and post D-dimer (start point at the time of D-dimer
measurement) (Figure 2).
Pre D-dimer model: start point at cessation of therapy
The first aim was to develop a prognostic model which could be used to predict individual’s risk of
recurrent VTE at the time of cessation of therapy. As such, candidate predictors would include age, sex,
BMI, site of index event and treatment duration. Such a model could be used to obtain individual risk
predictions at the exact time when cessation of therapy is being considered. This could therefore inform
decisions on whether or not to continue or stop therapy, based on a patients predicted risk of recurrence,
balanced against the risk of bleeding and patient preference.
Post D-dimer model: start point when D-dimer measured
The second aim was to utilise D-dimer post cessation of therapy to potentially improve the predictive
performance of the prognostic model, as the predictive ability of D-dimer is well documented2,11,58,60,61,67–70
Such a model could be used to inform a decision on extended duration of therapy in patients who have
already stopped therapy for a given lag time. All seven candidate predictors could be included for predictor
selection in the model.
Univariable (unadjusted) summary of candidate predictors
The univariable (unadjusted) association between each variable and recurrence was assessed using a Cox
proportional hazards model,71 so as to assess the impact of each variable individually in relation to
recurrence. A summary table of the univariable association with recurrence for each candidate variable was
presented, including the estimated HR with 95% CIs and the corresponding p-value.




Start point for use
of pre D-dimer
model








FIGURE 2 Timeline of patient therapy and start points for pre and post D-dimer use.
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Development of prognostic model
Sample size considerations
A general rule of thumb is for at least 10 events to be available for each candidate predictor considered
in a prognostic model.51 There were seven candidate predictors (age, sex, site of VTE, BMI, D-dimer
post-treatment, lag time and treatment duration) for consideration, but some of these were continuous
predictors, which may potentially require non-linear modelling (e.g. fractional polynomials) that would
slightly increase the number of variables further (e.g. if age+ age2 is included, then ‘age’ relates to
two predictors).
The RVTEC database has seven trials in total, with 1634 patients with follow-up information
post-treatment and 230 of these have a recurrence [there is good follow-up (median 22 months) and
nearly all patients have data on all seven candidate predictors available]. During the IECB procedure
(see Internal–external cross-validation), six of the seven trials are used for model development, so there are
between 1196 and 1543 patients and between 161 and 221 recurrences available for the development
phase of the prognostic models. Thus, there will be at least 23 (= 161 events divided by seven candidate
predictors) events for each of the seven candidate predictors, which is considerably greater than the
minimum 10 per variable required, this gives adequate scope for fractional polynomial modelling of
non-linear trends as necessary. Subsequently, the sample size for the development of the prognostic model
is suitable. Furthermore, the external validation databases also had large numbers. The RIETE database has
6291 patients with follow-up information post-treatment and 742 of these have a recurrence (though only
10% of patients have D-dimer values). The MEGA database has 1218 patients with follow-up information
with 278 recurrences (though none have D-dimer levels and so cannot be used to externally validate the
post D-dimer model).
Model structure
As the outcome of interest was time to event (time to recurrence), prognostic models were developed
using a flexible parametric survival model, fitted using the methods of Royston and Parmar.72,73 Flexible
parametric models allow first, a risk score to be calculated for an individual patient, which is the
combination of parameter estimates (log-HR estimates) from the model with the individual patient’s values
for the predictors included in the model; and second, the probability of recurrence by particular time points
to be estimated for an individual patient, by utilising the risk score alongside the estimated baseline hazard
in the population.
The flexible parametric survival methods of Royston and Parmar72,73 model the baseline hazard (on the
log-cumulative hazard scale) using restricted cubic splines and, under a proportional hazards assumption,
produce hazards ratios that are very similar to a Cox regression. The advantage of modelling the baseline
hazard explicitly is that individual risk can be predicted over time and predicted individual survival curves
obtained. In contrast a standard Cox regression approach does not model the baseline hazard and so does
not allow individual prediction, with patients generally categorised into a number of risk groups based on
their risk score. The Royston and Parmar models were fitted using maximum likelihood estimation via the
stpm274 command in Stata 12.1 (StataCorp LP, College Station, TX, USA), with extension to random
effects (frailty modelling) as required. Model assumptions (e.g. proportional hazards) and model fit were
suitably checked throughout (see Model checking).
Modelling baseline hazard
A key part of model development in the Royston and Parmar framework is to estimate the baseline
hazard. First, the spline complexity for the baseline hazard which best fits the available data was
investigated visually and through model fit statistics, considering possible degrees of freedom (df) ranging
from 1 df to 5 df. Cubic splines in the Royston and Parmar framework allow the baseline hazard to be
modelled more flexibly than a standard parametric model (such as the Weibull model), better capturing the
true form of the underlying hazard.75
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Comparisons were made between models with different df using the Akaike information criterion (AIC)
and Bayesian information criterion (BIC) statistics, with smaller values preferred. The AIC and BIC provide a
measure of how well the model fits the data, while penalising models with greater complexity.76 The AIC
and BIC are somewhat subjective in isolation and therefore should be compared as a difference relative
to the lowest value. As a guideline when comparing models, a difference of < 2 (in AIC or BIC) would
provide strong evidence of an appropriate model fit, differences between 4 and 7 weaker evidence and
differences > 10 essentially no evidence of a strong model fit.76 For example, when comparing a model
with additional predictors to a model without, a difference of < 2 in the AIC or BIC would suggest that the
additional predictor is not required to improve the model fit.
Accounting for clustering by trial
Recall that the RVTEC database contained seven trials and so accounting for clustering of patients within
trials is potentially important. During model development a comparison of the baseline hazards across the
trials was carried out. If the shape and magnitude of the baseline hazard was similar between trials a
simplistic model would consider using a common baseline hazard for all seven trials. This could be achieved
by stacking all seven trial data sets into one large data set and ignoring the clustering of patients within
trials, thereby calculating a single baseline hazard. However, ignoring the clustering of patients within trials is
known to create bias in the predictor–outcome associations.52 Therefore, if the baseline hazard between
trials did not appear similar, clustering of patients within trials was accounted for by allowing for any
between-trial heterogeneity in the baseline hazard across trials.52 This was achieved using flexible parametric
models with a random-effect on the baseline hazard, thereby producing a weighted mean baseline hazard
and an estimate of between-study variability around this mean. This approach thus allows a separate
baseline hazard for each trial and estimates the distribution of these (proportional) baselines across trials.65
The average baseline hazard was taken as the baseline hazard to be used in the final model, though it was
recognised that large between-study variability in the baseline may affect calibration of the model in some
populations. This would be investigated using IECV (see Internal–external cross-validation).
Predictor selection and specification
In order to identify a suitable set of predictors within the risk score for the prognostic model, the
multivariable fractional polynomial (MFP) algorithm described by Sauerbrei and Royston49 and Sauerbrei
et al.50 was used. The MFP algorithm selects predictors and their transformations as appropriate using a
backward selection process with a nominal alpha of 0.15 used to warrant exclusion from the model and
prevent overfitting. However, variables considered to be of clinical importance were forced to remain in
the model, where clinical evidence suggested that they were strong predictors of outcome (see Selection
of predictors and model estimates during internal–external cross-validation cycles). The MFP algorithm
allows continuous variables to be modelled appropriately using fractional polynomials for non-linear
trends50 as opposed to being categorised, which has been discussed throughout the literature as
suboptimal (e.g. leading to a loss of power).46–48
Where a final model could be developed, a potential interaction effect between the candidate predictors,
age and D-dimer, was considered based on clinical judgement and prior external evidence of a potential
interaction effect. Potential time-dependent effects (non-proportional hazards) were also evaluated for the
final models.
Handling missing data
Complete case data were used in the development of all models. As a sensitivity analysis, and under the
assumptions of a missing at random (MAR) mechanism, multiple imputation was used to impute missing
values of patient-level data for the predictors included in the final model so as to avoid excluding patients
from the analysis.77 Model coefficients were compared with those of the complete case as a sensitivity
analysis. Data omission may not have occurred at random, but rather selectively (i.e. selectively missing
data). To give an indication whether or not missing data were indeed missing at random, summary
statistics for population characteristics were compared between complete cases and those with
missing information.
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Multiple imputation uses the distribution of the observed data to estimate the missing data, incorporating
the uncertainty associated with imputing unknown values.78 It follows three steps. First, missing data are
imputed several times, creating several new data sets of imputed data. Second, each of the new imputed
data sets are analysed identically; the results will vary because different values will have been imputed for
the missing data in each new data set. Third, the estimates from each of the analysed data sets are
combined using Rubin’s rules.79
As there was more than one predictor with missing data to be included in the model, multiple imputation
by chained equations was used. This approach uses a set of imputation equations including one for each
of the predictors with missing data; all equations include all of the predictors of interest. Missing values for
the first predictor are imputed by initially regressing the predictor on all other predictors of interest and
then drawing from the corresponding posterior predictive distribution of the predictor.78 The second
predictor with missing values is imputed in the same manner, but includes the imputed values of the first
predictor in the regression model. The imputation is repeated for all predictors with missing values and this
forms one cycle; cycles are repeated to stabilise the results and then the whole process is repeated to
create a set of m imputed data sets. As a rough guide, the number of imputed data sets should equal the
largest proportion of incomplete data observed within individual trial populations,78 in this analysis 48%
was the largest proportion of incomplete data, resulting in 50 imputed data sets being used.
Multiple imputation was performed assuming that all missing variable data was MAR. This missing data
mechanism assumes that the probability of an observation being missing is dependent on the observed data.80
For example, where missingness may be dependent on patients BMI, missing data may lead to a subgroup of
the population without clinically obese patients being recorded. Specification of the imputation models should
take into account all predictors within the analysis model; including more predictors within the model makes
the MAR assumption more plausible by potentially including factors that may explain the missingness. As a
survival model was used in the final model development, predictors for the observed recurrences and the
baseline hazard were also included within the imputation models as suggested by White et al.78
In order to ensure that the results of the multiple imputation are reproducible (delivering the same
conclusions when repeated), the Monte Carlo (MC) error of the results was examined. The MC error
equates to the SD of the estimated statistic; for example, a HR, across all repetitions of the imputation
procedure. As a rule of thumb described by White et al.78 the MC error of a derived estimate should be no
greater than 10% of the estimates standard error to give an appropriate level of consistency. To achieve a
MC error of this level requires approximately a number of imputed data sets, m, equal to or greater than
the percentage of missing information,78 in this case 50 imputed data sets were used.
Assumption checks and sensitivity analyses
Continuous predictor variables were assumed to be normally distributed and this assumption was checked
using graphical methods. After inspection of the distribution of candidate factors a log-transformation was
applied as necessary to achieve approximate normality (prior to the use of the MFP algorithm). Influence of
individual data points was assessed by plotting leverage residuals against fitted data. The proportional hazards
assumption for each predictor was tested using scaled Schoenfeld residuals plotted against the variable of
interest. Plots of Martingale residuals against continuous covariates were used to assess their functional form.
Deviance residuals were used to identify outliers. When running the final model, sensitivity analyses were
performed by excluding any outlying values and checking the robustness (accuracy) of the model to these.
Internal–external cross-validation
Internal–external cross-validation framework
The model development strategy outlined in Development of prognostic model was implemented within
the framework laid out by Debray et al.65 for developing, implementing and evaluating clinical prediction
models using an IPD meta-analysis (IPD from multiple studies). This approach adapts the IECV procedure
first described by Royston et al.,64 whereby N-1 trials are iteratively selected from the N total trials in the
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IPD meta-analysis, and the prognostic model is developed within this subset of trials, leaving the remaining
trial for validation of the model (Figure 3). Thus, N different models are derived (one for each set of
included trials) and each is subsequently validated in the other omitted trial. In this manner, it is possible to
investigate (across all permutations of the excluded trial) whether or not model performance remains
consistent when applied in another trial’s population that is not included during model development
(external validation).
Validation performance statistics
For each cycle of the IECV approach, the Royston and Parmar model was developed and estimated
according to Development of prognostic model, thereby producing a model with an average baseline
hazard and risk score equation for the included predictors. The performance of this model was then
assessed in the excluded validation trial based on both its discrimination and calibration.81
The discriminatory ability of the developed model (to distinguish between those who will and those who
will not have a recurrence) was examined in the external data set using Harrell’s c-statisitc82,83 with
bootstrap (1000 resamples) 95% CIs. Larger c-statistics indicate a greater degree of separation in a
prognostic models risk score, with a c-statistic of 1 showing perfect discrimination and a value of 0.5
showing no discrimination beyond chance.
Calibration of the developed model was assessed by comparing E/O probabilities of recurrence over time,
both visually and statistically. To do this, in the external data set each individual’s predicted probability of
recurrence was calculated over time and the population average of these predicted survival curves was
then plotted against the Kaplan–Meier curve of observed event risk over time in the population. Excellent
calibration would be revealed by the Kaplan–Meier and predicted survival curves matching closely.
To quantify differences in the curves for each group at particular time point, the observed recurrence-free
probability (from the Kaplan–Meier curve) and the predicted recurrence-free probability were calculated,
and then their difference calculated with 95% CIs. A difference of zero would indicate perfect calibration.
Meta-analysis to summarise performance
Development and validation was repeated across all cycles of the IECV, each time excluding a different trial
from model development for external validation (see Figure 3). Therefore across all cycles, n of each
validation statistic was obtained (n discrimination statistics, and n calibration statistics at each time point,
etc.). For each statistic, a random-effects meta-analysis was undertaken to summarise the performance
across all cycles of the IECV. This analysis weights by the inverse of the variance of each omitted study’s
estimated statistic plus the estimated between-study heterogeneity in the true statistic value. The model
was estimated using the method of moments (DerSimonian and Laird), giving an estimate of the average
Exclude a trial
Develop model
Validate model using excluded trial
Repeat steps 1–3 for a different omitted trial, until all trials
have been omitted







FIGURE 3 Schematic of IECV approach.
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statistic, the between-study heterogeneity in the statistic and a 95% prediction interval for the statistic in
an external validation population.17 Good prognostic models would have excellent average estimates for
each calibration and discrimination statistic, and ideally have little or no heterogeneity in the statistic across
different external validation populations.
Production of final model after completion of internal–external
cross-validation
If the meta-analysis showed that the performance of the model produced by the IECV approach was
consistently good across all cycles, then a final model was developed using all the trial data combined,
with clear guidance for how to use the model to make individual predictions of recurrence risk over time.
However, where model performance was not consistently good across each cycle, trials in which the model
performed badly in external validation were identified and investigated for any unusual features. Potential
trial features that may lead to poor validation included different methods of measuring variables or
different treatment strategies. Where trials with poor validation were identified a model based on a set of
IPD, excluding these trials was considered.
Finally, where a suitable model was identified, the performance of simpler versions was also examined, to
check whether or not adequate model performance could be achieved with fewer included predictors, so
as to ensure the simplest and most easily applicable, yet accurate model for clinical practice was derived.84
External validation of performance
Where possible the final developed models were also externally validated in data outside of the RVTEC
database, using the same validation techniques for calibration and discrimination as described in
Internal–external cross-validation, by applying it to those patients in the RIETE and MEGA databases. All
these patients are independent of model development and thus help gauge generalisability (also called
transportability) to other populations.
Of the seven candidate predictors available for consideration, the variables age, sex, site of index event,
treatment duration and BMI were available in all databases. D-dimer levels post-treatment and time from
treatment cessation to D-dimer testing were only available in the RVTEC database. Thus, the MEGA and
RIETE databases could only be used to validate a prognostic model without D-dimer variables included (the
pre D-dimer model). However, validation of a prognostic model including D-dimer variables was still
possible in the RVTEC database through the IECV procedure, as discussed above (see Development of
prognostic model).
Comparison to existing prognostic models
The performance of any existing prognostic models or decision rules identified by the systematic review
(see Chapter 3) were examined in the RIETE, MEGA and RVTEC databases, if the necessary predictors
within these models were available in these databases. In particular, comparisons were made of their
performance in relation to the newly developed model.
NB: the following results sections are split into three parts to aid clarity. Part I summarises the
characteristics of the individuals and their candidate predictor values in the RVTEC database. Part II
summarises the development and validation of the pre D-dimer model. Part III summarises the
development and validation of the Post D-dimer model.
Results I: summary characteristics of available data
Within this section a description and summary of the individuals and candidate predictors in the RVTEC
database are presented.
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Description of data
Summary statistics for the baseline patient characteristics and available predictors in the RVTEC database
are described in Table 6 and show that across the whole database there were 230 recurrent events out of
1634 patients with a first unprovoked VTE. There are some trials with very small numbers of recurrences,
for example Tait et al.63 and Shrivastava et al.,62 with 17 and 9 recurrent events respectively. Other trials
are larger, with the Eichinger et al.60 trial having the largest number of events and patients, with
69 recurrent events out of 391 patients. The exclusion of hormone-related index VTE events, in line with
the definition of unprovoked VTE within the study (see Population at baseline and outcome of interest),
showed that there were 14 hormone-related recurrent events excluded.
The median follow-up across all seven trials was 22 months, with the longest follow-up being almost
10 years in the Eichinger et al.60 trial, giving sufficient follow-up time to yield meaningful conclusions from
the prognostic model.
Summary statistics for each of the candidate predictors are also presented in Table 6, with continuous
predictors described as means and SDs and categorical predictors described as counts and percentages.
Across the seven trials patient age appeared to be similar, with an overall average age of 61 years for the
whole population. Treatment duration appeared generally similar across trials, with an average across trials
of around 12 months, and the greatest average treatment duration seen in the Palareti et al.58 trial of
21 months. D-dimer levels appeared to have large variability, with high SDs and two trials having
noticeably lower mean D-dimer levels (Poli et al.59= 432 and Eichinger et al.60= 490). There may be
significant outliers causing the large variation seen in D-dimer levels recorded in each trial and this was
investigated in the exploratory analysis (see Distribution of candidate predictors, correlation and outliers).
The mean BMI across the seven trials was around 28 kg/m2; however, there was a large proportion of
missing data across the trials for BMI. There were also missing data from one trial for lag time, but overall
across the trials there was an average lag time of around 38 days, with the greatest mean lag time being
143 days in the Shrivastava et al.62 trial. The percentage of males and females were consistent across the
trials (see Table 6), as were the proportions of index site, except for distal DVT where the Eichinger et al.60
trial had a noticeably greater proportion of patients with a first distal DVT, possibly explained by
differences in inclusion criteria across the studies (Table 7).
A summary of the percentage of missing data across the trials, and as a whole, is presented by candidate
predictors in Table 8. As mentioned previously, there were a large number of missing data across the trials
for the candidate factor BMI, with around 57% of BMI data missing over the whole database. This mostly
consisted of three trials (Palareti et al.57,58 and Poli et al.59) where patient BMI data were not originally
recorded, but there were also a significant number of missing BMI data in the Baglin et al.61 trial (27% missing).
Across the trials there were also missing data on D-dimer values and lag time, with 15% and 11.4%
missing respectively. There was a large percentage of missing D-dimer values in the Palareti et al.58 (38%)
and Poli et al.59 (48%) trials. Lag time data were not available by individual patient within the Baglin et al.61
trial, though D-dimer was reported to have been measured between 1 and 2 months after cessation of
therapy.61 No missing data were present for the age, sex, treatment duration or site of index event variables.
Given that no BMI data was recorded for any patient in three of the trials,57–59 and the need to recognise
the clustering of patients within the same trial, it was not deemed sensible to impute these missing values
using the data available from the other trials in which BMI was recorded.85 Therefore, in the primary
analyses for both models (pre and post D-dimer models), utilising all seven trials’ data, it was decided to
exclude BMI as a candidate predictor due to the number of missing data.
Other candidate predictors were known in all studies for at least some patients. As there was a degree of
missing data in these candidate predictors (D-dimer, lag time, treatment duration), a sensitivity analysis
imputing any missing information was considered. Therefore, as mentioned in the methods section above
(see Development of prognostic model), prognostic models were developed based first on a complete case
scenario and second on a scenario using multiple imputation techniques to impute missing patient data.
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Comparisons were made between the two scenarios in terms of the models’ predictive performance
(calibration and discrimination), to ascertain if models based on multiple imputation improved or changed
performance importantly (see Sensitivity analysis).
Distribution of candidate predictors, correlation and outliers
An exploratory analysis was performed on each of the candidate predictors, first considering their
empirical distributions and assessing these for normality using histograms and normal probability plots
(see Appendix 4), with transformations considered as appropriate where there were departures from
normality. Possible outliers were inspected, with erroneous patient values leading to removal of patient
data, and outliers deemed to be extreme (but plausible) considered for sensitivity analysis to assess their
effect on the final model. Associations between the candidate predictors were investigated using
scatterplots (see Appendix 4) and correlation statistics (Table 9) for continuous factors, and box plots
(see Appendix 4) to assess the relationship between categorical and continuous factors.
TABLE 8 Percentage of missing data for candidate predictors
Candidate factor Palareti57 Palareti58 Poli59 Tait63 Eichinger60 Baglin61 Shrivastava62 All
Age 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
BMI 100.0 100.0 100.0 0.0 1.8 27.0 0.0 56.9
Treatment duration 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
D-dimer 0.0 38.4 48.1 0.0 0.0 0.0 2.2 15.0
Lag time 0.0 0.0 0.0 0.0 1.0 100.0 5.5 11.4
Sex 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Site of index event 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
TABLE 7 Inclusion and exclusion criteria of trials within the RVTEC database11
Trial Inclusion criteria Exclusion criteria
Palareti57 First VTE Lupus anticoagulant
Palareti58 First unprovoked VTE Recent pregnancy or puerperium, leg fracture, immobilisation for > 3 days,
surgery, APS, active cancer, antithrombin deficiency, serious liver or renal
disease, other indication or contraindication for anticoagulation, limited life
expectancy, geographic inaccessibility
Poli59 First unprovoked VTE APS, active cancer
Tait63 Acute VTE (last 5 weeks) Life expectancy < 3 months, anticipated duration of OAC > 1 year,
unavailable for follow-up
Eichinger60 First unprovoked VTE Surgery, pregnancy or trauma in previous 3 months, cancer, APS, natural
coagulation inhibitor deficiency, long-term anticoagulation
Baglin61 First VTE Postoperative or pregnancy-associated VTE, APS, cancer, thrombosis within
6 weeks of surgery, other indication for prolonged anticoagulation
Shrivastava62 First unprovoked VTE Surgery or trauma within 90 days of first VTE, APS, previous or active cancer,
life expectancy < 3 years
APS, antiphospholipid antibody syndrome.
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The candidate factors of patient age and BMI were found to be approximately normally distributed, with
some extreme values identified (patient ages of 0 years and BMI values < 10 kg/m2) which were removed
from the data set as erroneous data. D-dimer score, lag time and treatment duration were all found to
have a strong positively skewed empirical distribution and a log-transformation was therefore considered in
order to approximate normality (for histograms and normal plots of transformed factors see Appendix 4).
Patients with treatment durations > 1000 days were removed as this was considered erroneous data based
on clinical expertise.
Continuous candidate predictors were examined visually using scatterplots (see Appendix 4, Figure 63) and
empirically using correlation coefficients (see Table 9). It is clear from Table 9 that there were low to moderate
correlation between the continuous candidate factors and visual inspection of the scatterplots confirmed
these findings. The strongest correlation was between age and log-D-dimer, which was 0.5 (see Table 9).
Investigation of relationships between continuous factors and categorical factors for sex and site of index
event was undertaken using box plots (see Appendix 4, Figures 64–75). Across the five continuous factors
considered for inclusion there appeared to be no distinct differences between males and females, or between
proximal DVT, distal DVT and PE based on visual examination of the box plots. There were several outliers
observed in the box plots, particularly for treatment duration and lag time, but also in the other candidate
factors. When establishing the final prognostic models a sensitivity analysis was performed by excluding any
outlying values for any predictor and checking the robustness of the model to these extreme values.
Results II: development and validation of pre D-dimer model
The results of model development and validation for the pre D-dimer model to predict risk of VTE
recurrence are now described.
Complete case data
The complete case data for the development of the pre D-dimer were almost identical to the original
RVTEC database described in Table 6. Given the predictors included in the pre D-dimer model (see Aims:
development and validate two models, based on different start points), there was no missing predictor
information (see Table 8) and therefore no patients were excluded due to missing data. Eight patients
were excluded based on the exploratory analysis conducted above (see Distribution of candidate
predictors, correlations and outliers). As discussed previously, extreme values of predictors were excluded
from the data set; age equal to 0 years (n= 1), BMI < 10 kg/m2 (n= 3) and treatment durations > 1000 days
(n= 4). These exclusions led to a reduction in overall sample size to 1626 patients, but did not affect the
number of included events, remaining at 230 recurrent events (Table 10).
Univariable analysis
Initial univariable analyses were performed by fitting each candidate predictor against recurrence
individually using a Cox proportional hazards model, to assess the association between each predictor and
recurrence. Summaries of the univariable association between each predictor and recurrence including the
HR and a 95% CI are presented in Table 11.
TABLE 9 Correlation coefficients between continuous candidate predictors
Candidate factor Age BMI Log-D-dimer Log-lag time Log-treatment duration
Age 1.00
BMI –0.03 1.00
Log D-dimer 0.50 0.02 1.00
Log lag time 0.02 0.14 0.08 1.00
Log treatment duration –0.13 0.06 –0.06 –0.02 1.00
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The results of the univariable analysis for the pre D-dimer scenario (see Table 11) show that unadjusted
HRs for patient age and treatment duration are close to 1, with HRs of 0.997 (95% CI 0.99 to 1.02) and
1.005 (95% CI 0.99 to 1.02) respectively. As these are continuous predictors, the HRs compared the
change in rate of VTE recurrence for each 1-unit change in the predictor, and so HRs close to 1 may
actually have a large impact when multiplied by a large predictor value. However, CIs for both predictors
included 1, with large p-values, providing no statistical evidence that the unadjusted recurrence rate was
affected by age or duration of treatment. Conversely, the effect of male sex appears to be significantly
different from 1 with a HR of 1.83 (95% CI 1.36 to 2.46), indicating that the unadjusted recurrence rate is
around 80% higher for men than for women. Compared with distal DVT, both proximal DVT and PE have
a greater than fivefold increase in recurrence rate, with HRs of 5.74 (95% CI 2.12 to 15.53) and 5.36
(95% CI 1.96 to 14.65) respectively. Although sex and site of index event appear to have significant
prognostic value independently, multivariable analysis will assess whether or not they retain prognostic
value when adjusted for other predictors (see Development of multivariable prognostic model).
Development of multivariable prognostic model
Given its large number of patients relative to the other trials, the Eichinger et al.60 trial was forced to remain
in the development data set throughout all cycles of the IECV approach. Therefore no model was built
without the Eichinger et al.60 trial population and subsequently no external validation was performed in the
Eichinger et al.60 trial. The trial was included in all models developed because it was the largest population
available and therefore would have a large impact on any final model produced. Thus, although there were
seven trials available, there were only six cycles of the IECV approach for the pre D-dimer model.
Baseline spline complexity
In order to consider the complexity (number of knots) required for the baseline spline function a series of
preliminary models were fit with varying numbers of knots for the spline function. Comparisons were then
made between the models using the AIC and BIC statistics, with smaller values preferred. Although simply
concerned with the complexity of the model there is no need for variable selection and so a saturated
model is fit, assuming linearity for continuous predictors.75
Table 12 shows the AIC and BIC values for proportional hazards models with between 1 df and 5 df for
each of the seven models fitted (seven cycles of the IECV), where the model is built using a derivation data
set based on six trials excluding the trial named in the column header. For simplicity at this stage, the
clustering of patients within trials was ignored and so the set of six trials used in each cycle of the IECV
approach was analysed as one large data set.
Given that lower values of the information criteria represent a better fit, it can be seen that, in general,
across the seven derivation data sets a model with 3 df minimises the BIC. The lowest values of AIC vary
between 3 df and 5 df across the derivation data sets, but the unit value of the AIC actually varies very
little. The BIC often selects simpler models because increasing numbers of parameters carry greater
TABLE 11 Univariable analysis of the pre D-dimer model candidate predictors
Candidate factor HR Lower 95% CI Upper 95% CI p-value
Age 0.997 0.989 1.006 0.513
Treatment duration (months) 1.075 0.859 1.346 0.526
Sex
Male 1.828 1.360 2.458 < 0.001
Site of index event
Proximal DVT 5.735 2.118 15.529 0.001
PE 5.360 1.961 14.648 0.001
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penalties on the BIC,76 as such increasing the number of df increases the internal knots used and so
inflates the number of parameters giving higher BIC values.
A strong tendency for BIC towards 3 df and a relatively small unit difference in AIC between a 3 df model
and the model with the minimum AIC value was observed. The greatest difference between the minimum
AIC and that of a 3 df model was around 4, with the majority of differences being < 2 (see Development
of prognostic model). Visually a convergence in the survival curves at higher df could be seen (Figure 4)
and the curve with the lowest number of internal knots was the 3 df model. Therefore given these results,
3 df were selected to represent the baseline spline complexity for models in the pre D-dimer scenario.
This relates to a baseline spline function with four knots.
Baseline hazard within and across trials
Investigation of the baseline hazard function using a null model (with no predictors) within each trial in the
RVTEC database was undertaken to ascertain whether or not the shape and magnitude of the baseline
hazards in each trial were noticeably different from one another.
TABLE 12 Comparison of df for baseline spline complexity across derivation data sets for the pre D-dimer model
Information criterion df
External validation trial namea
Palareti57 Palareti58 Poli59 Tait63 Baglin61 Shrivastava62
AIC 1 1523.6 1449.0 1603.8 1661.6 1511.1 1721.3
2 1513.0 1438.2 1589.4 1652.5 1501.3 1707.6
3 1503.8 1425.4 1582.7 1639.7 1489.7 1693.0
4 1503.7 1425.1 1582.8 1638.3 1488.5 1693.0
5 1499.5 1425.9 1581.6 1637.0 1490.2 1692.2
BIC 1 1546.6 1471.8 1627.1 1685.1 1533.8 1745.1
2 1539.3 1464.3 1616.0 1679.4 1527.3 1734.8
3 1533.5 1454.7 1612.5 1670.0 1518.9 1723.6
4 1536.6 1457.7 1616.0 1671.9 1521.0 1726.9
5 1535.7 1461.7 1618.1 1673.9 1525.9 1729.6
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1 df: AIC = 1523.6, BIC = 1546.6
2 df: AIC = 1513.0, BIC = 1539.3
3 df: AIC = 1503.8, BIC = 1533.5
4 df: AIC = 1503.7, BIC = 1536.6
5 df: AIC = 1499.5, BIC = 1535.7
FIGURE 4 Comparison of baseline spline complexity with differing numbers of internal knots (example shown for
development data set excluding the Palareti et al.57 trial).
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Figure 5 illustrates the baseline hazard function within each trial population plotted against years from
cessation of therapy. It is clear that for all trials there is a similar peak in hazard at just under 1 year from
cessation of therapy; however, this peak is of varying magnitude across the seven trials. There is also a rise
in the baseline hazard seen in the Poli et al.59 trial after 2 years from cessation of therapy, which is not
seen in the other trials; however, this was considered to be potentially due to the small number of
individuals in this trial, as illustrated in Figure 6 by the large CI surrounding the tail of the hazard function.
Given the differences seen in the magnitude of the hazard function for each trial, it was deemed
appropriate for model development to include a random effect on the baseline hazard, to allow for
variability in the baseline hazard between trials. However, given the similarities in the general shape of the
baseline hazard function in individual trials, it was deemed appropriate to assume the baseline hazards for
the trials were proportional to one another.
Selection of predictors and model estimation
Candidate predictors were entered into the MFP algorithm of Royston and Sauerbrei49 and Sauerbrei
et al.50 (see Development of prognostic model).
Candidate predictors considered for variable selection in the pre D-dimer model were age, sex, site of
index event and treatment duration (see Aims: develop and validate two models, based on different start
points). The results of variable selection for the pre D-dimer model using a random effect on the baseline
hazard are shown in Table 13 and reveal that very similar coefficient estimates were obtained across all
cycles of the IECV.
Throughout the cycles, the only factors selected for inclusion in the model were sex and site of index
event; with both factors showing similar effect sizes to those estimated through univariable analysis
(see Table 11). The HR for male compared with female sex ranges from 1.62 to 1.97, indicating a higher
recurrence rate in males compared with females. The 95% CIs estimated for the effect of sex are
substantially larger than seen in univariable analysis, suggesting greater uncertainty surrounding the
adjusted HR for sex.
Hazard ratios for proximal DVT range from 5.87 to 6.17, showing a greater recurrence rate for patients
with proximal compared with distal DVT. Similarly, HRs for PE compared with distal DVT show higher
recurrence rates in patients with PE. The estimated CIs for site of index event appear to be smaller than
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FIGURE 5 Baseline hazard within each trial for the pre D-dimer scenario (null model).
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FIGURE 6 Baseline hazard within each trial with 95% CIs for the pre D-dimer scenario (null model). (a) Palareti;57
(b) Palareti;58 (c) Poli;59 (d) Tait;63 (e) Eichinger;2,42 (f) Baglin;61 and (g) Shrivastava.62
TABLE 13 Model coefficients for the final selected model in each IECV cycle for the pre D-dimer model
Trial excluded
Candidate factors, HR (95% CI)
Sex, male
Site of index event
ConstantProximal DVT PE
Palareti57 1.92 (1.37 to 2.70) 5.93 (2.03 to 17.36) 5.26 (1.8 to 15.4) 0.01 (0.00 to 0.03)
Palareti58 1.8 (1.28 to 2.53) 6.05 (2.19 to 16.72) 5.7 (2.01 to 16.13) 0.02 (0.01 to 0.06)
Poli59 1.73 (1.27 to 2.35) 6.17 (2.11 to 18.07) 5.58 (1.86 to 16.71) 0.01 (0.00 to 0.03)
Tait63 1.97 (1.45 to 2.68) 6.05 (2.07 to 17.71) 5.58 (1.86 to 16.71) 0.01 (0.00 to 0.03)
Baglin61 1.62 (1.19 to 2.20) 5.87 (2.00 to 17.19) 5.99 (2.05 to 17.54) 0.01 (0.00 to 0.03)
Shrivastava62 1.82 (1.36 to 2.43) 5.99 (2.07 to 17.34) 5.16 (1.78 to 14.94) 0.02 (0.01 to 0.06)
DOI: 10.3310/hta20120 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 12
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Ensor et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR




The final step of the IECV approach (see Internal–external cross-validation) is to assess model performance
within the validation trial, at each cycle of the IECV approach. As the validation trial was excluded from
model development, the performance of the model within this data set can be deemed as external
validation. Model performance is now assessed in terms of both discrimination and calibration (see
Internal–external cross-validation).
Discrimination and calibration results for each cycle of the IECV for the pre D-dimer model are presented in
Table 14, under a random-effects assumption on the baseline hazard. c-statistic estimates for the developed
model range from 0.47 in the Tait et al.63 trial to 0.58 in both the Palareti et al.58 and Poli et al.59 trials.
A random-effects meta-analysis of the c-statistics from each validated model (each cycle of the IECV)
provides a pooled estimate of the performance across all developed models (Figure 7). A random-effects
meta-analysis was performed as there were expected to be different discriminatory effects within each
validation trial, as opposed to one true c-statistic in all trials as assumed under a fixed-effects meta-analysis.
The pooled c-statistic of 0.56 (95% CI 0.51 to 0.60) represents the overall weighted average c-statistic from
all validation trials, showing poor discriminatory ability of the models developed in the cycles of the IECV
approach. However, as this is a weighted average of the performance within each validation trial, it is
expected that the discrimination would average out to that of a model built using the whole data set. In this
case it is of more interest to examine the heterogeneity across the trials and the 95% prediction interval.86
The prediction interval provided is a useful tool for interpreting the potential range of performance of the
new model in a new setting (where the model will be applied), by accounting for the uncertainty in the
pooled estimate, the heterogeneity between trials and the between trial SD.17 The interval suggests that
the c-statistic for the model used in a new setting could vary anywhere between 0.49 and 0.62, which
represents a potentially broad range of performance from awful discrimination to a higher but still
quite poor level. The heterogeneity, or variability, across the trial populations appears to be minimal
(I2-statistic= 0), indicating that the discrimination of the model appears consistent in new populations and
that any variation is due to chance.17 However, as this zero heterogeneity is only an estimate, its uncertainty
is propagated in the 95% prediction interval, which is why the prediction interval is so wide.
TABLE 14 Summary statistics for discrimination and calibration of the pre D-dimer model
Summary
statistics
External validation trial, estimate (95% CI)
Palareti57 Palareti58 Poli59 Tait63 Baglin61 Shrivastava62
Recurrences/
total patients









































































S(t) – Sˆ(t), expected minus observed proportion survived at time point t.
Note
S(t) is the probability of recurrence.
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Calibration is examined visually across all time points in Figure 8. It is then quantified further in Table 14 at
four time points: 6 months, 1 year, 2 years and 3 years after cessation of therapy. The model appears to be
well calibrated (see Table 14), with expected minus observed, S(t) – Sˆ(t), probabilities with a recurrence very
close to zero and 95% CIs including zero across all cycles of the IECV. Plots of the observed probability of
recurrence (based on the Kaplan–Meier survival estimates) compared with the expected probability of
recurrence (based on the predictions of the model) are presented for each validation trial in Figure 8. A
perfectly calibrated model would give a predicted curve very similar to the observed Kaplan–Meier curve,
which can be seen for validation trials Palareti et al.57 and Poli et al.59 Within the remaining validation trials
the developed model either over or underpredicted the probability of recurrence, compared with the
observed probabilities within the validation trial. For example, over prediction can be seen in the Palareti
et al.58 trial beyond 6 months post cessation of therapy (see Figure 8). Plots of the S(t) – Sˆ(t) statistic and
95% CIs for each validation trial can be seen in Figure 9, showing the difference in proportion survived
remains close to zero over time from cessation of therapy.
The pooled calibration from a random-effects meta-analysis gives an overall S(t) – Sˆ(t) statistic of zero
(95% CI –0.03 to 0.03) at 1 year post cessation of therapy (Figure 10), showing excellent calibration on
average. However, there appears to be large heterogeneity across trials, with an I2-statistic of 71.5%
suggesting that the calibration of the model is not consistent in all populations. Indeed, the 95% prediction
interval ranges from 0.1 to –0.09, indicating that the discrepancy in the predicted and true observed S(t)
could range from 0.1 to –0.09 in a particular population. The wide CI is also a reflection of uncertainty in
the heterogeneity estimate. Similar results can be seen for a random-effects meta-analysis of calibration
statistics at 2 years post cessation of therapy (Figure 11) showing consistent agreement on average in the
validation trials at 2 years.
In summary, discrimination of the model developed is generally poor with c-statistics ranging from 0.47
to 0.58 (see Table 14 and Figure 7); other published clinical prediction models have shown stronger
discriminatory ability.87 Furthermore, although on average across all trials calibration appears good, there is
a large amount of heterogeneity in calibration performance across the different trial populations.
.       (0.49 to 0.62)With estimated predictive interval








0.56 (0.51 to 0.60)
0.56 (0.44 to 0.65)
0.52 (0.34 to 0.69)
0.47 (0.31 to 0.61)
0.57 (0.48 to 0.65)
c-statistic (95% CI)
0.58 (0.50 to 0.67)
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FIGURE 7 Random-effects meta-analysis of c-statistic estimates obtained from each external validation of the pre
D-dimer models from the IECV cycle.
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FIGURE 8 Observed vs. expected recurrence probabilities over time, obtained from each external validation of the
pre D-dimer models from the IECV cycle. (a) Palareti;57 (b) Palareti;58 (c) Poli;59 (d) Tait;63 (e) Baglin;61 and
(f) Shrivastava.62 (continued )
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FIGURE 8 Observed vs. expected recurrence probabilities over time, obtained from each external validation of the
pre D-dimer models from the IECV cycle. (a) Palareti;57 (b) Palareti;58 (c) Poli;59 (d) Tait;63 (e) Baglin;61 and
(f) Shrivastava.62
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FIGURE 9 Expected minus observed probabilities with a recurrence for each validation trial for the pre D-dimer
model. (a) Palareti;57 (b) Palareti;58 (c) Poli;59 (d) Tait;63 (e) Baglin;61 and (f) Shrivastava.62
Exp-obs, expected–observed. (continued )
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FIGURE 9 Expected minus observed probabilities with a recurrence for each validation trial for the pre D-dimer
model. (a) Palareti;57 (b) Palareti;58 (c) Poli;59 (d) Tait;63 (e) Baglin;61 and (f) Shrivastava.62
Exp-obs, expected–observed.
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.       (– 0.10 to 0.08)With estimated predictive interval
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0.01 (– 0.05 to 0.08)
– 0.05 (– 0.08 to – 0.02)
0.03 (– 0.03 to 0.08)
Exp-obs (95% CI)
0.06 (– 0.02 to 0.14)
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0.0– 0.16 – 0.08 0.08 0.16
FIGURE 11 Random-effects meta-analysis of calibration performance (at 2 years post therapy) estimates from each
external validation trial in the IECV cycles for the pre D-dimer model. Exp-obs, expected–observed.
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– 0.00 (– 0.03 to 0.03)
0.00 (– 0.03 to 0.03)
0.01 (– 0.04 to 0.05)
Exp-obs (95% CI)
0.06 (0.00 to 0.11)
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FIGURE 10 Random-effects meta-analysis of calibration performance (at 1 year post therapy) estimates from each
external validation trial in the IECV cycles for the pre D-dimer model. Exp-obs, expected–observed.
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Final pre D-dimer model
Although model performance was generally weak, it was considered important to present a final pre
D-dimer model for future research to build on. The final model therefore used the data from all trials and
estimated predictor effects and the baseline hazard with a random effect on the baseline hazard to allow
for trial differences.
A description, performance and sensitivity analyses of the final model is now discussed.
Specification and parameter estimates
The pre D-dimer model was fitted to the whole data set, with the candidate predictors for patient age, sex,
treatment duration and site of index event (distal DVT, proximal DVT and PE) considered. A random-effects
model on the baseline hazard was estimated using a Royston and Parmar model with 3 df on the
proportional hazards scale. The MFP algorithm was used to perform predictor selection as described
previously (see Development of prognostic model); subsequently, only sex and site of index event were
selected for inclusion in the final pre D-dimer model. The estimated HRs for included predictors remained
similar to those seen throughout the IECV cycles as expected (Table 15). Sex and site of index event had
large HRs consistent with the literature.2,7,88 Male sex was associated with an almost 80% increase in
recurrence rate compared with females (HR 1.79, 95% CI 1.33 to 2.41), whereas proximal DVT and PE
were associated with around a sixfold increase in recurrence rate compared with patients with a first distal
DVT (see Table 15).
To make predictions from the model, Equation 1 (equation to predict probability of recurrence-free survival
at time t) is required:
S(t) = S0(t)
expðβχÞ, (1)
where for the pre D-dimer model, βχ within Equation 1 is the risk score which is equal to Equation 2
(risk score equation for the pre D-dimer model):
βχ = (058 × Sex if Male) + (1:82 × Site if Proximal DVT ) + (1:71 × Site if PE), (2)
and where S0(t) is the average baseline survival function at a specific time t, which is shown in Figure 12 up
to 4 years post cessation of therapy. Values of S0(t) can be read from the Kaplan–Meier plot at specific time
points (see Figure 12), as presented in Table 16 for 6 months, 1, 2 and 3 years post cessation of therapy.
Equation 1 allows the prediction of a recurrence-free survival probability at a particular time point after
cessation of therapy, meaning that the probability of recurrence by a specific time point, R(t), is defined by
Equation 3:
R(t) = 1−S(t). (3)
TABLE 15 Final specification and estimates for the pre D-dimer model after fitted to all trial data, with a random
effect on the baseline hazard
Predictor Beta coefficient (95% CI) HR (95% CI) p-value
Sex
Male 0.58 (0.29 to 0.88) 1.79 (1.33 to 2.41) < 0.001
Site of index event
Proximal DVT 1.82 (0.76 to 2.88) 6.17 (2.13 to 17.86) 0.001
PE 1.71 (0.64 to 2.79) 5.55 (1.90 to 16.23) 0.002
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The apparent calibration of the predicted probability of recurrence to the observed probabilities
(Kaplan–Meier estimates) within this whole trial data set appeared under visual inspection to calibrate well
up to 4 years from cessation of therapy (Figure 13). This is expected, as the model is estimated on the
same data set, so the apparent calibration is naturally a good fit.
The probability of recurrence over time from cessation of therapy varies across the risk spectrum,
illustrating what happens to individuals at the edges of the risk spectrum.75 It can be seen that individuals
in the 90th centile of the distribution of the prognostic index having higher probability of recurrence
compared with those in the 10th centile of the prognostic index (Figure 14). However, the range of
discrimination for the model appears to be limited, with little gap between some centiles, which
corresponds with the discrimination statistics observed during model development (see Model validation).
This is expected, as the IECV showed the discrimination is low, with the average c-statistic of 0.56 across
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FIGURE 12 Average baseline (recurrence-free) survival function [S0(t)] for the pre D-dimer model.
TABLE 16 Baseline (recurrence-free) survival at particular time points to combine with patient-specific predictor
values for individual risk prediction (pre D-dimer model)
Model predictor
Time from cessation of therapy
6 months 1 year 2 years 3 years
S0(t) 0.9938 0.9895 0.9835 0.9780
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Model checking
The final model above was checked in terms of proportional hazards assumptions, functional form of
continuous predictors (non-linear trends), outliers, leverage, interactions and time-dependent effects (see
Appendix 5). There was no evidence of any concerns and no indication that the model could be improved
or modified in regard these aspects. None of the predictors had missing observations (see Table 8) and,
as such, a sensitivity analysis using multiple imputation was not required.
External validation in RIETE and MEGA data sets
Two independent databases were available for potential external validation of the pre D-dimer prognostic
model (see Identifying, obtaining and cleaning individual patient data). First, the RIETE database, a Spanish
registry database containing approximately 15,000 unprovoked VTE patients. Second, the MEGA database
containing almost 5000 patients with a first unprovoked VTE from two centres in the Netherlands.
RIETE data set
The RIETE database contained factors describing the site of index event but only described categories in
terms of either (1) DVT and PE, (2) DVT or (3) PE. The site of index event factor used in the development of
the pre D-dimer model included categories for distal DVT, proximal DVT and PE, therefore breaking down
the types of DVT into the lower-risk distal DVT and higher-risk proximal DVT. As no other information was
provided within the RIETE database, with regard to site of index event, the required categories as described
in the development database could not be recreated. Therefore the pre D-dimer model unfortunately
could not be validated in the RIETE database.
MEGA data set
Within the MEGA data set there was no variable describing the site of index event using the same
categorisation as the RVTEC database, which was essential for validation of the developed models.
To overcome this, a separate variable identifying the patients site of index event in categorisations
representing the vein or artery location was recategorised according to Martinelli et al.89 (Table 17). After
recategorisation, summary statistics showed a small number of distal DVT’s (6.5%) compared with the
higher-risk proximal DVT (29%) and PE (42%) (Table 18).
The median follow-up within the MEGA database was around 69 months providing substantial
information on patient’s long-term prognosis. Summary statistics from the MEGA database, for the
predictors included within the pre D-dimer model, are presented in Table 18. The average (mean) age of
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FIGURE 14 Probability of recurrence across the risk spectrum (the pre D-dimer model).
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The summary statistics appeared to indicate that the population in the MEGA database was different in a
number of ways to that of the RVTEC database. The distribution of index events was different between the
two databases with the proportion of proximal DVTs around double that seen in the MEGA data set
(58.9% to 29.4%). The RVTEC population had a higher average age (approximately 60 years) and greater
proportion of males (approximately 60% males) (see Table 18).
To assess the external performance of the pre D-dimer model, predicted risk of recurrence over time was
calculated for all individuals in the MEGA data set using the pre D-dimer model equation as shown in
Specification and parameter estimates (see Equation 1). The predicted recurrence probabilities were
compared with the true observed recurrence probabilities estimated by a Kaplan–Meier survival curve
(Figure 15). On visual inspection the expected probability of recurrence appeared to be overpredicted
slightly up to 1 year from cessation of therapy and underpredicted beyond 1 year post therapy. This was
reflected in the expected minus observed statistics at 6 months, 1 year, 2 years and 3 years post cessation
of therapy (Table 19). CIs for S(t) – Sˆ(t) showed increasing uncertainty over time from cessation of therapy,
TABLE 17 Reclassification of site of index event in MEGA database
Original MEGA classification Recategorisation to concur with RVTEC
Isolated inferior vena cava Proximal DVT
Isolated iliac vein Proximal DVT
Iliofemoral vein Proximal DVT
Isolated femoral vein Proximal DVT
Popliteal-iliofemoral vein Proximal DVT
Popliteal-femoral vein Proximal DVT
Isolated popliteal vein Proximal DVT
Distal Distal DVT
PE PE




Follow-up (months)a 69.3 (16.4–91.9) 22.1 (14.2–32.0)
Ageb 49.37 (13.28) 62.2 (15.1)
Sexc
Female 2588 (54.14) 633 (38.9)
Male 2192 (45.86) 993 (61.1)
Site of index eventc
Distal DVT 311 (6.51) 112 (6.9)
Proximal DVT 1404 (29.37) 957 (58.9)
PE 2025 (42.36) 557 (34.3)
Unspecified 1040 (21.76) 0 (0)
a Median (interquartile range).
b Mean (SD).
c Count (%).
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with the greatest difference in probability of recurrence at 3 years from therapy. Predictions appeared to
calibrate very well at 1 year from cessation of therapy with a difference of < 0.1 in the percentage of those
observed and expected to have a recurrence by 1 year. Before 1 year and after 1 year the calibration is not
as close, but the difference in observed and expected percentage with a recurrence is quite small. In terms
of discrimination the c-statistic for the pre D-dimer model within the MEGA database remained similar to
that seen in the RVTEC database (0.56). This again indicates poor ability to separate high- and low-risk
patients. Moreover, the performance seen in the MEGA data set lies well within the 95% prediction
interval (0.49 to 0.62) estimated from the random-effects meta-analysis of c-statistics from the IECV
approach (see Figure 7).
External validation by risk groups in RIETE and MEGA data sets
Though Figure 15 shows calibration in the overall data set is reasonable, Figures 16–18 and Table 20
reveal that calibration in categories of risk is less adequate. In particular, in the lower predicted risk
categories (e.g. < 3%), the observed risk is noticeably higher.
A comparison of the characteristics of patients classified as low risk in the two data set populations was
performed (Table 21). There appeared to be some distinct differences between the two low-risk
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FIGURE 15 Calibration of the pre D-dimer model predicted probability of recurrence (expected) compared with
observed probabilities (from Kaplan–Meier curve) within the MEGA external data set.
TABLE 19 Performance statistics for the pre D-dimer model validation in external MEGA data set
Statistic
Time from cessation of therapy
6 months 1 year 2 years 3 years
Observed %a 1.49 4.92 9.41 12.73
Expected %a 3.13 4.99 7.04 8.71
Expected % –
observed %b
1.64 (1.29 to 1.29) 0.06 (–0.58 to 0.71) –2.37 (–3.27 to –1.48) –4.02 (–5.06 to –2.98)
c-statistic (MEGA) 0.56 (0.54 to 0.57)
c-statistic (RVTEC)c 0.56 (0.51 to 0.60)
a Percentage with a recurrence (%).
b Difference in percentage with a recurrence (%) with 95% CI.
c The summary c-statistic across all cycles of the IECV approach.
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FIGURE 16 Comparison of observed and expected probability of recurrence at 1% annual recurrence risk threshold
within the MEGA data set (external validation of decision rule).
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FIGURE 18 Comparison of observed and expected probability of recurrence at 5% annual recurrence risk threshold
within the MEGA data set (external validation of decision rule).
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FIGURE 17 Comparison of observed and expected probability of recurrence at 3% annual recurrence risk threshold
within the MEGA data set (external validation of decision rule).
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(see Figures 16–18). The greatest difference was in the proportion of patients suffering higher-risk index
events. In the RVTEC database only patients suffering a distal DVT were classified as low risk, whereas
in the MEGA database 42% of patients classified as low risk suffered a PE, which is associated with a
significant increase in risk of recurrence (see Table 15). This increased risk due to site of index event
explains the higher observed risk of recurrence in the ‘low-risk’ category for the MEGA data set and
therefore the poor fit of the decision rule (which is based on a lower-risk population from the
RVTEC database).
As such, the external validation of the risk groups derived from prognostic model does not appear to
validate well and therefore may be inappropriate for use in new patient populations. This is likely due to
the differences in the two populations risk profiles.
TABLE 20 Comparison of observed and expected probabilities of recurrence at different decision rule thresholds







Proportion of recurrences (%)
6 months 1 year 2 years 3 years
O E O E O E O E
1% Below 732 1.16 0.53 3.48 0.85 5.99 1.21 7.80 1.52
1% Above 4048 1.55 3.60 5.17 5.74 10.00 8.09 13.58 10.01
3% Below 1351 1.72 0.71 5.67 1.15 9.43 1.64 12.33 2.05
3% Above 3429 1.40 4.08 4.64 6.50 9.40 9.16 12.87 11.33
5% Below 2485 1.38 1.71 4.45 2.74 8.20 3.89 10.91 4.84
5% Above 2295 1.61 4.66 5.42 7.42 10.66 10.45 14.60 12.90
E, expected; O, observed.





Follow-up (months)a 69.8 (15.2–92.2) 30.4 (15.8–53.3)
Ageb 48.4 (13.5) 54.2 (13.8)
Sexc
Female 1866 (75.1) 53 (47.3)
Male 619 (24.9) 59 (52.7)
Site of index eventc
Distal DVT 311 (12.52) 112 (100)
Proximal DVT 0 (0) 0 (0)
PE 1134 (45.63) 0 (0)
Unspecified 1040 (41.85) 0 (0)
a Median (interquartile range).
b Mean (SD).
c Count (%).
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This external validation therefore confirms the findings of the IECV approach: the final pre D-dimer model
is unlikely to be suitable given its poor discrimination ability and heterogeneity in calibration performance
across different populations. Further predictors are required to improve the model, building on the model
presented here as a basis.
Summary
The final pre D-dimer model proposed in this chapter contained site of index event and sex as predictors.
It forms a starting point for individual recurrence risk prediction at the time of stopping therapy, to help
inform immediate decisions on the need for extended therapy. However, throughout the IECV approach
and through external validation of the final model, the performance of the model was rather poor in terms
of discrimination and there was heterogeneity in calibration performance across populations. Thus the pre
D-dimer model should not currently be recommended for use in practice and needs improving. One way
the model performance may be improved is through the inclusion of more candidate predictors, which
may better explain individuals risk and the variation between patients. As such, the next section will
investigate the addition of D-dimer post therapy as a further predictor. D-dimer has been shown to be
predictive of recurrence throughout the literature.2,11,57,60,61,67–70
Results III: development and validation of post D-dimer model
The results of the development and validation of the post D-dimer model for prediction of the risk of VTE
recurrence are now described below. Candidate predictors available for the post D-dimer model were age,
sex, site of index, treatment duration, D-dimer and lag time (the number of days from cessation of therapy
to measurement of D-dimer) (see Aims: develop and validate two models, based on different start points).
This involved six trials within the RVTEC database. For the IECV approach, due to its large size, the
Eichinger et al.60 trial was always included in the model development set of studies and thus there were
five cycles of the IECV approach when it was conducted.
Complete case data
The complete case data for the development of the post D-dimer were somewhat different from the
original RVTEC database described previously in Table 6. Given the predictors included in the post D-dimer
model (see Aims: develop and validate two models, based on different start points), there was missing
predictor information (see Table 8) and therefore these patients with missing data were excluded from
the complete-case analysis. Eight patients were excluded based on the exploratory analysis conducted
previously (see Distribution of candidate predictors, correlation and outliers) and as discussed in Complete
case data. There were substantial missing data for both D-dimer and lag time predictors investigated in
the post D-dimer model; 243 patients were excluded from the analysis based on missing D-dimer levels,
while a further 183 patients were excluded based on missing lag time data (despite having recorded
D-dimer levels). The whole of the Baglin et al.61 trial had to be excluded from the complete-case analysis
due to missing (unspecified) lag time data. These exclusions led to a reduction in overall sample size to
1200 patients and a reduction in the number of included events down to 161 recurrent events (Table 22).
Univariable analysis
Initial univariable analyses were performed by fitting each candidate predictors against recurrence individually
using a Cox proportional hazards model, so as to assess the association between each predictor and
recurrence (ignoring clustering of patients within trials). Summaries of the univariable association between
each predictor and recurrence including the HR and a 95% CI are presented in Table 23. These unadjusted
results do not consider each factor’s independent prognostic association, which is more important for the
prognostic model (see Selection of predictors and model estimates during internal–external cross-validation
cycles), but provide an initial summary.
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TABLE 22 Summary of baseline characteristics and candidate predictors for the complete case data used for
development of the post D-dimer model
Characteristic Palareti57 Palareti58 Poli59 Tait63 Eichinger60 Baglin61 Shrivastava62 All
Recurrences/total 31/280 23/268 12/81 17/99 69/387 – 9/85 161/1200
Follow-up (months)
Median 20.8 20.2 19 21.9 28.5 – 26.2 21.6


























































































Site of index eventb
Distal DVT 12
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Unspecified DVT 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – 0 (0) 0 (0)
a Mean (SD).
b Count (%).
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Univariable analyses of the predictors considered in the post D-dimer scenario (see Table 23) show similar
results for patient age, treatment duration, sex and site of index event to those seen in the pre D-dimer
scenario (see Complete case data). The effect of a patient’s D-dimer score appears to indicate an increase
in recurrence rate of around 70% for every 1 ng/ml increase in D-dimer score, with a HR of 1.716 (95% CI
1.43 to 2.06). Conversely, the lag time between cessation of therapy and measurement of a patient’s
D-dimer appears to decrease recurrence rate by around 20% for every day increase in lag time.
Development of multivariable prognostic model
Baseline spline complexity
In order to consider the complexity (number of knots) required for the baseline hazard spline function in
the post D-dimer model, a series of preliminary models were fit with varying numbers of knots for the
spline function. Comparisons were then made between the models using the AIC and BIC information
criteria statistics, as described previously (see Development of prognostic model). The information criteria
for proportional hazards models fitted for the post D-dimer model through five cycles of the IECV
approach (Table 24) show a similar trend to those seen for the pre D-dimer scenario (see Baseline spline
complexity). The BIC criteria are consistently minimised by a model with 3 df except in one instance where
TABLE 23 Univariable Cox regression analysis of the candidate predictors for the post D-dimer model
Candidate factor HR Lower 95% CI Upper 95% CI p-value
Age 1.003 0.993 1.014 0.513
Treatment duration (months) 1.199 0.926 1.552 0.169
Sex
Male 1.564 1.108 2.207 0.011
Site of index event
Proximal DVT 5.498 2.015 15.007 0.001
PE 5.693 2.060 15.736 0.001
D-dimer (log) 1.716 1.428 2.061 < 0.001
Lag time in days (log) 0.824 0.627 1.083 0.166
TABLE 24 Comparison of df for baseline spline complexity across derivation data sets for the post D-dimer scenario
Information criterion df
External validation trial name
Palareti57 Palareti58 Poli59 Tait63 Shrivastava62
AIC 1 974.0 1026.6 1141.8 1110.5 1173.2
2 969.2 1020.0 1134.6 1106.6 1165.0
3 964.7 1012.6 1128.9 1097.3 1154.4
4 963.2 1012.2 1127.6 1094.0 1153.7
5 962.8 1014.5 1129.4 1095.7 1155.5
BIC 1 999.8 1053.0 1168.8 1137.2 1200.5
2 997.9 1049.3 1164.6 1136.3 1195.2
3 996.2 1044.8 1161.9 1130.0 1187.7
4 997.6 1047.3 1163.6 1129.6 1190.0
5 1000.0 1052.5 1168.5 1134.3 1194.8
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the minimum value is very close (difference < 1) to the BIC for a 3 df model. The AIC is variable, with the
minimum AIC most often occurring for models with 4 df; however, the unit value of the AIC is very close
(difference no greater than three) to that for 3 df models. Given that 3 df minimises the BIC consistently
and the minimal AIC values are close to 3 df models, as well as considering visually the shapes seen in the
baseline hazards for each trial (Figure 19), a complexity of 3 df was deemed appropriate for the post
D-dimer model.
Baseline hazard within trials
Investigation of the baseline hazard function using a null model (with no predictors) was also undertaken
within each trial in the RVTEC database, to ascertain whether or not the shape and magnitude of the
baseline hazard in each trial was noticeably different. Examination of the baseline hazard functions within
each trial (see Figures 19 and 20) shows a similar pattern to that seen for the pre D-dimer investigation
(see Baseline hazard within and across trials). The shape of the baseline hazard across trials is similar, with
a peak in hazard just under 1 year from cessation of therapy and a fall in hazard thereafter. Similarly to the
pre D-dimer scenario, a rise in the hazard after around 1 year is observed in the Poli et al.59 trial, which
contains very low numbers of events (see Complete case data). Although the shape of the baseline hazard
across trials appeared to be homogenous, the magnitude of the baseline hazard varied across
trials distinctly.
Given that the shape of the baseline hazard appeared similar across trials, but there was variation in the
magnitude, it was considered appropriate to develop the post D-dimer model by assuming proportional
baseline hazards across trials and placing a random effect on the baseline hazard. This therefore allowed
estimation of an average baseline hazard across trials and allowed for variability in each trial’s own
baseline hazard away from this average.
Selection of predictors and model estimates during internal–external
cross-validation cycles
Candidate predictors were entered into the MFP algorithm of Royston and Sauerbrei49 and Sauerbrei
et al.50 (see Development of prognostic model).
As mentioned, the Eichinger et al.60 trial was selected to remain in the development data set throughout
all cycles of the IECV approach, therefore no model could be built without the Eichinger et al.60 trial
population and, subsequently, no validation was performed in the Eichinger et al.60 trial. The trial was
included in all models developed because it was the largest population available and therefore would have
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FIGURE 19 Baseline hazard within each trial for the post D-dimer scenario (null model).
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Candidate predictors considered in variable selection for the post D-dimer scenario included age, sex, site
of index event, treatment duration, D-dimer post cessation of therapy and lag time between ceasing
therapy and measurement of D-dimer (see Aims: develop and validate two models, based on different start
points). The results of variable selection and parameter estimates at each cycle of the IECV approach are
shown in Table 25.
Treatment duration was not significant during variable selection and so was excluded from the developed
models in all cycles. The effect of age was estimated in the opposite direction to that estimated in
univariable analysis. All other variable coefficients were estimated to be similar in magnitude to those seen
during univariable analysis for the post D-dimer scenario (see Univariable analysis), although 95% CIs


















































































































FIGURE 20 Baseline hazard within each trial with 95% CIs for the post D-dimer scenario (null model). (a) Palareti;57
(b) Palareti;58 (c) Poli;59 (d) Tait;63 (e) Eichinger;2,42 and (f) Shrivastava.62
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Model validation in the internal–external cross-validation cycles
The final step of the IECV approach (see Internal–external cross-validation) is to assess the developed
model’s performance within the validation trial for each cycle of the IECV. As the validation trial was
excluded from model development, the performance of the model within this data set can be deemed as
external validation. Model performance is now assessed in terms of both discrimination and calibration
as described previously (see Internal–external cross-validation).
Model performance statistics for the post D-dimer model developed in each cycle of the IECV approach are
presented in Table 26 and show c-statistics ranging from 0.65 in the Poli et al.59 trial to 0.80 in the
Shrivastava et al.62 trial. Discrimination overall across all validation trials appears to be substantially greater
than that of the pre D-dimer model (see Model validation), with a pooled c-statistic from a random-effects
meta-analysis (Figure 21) of 0.69 (95% CI 0.63 to 0.75), which reveals moderately good discrimination on
average. Importantly, the observed heterogeneity in the c-statistic is low (I2-statistic= 3%) (see Figure 21),
which indicates that the discrimination performance of the model is very consistent across the different
trial populations. The 95% prediction interval for the c-statistic in a new population is 0.59 to 0.79, which
represents consistently moderate to good discriminatory ability and improves substantially on the pre
D-dimer model which had a prediction interval with a maximum c-statistic of only 0.62 (see Figure 7).
Calibration for the post D-dimer model (see Table 26) was also consistently strong across all cycles of the
IECV up to 2 years post cessation of therapy. The S(t) – Sˆ(t) statistics were close to zero for time points up
to 2 years, but larger discrepancies were apparent thereafter (e.g. in the Palareti et al.58 and Poli et al.59
trials). The close relationship between the models predictions (expected) and the true observed recurrence
risk (observed) up to 2 years can be seen for each trial in Figure 22. There does not seem to be any
systematic under or overprediction in the external validation data sets.
TABLE 25 Model coefficients and selected predictors for each IECV cycle for the post D-dimer model
[beta coefficients (95% CI)]
Candidate predictora
External validation trial name, beta coefficients (95% CI)
Palareti57 Palareti58 Poli59 Tait63 Shrivastava62

































































a Treatment duration was not selected for inclusion in any cycle of the IECV.
Note
An empty cell indicates the predictor was not selected for inclusion in the model.
DOI: 10.3310/hta20120 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 12
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Ensor et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
69
.       (0.59 to 0.79)With estimated predictive interval







0.69 (0.63 to 0.75)
0.67 (0.52 to 0.80)
0.80 (0.68 to 0.93)
0.65 (0.48 to 0.82)
c-statistic (95% CI)
0.66 (0.55 to 0.76)









FIGURE 21 Random-effects meta-analysis of discrimination performance as measured by the c-statistics obtained,
for each cycle of the IECV approach for the post D-dimer model.
TABLE 26 Summary statistics for discrimination and calibration of the post D-dimer model in each cycle of the
IECV approach
Summary statistics
External validation trial, estimate (95% CI)
Palareti57 Palareti58 Poli59 Tait63 Shrivastava62




























































S(t) is the probability of recurrence by time t.
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FIGURE 22 Observed vs. expected within the validation trial for each cycle of the IECV (the post D-dimer model).
(a) Palareti;57 (b) Palareti;58 (c) Poli;59 (d) Tait;63 and (e) Shrivastava.62 (continued )
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A random-effects meta-analysis of the calibration statistics at 1 year post cessation of therapy (Figure 23)
gave a pooled value of –0.02 (95% CI –0.05 to 0.01), indicating close agreement on average in the
validation trials. There is heterogeneity in calibration performance (I2-statistic= 61.7%) and the 95%
prediction interval for the calibration at 1 year in a new population is –0.12 to 0.08. The interval is wide
partly due to the observed heterogeneity, but also partly reflecting the uncertainty in the between-study
heterogeneity estimate (due to there being only five validation trials). Similar results can be seen for a
random-effects meta-analysis of calibration statistics at 2 years post cessation of therapy (Figure 24),
showing consistent agreement on average in the validation trials at 2 years.
Final model: post D-dimer model
Given that the post D-dimer model had moderately good discrimination, with an average c-statistic of 0.69
(similar to other published risk prediction models87) and good calibration on average across trials (especially
up to 2 years), it was deemed appropriate to produce a final D-dimer model based on all the
trials combined.
Thus model development proceeded as before, but now with all six trials included. The specification and
parameter estimates of this final post D-dimer model are now described, alongside sensitivity analysis
evaluating some aspects of model fit.
Specification and parameter estimates
The final post D-dimer model was developed using the whole trial data set, with potential candidate
predictors including patient age, sex, treatment duration, site of index event, D-dimer and lag time as
discussed previously (see Aims: develop and validate two models, based on different start points). A
random effect was placed on the baseline hazard to allow for between-trial heterogeneity (see Baseline
















































FIGURE 22 Observed vs. expected within the validation trial for each cycle of the IECV (the post D-dimer model).
(a) Palareti;57 (b) Palareti;58 (c) Poli;59 (d) Tait;63 and (e) Shrivastava.62
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hazard within trials). The MFP algorithm was used to perform predictor selection, as described previously
(see Development of prognostic model), with patient age, sex, site of index event, D-dimer and lag time
(note the natural logarithm of D-dimer and lag time were used due to skewness) being selected for
inclusion in the final post D-dimer model. Estimated HRs remained similar to those seen through cycles of
the IECV as expected (Table 27), and the effect of age, sex and site of index event was similar to that of
the final pre D-dimer model (see Final pre D-dimer model). D-dimer was associated with a twofold increase
in recurrence rate for every 1 unit increase in log-ng/ml. Lag time was associated with a 25% reduction in
recurrence rate, which is likely to reflect that healthier patients live longer, therefore the more time that
passes before measuring D-dimer, the more likely patients remaining in the trial are healthier and therefore
have a lower recurrence rate (see Table 27).
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FIGURE 23 Random-effects meta-analysis of calibration performance (at 1 year post therapy) within validation
trials across IECV cycles (the post D-dimer model). Exp-obs, expected–observed.
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FIGURE 24 Random-effects meta-analysis of calibration performance (at 2 years post therapy) within validation
trials across IECV cycles (the post D-dimer model). Exp-obs, expected–observed.
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The estimated average baseline S0(t) from this model is shown in Figure 40 and allows practitioners to
estimate the average baseline survival for a specific time point, which can be used to predict recurrence-free
survival probability using Equation 1. Using the post D-dimer model to make predictions for new individuals:
a detailed illustration of the model in practice details how to use the estimated baseline S0(t) in combination
with the estimated predictor effects to make predictions over time for new individuals.
The apparent calibration of the model in the entire data set is excellent, as expected due to the final model
being developed on the same set of data. There is a very slight underprediction at some time points
(Figure 25). A plot of the recurrence probabilities over time in centiles of the distribution of the prognostic
index was used to give an idea of what may happen to individuals at the fringes of the risk spectrum
(Figure 26).75 It is clear from Figure 26 that while the 50th centile corresponds roughly to the predicted
curve seen in Figure 25, there is a marked increase in the probability of recurrence for those in the 90th
centile of the prognostic index. This separation reflects the good discrimination observed during the IECV
approach, where the average c-statistic was 0.69 (see Figure 21). The superior discrimination in the post
D-dimer model compared with the pre D-dimer model is illustrated by far larger separation in the centiles
of risk predictions from the model (see Figures 14 and 26).
Validation of final post D-dimer model in risk groups
Figures 25 and 26 show the apparent overall calibration of the final model across all patients in all trials.
One can also examine the calibration in subgroups of patients, across different risk groups.
TABLE 27 Specification and estimates of the final post D-dimer model fitted to all trial data
Predictor Beta coefficient (95% CI) HR (95% CI) p-value
Age –0.0105 (–0.022 to 0.0011) 0.99 (0.98 to 1.001) 0.075
Sex
Male 0.55 (0.19 to 0.89) 1.72 (1.22 to 2.44) 0.002
Site of index event
Proximal DVT 1.74 (0.67 to 2.79) 5.67 (1.96 to 16.43) 0.001
PE 1.76 (0.68 to 2.83) 5.79 (1.98 to 16.94) 0.001
D-dimer (log) 0.7 (0.51 to 0.89) 2.01 (1.66 to 2.45) < 0.001
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FIGURE 25 Calibration of the post D-dimer model fit to all trial data. KM, Kaplan–Meier.
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Here high- and low-risk groups are considered according to a particular threshold of risk, with 1%, 3%
and 5% risk of recurrence at 1 year from cessation of therapy used. The observed probability of recurrence
within the high- and low-risk groups was compared over time with the expected predictions from the
model (Table 28).
The complete case data set (see Table 22) for the post D-dimer model contained 29, 135 and 292 patients
categorised as low risk at the 1%, 3% and 5% thresholds respectively (see Table 28). The calibration of
the decision rule in the high-risk group across all thresholds considered appeared strong even up to around
3 years post cessation of therapy. Calibration in the low-risk groups was also very close at the 3% and 5%
thresholds, though the smaller numbers of patients classified as low risk at 1% makes the low-risk group
at this threshold hard to examine (Figures 27–29).
Overall the final post D-dimer model appears to calibrate well, and within high- and low-risk groups. As
this validation was performed using patient data also used in the development of the model, it should be
interpreted as merely evidence of a good fit of the model to the data. The true calibration performance in
new data is better revealed by the external validation results from the cycles of the IECV approach, which
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FIGURE 26 Probability of recurrence across the risk spectrum (the post D-dimer model).
TABLE 28 Comparison of observed and expected probability of recurrence at different decision rule thresholds,







Probability of recurrence (%)
6 months 1 year 2 years 3 years
O E O E O E O E
1% Below 29 0.00 0.47 0.00 0.79 0.00 1.28 0.00 1.74
1% Above 1171 5.55 5.43 7.95 8.97 12.91 13.90 17.75 18.29
3% Below 135 0.00 0.93 0.00 1.58 0.96 2.54 2.40 3.45
3% Above 1065 6.10 5.86 8.73 9.68 14.11 14.99 19.69 19.72
5% Below 292 2.09 1.73 2.45 2.93 3.35 4.68 6.43 6.34
5% Above 908 6.49 6.46 9.46 10.65 15.64 16.46 21.32 21.61
O, the observed % of recurrences from a Kaplan–Meier curve; E, the expected % of recurrences from the final post
D-dimer model.
a Risk of recurrence at 1 year after cessation of therapy.
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FIGURE 27 Comparison of observed and expected probability of recurrence in risk groups above or below a 1% risk
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FIGURE 29 Comparison of observed and expected probability of recurrence in risk groups above or below a 5% risk
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FIGURE 28 Comparison of observed and expected probability of recurrence in risk groups above or below a 3% risk
of recurrence (at 1-year) threshold as defined by the post D-dimer model.
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Model checking
During development of the post D-dimer model, a number of assumptions were made and only complete data
were used. The robustness of the final model to these assumptions and other issues is investigated below.
Proportional hazards assumption
A scatterplot of the scaled Schoenfeld residuals against log-time, with a lowess smoother, was used to
check the proportional hazards assumption for factors in the post D-dimer model as described previously
(see Development of prognostic factor). Plots for log-D-dimer (Figure 30) and log-lag time (Figure 31) show
that the proportional hazards assumption is valid for the post D-dimer model; the lowess smoothed line
roughly follows the reference line for each covariates log-HR, indicating proportionality. Similar plots
testing the proportional hazards assumption were inspected for the remaining covariates in the post
D-dimer model, the proportional hazards assumption was valid for all predictors (see Appendix 5).
Functional form
To check that continuous predictors were included in the model with appropriate functional form,
scatterplots of Martingale residuals against the predictors with a lowess smoother applied were inspected.
Patient age, log-D-dimer and lag time were the only continuous predictors included in the post D-dimer
model and the functional form of these covariates was checked using Martingale residuals. Figures 32 and 33
show a lowess smoother applied to a scatter of Martingale residuals against log-D-dimer and log-lag time
respectively. In both cases the smoother appears to follow a linear trend over the covariate values, indicating

















































FIGURE 31 Scaled Schoenfeld residuals vs. log-time from cessation of therapy for log-lag time (HR –0.19).
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As seen for the pre D-dimer model (see Appendix 5), plots of the deviance residuals against a patient
indicator (Figure 34) and against time (Figure 35) indicate some outlying individuals. Figure 34 illustrates a
scatter of the deviance residuals for the post D-dimer model; they clearly do not follow a normal
distribution and this may again be due to heavy censoring in the data set, a small number of individuals
fall above the 1.96 critical z-value.
A plot of the deviance residuals against years from cessation of therapy allows investigation of any trend in
the deviance residuals. In Figure 35 for the post D-dimer model there is again a trend in the deviance
residuals over time based on the cumulative hazard at the event time (or censoring time). The deviance
residuals which lie in the top left of the plot are, as for the pre D-dimer model, likely to be those
individuals who had a recurrence early and therefore did not accumulate much hazard.
Leverage
To check the influence of individuals on the parameter estimates, leverage can be assessed using
delta–beta changes for each covariate as seen in the pre D-dimer model (see Appendix 5). Scatterplots
of delta–betas for log-D-dimer (Figure 36) and log-lag time (Figure 37) show that even individuals with the
greatest leverage on these parameter estimates have very small effects on the log-HR as seen for the pre
D-dimer model. Similar, small delta–beta changes were observed for the other covariates included in
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FIGURE 33 Scatterplot of Martingale residuals against log-lag time (the post D-dimer model).
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FIGURE 36 Scatterplot of delta–beta for log-D-dimer vs. years from cessation of therapy (log-HR 0.666).
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Interaction effects quantify a differential effect of a predictor in a specific subgroup of the population.
An interaction effect can be either an increased risk or decreased risk beyond that associated with a single
characteristic. For example, within the pre D-dimer model, both sex (being male) and site of index event
(having a first PE) are associated with significant increases in recurrence rate; thus, an interaction between
sex and site of index event would imply that patients who are both male and have a PE are at increased
risk beyond that associated with being male or having a PE alone.
As genuine interaction effects are rare and hard to identify, and because data dredging to identify
interactions may find spurious results, the clinical team were asked for their guidance regarding which
interaction terms are most important to examine. The clinical team suggested investigating an interaction
of D-dimer and age, as it was felt plausible that the predictive effect of D-dimer value (a measure of
general coagulability) may change as age increases.
To test for an interaction between age and D-dimer, the final post D-dimer model was refitted including a
term for the multiplication of age and D-dimer score. The interaction effect was shown to be insignificant
at the 5% level, with a 95% CI ranging from 0.98 to 1.01 and a p-value of 0.3 (Table 29). Thus no
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FIGURE 37 Scatterplot of delta–beta for log-lag time vs. years from cessation of therapy (log-HR –0.361).
TABLE 29 Model specification including an age×D-dimer interaction effect (the post D-dimer model)
Predictor Beta coefficient (95% CI) HR (95% CI) p-value
Age 0.026 (–0.048 to 0.101) 1.03 (0.95 to 1.11) 0.49
Sex
Male 0.539 (0.185 to 0.894) 1.71 (1.2 to 2.44) 0.003
Site of index event
Proximal DVT 1.633 (0.623 to 2.643) 5.12 (1.86 to 14.05) 0.002
PE 1.671 (0.651 to 2.691) 5.32 (1.92 to 14.74) 0.001
D-dimer (log) 1.045 (0.309 to 1.781) 2.84 (1.36 to 5.94) 0.01
Lag time in days (log) –0.371 (–0.675 to –0.067) 0.69 (0.51 to 0.93) 0.02
Age ×D-dimer interaction term –0.006 (–0.018 to 0.006) 0.99 (0.98 to 1.01) 0.298
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Further to this, an interaction effect between D-dimer levels and lag time was examined as the two
predictors are inextricably linked; it is plausible that the prognostic importance of D-dimer levels varies over
lag time (the time taken between cessation of therapy and the measurement of D-dimer levels). As
previously, the final post D-dimer model was refitted including a term for the multiplication of D-dimer
level and lag time. The interaction effect was shown to be insignificant at the 5% level, with a 95% CI for
the HR ranging from 0.79 to 1.57 and a p-value of 0.552 (Table 30). Thus no interaction term for D-dimer
and lag time was included in the final model.
Time-dependent effects
Allowing for time-dependent predictor effects might improve the performance of the model if it better fits
the underlying data. Non-proportional hazards can be a sign of a time-dependent effect and, as such,
including time-dependent effects can account for departures from the proportional hazards assumption.
The validity of the proportional hazards assumption was assessed for predictors above (seeModel checking),
and the assumption was considered appropriate for all predictors. It was therefore not expected that any
time-dependent effects would be found to significantly improve the performance of either final model.
To further check this, a procedure proposed by Royston and Lambert75 was used to identify potential
time-dependent effects. The procedure first identifies the p-value associated with including each predictor in
the model as a time-dependent effect using a likelihood ratio test. A time-dependent effect is included for
the predictor with the smallest p-value, providing the p-value is less than a pre-defined alpha significance
level. The process is repeated until no time-dependent effects are significant at the chosen alpha level.
A 1% significance level was selected to test for time-dependent effects so as to account for multiple
testing. The baseline spline function for the post D-dimer model used 3 df (see Baseline spline complexity)
and therefore 3 df were used for the time-dependent effects to allow more flexibility. After one cycle of
the procedure no predictors in the post D-dimer model were found to be significantly time dependent at
the 1% level, though log-D-dimer was close to significance with a p-value from the likelihood ratio test of
0.02 (Table 31). Given the lack of formal significance, and the aim for a more parsimonious model, the
time-dependent effect was excluded.
Sensitivity analysis
Multiple imputation of missing data
As the RVTEC data set used for model development included some missing data for some of the potential
predictors, a complete-case analysis was performed for model development, excluding any patient with
missing data from the analysis. Sensitivity analysis was performed using multiple imputation, to evaluate
how model estimates compared with those from the complete-case analysis.
TABLE 30 Model specification including an D-dimer × lag time interaction effect (the post D-dimer model)
Predictor Beta coefficient (95% CI) HR (95% CI) p-value
Age –0.012 (–0.024 to –0.001) 0.988 (0.976 to 0.999) 0.037
Sex
Male 0.55 (0.2 to 0.91) 1.74 (1.22 to 2.48) 0.002
Site of index event
Proximal DVT 1.65 (0.64 to 2.66) 5.19 (1.89 to 14.24) 0.001
PE 1.68 (0.66 to 2.7) 5.38 (1.94 to 14.92) 0.001
D-dimer (log) 0.31 (–0.86 to 1.49) 1.37 (0.42 to 4.45) 0.601
Lag time in days (log) –1.02 (–3.23 to 1.18) 0.36 (0.04 to 3.27) 0.364
D-dimer × lag time interaction term 0.11 (–0.24 to 0.45) 1.11 (0.79 to 1.57) 0.552
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Of the included predictors only D-dimer and lag time had missing values, with 15% and 11.4%
incomplete data, respectively, across the whole data set of six trials (see Table 8). It was therefore possible
to consider multiple imputation for these two factors within the post D-dimer model. As the RVTEC data
set consisted of multiple trial populations for development of the post D-dimer model, it was important to
account for this clustering when imputing missing observations; imputation across trials can lead to bias
where the association between factors differs by trial.85 As such, missing data for lag time, which were
100% incomplete within the Baglin et al. trial,61 could not be imputed (see Table 8) and so the same set of
six trials (excluding Baglin et al.61) were used as in the complete data analysis for the post D-dimer model.
Imputation models were selected to include all included predictors from the final post D-dimer model as
well as predictors for the observed recurrences (event indicator) and the baseline hazard to account for the
time-to-event outcome;78 imputation was performed within trial populations. The largest proportion of
incomplete data observed within individual trial populations was 48.1% missing D-dimer observations
within the Poli et al. trial;59 therefore, 50 imputed data sets were created to provide the greatest
reproducibility.78 Imputation was performed for 10 cycles within each of the 50 imputed data sets to
stabilise the results.
Box plots were used to check that the distributions of the observed and imputed data broadly matched;
large differences could indicate an inappropriate imputation model.78 On inspection, the imputed
distributions for both D-dimer and lag time (Figures 38 and 39) appeared to be very similar to the
corresponding observed distributions (indicated as zero on the box plots). Therefore the imputation process
appeared to be appropriate.
The model, including all predictors identified as important in the complete-case analysis (age, site of index
event, sex, D-dimer and lag time), was fitted to the 50 imputed data sets and the coefficients of each were
combined using Rubin’s rules79 (Table 32). In comparison with the specification of the post D-dimer model
under a complete-case analysis (see Table 27), the estimated HRs after imputation were reasonably similar.
The effect of each factor within the model did not have a dramatically different interpretation between the
complete case and multiple imputation models. In particular, the effects of D-dimer and lag time are
relatively unchanged with HRs of 1.93 and 0.74 compared with 2.01 and 0.75 for the complete case
model. In general, the 95% CIs were similar with the exception of site of index event where the multiple
imputation model estimated slightly smaller 95% CIs, showing greater precision, likely due to the
increased number of observations. The effect of age and lag time were borderline significantly different
from null in the complete case model, but appeared to be significant in the multiple imputation model.
This adds further weight to the inclusion of age and lag time factors in the prognostic model.
The inclusion of treatment duration as a predictor in the multiple imputation model was investigated given
the increased complete patient data; treatment duration did not reach significance within the imputation
model with a HR of 1.07 (95% CI 0.85 to 1.35) and p-value of 0.574, providing confirmatory evidence
towards the exclusion of treatment duration within the complete case post D-dimer model.
TABLE 31 First cycle of stepwise forward selection of time-dependent effects (the post D-dimer model)
Predictors Deviance difference p-value vs. null
Age 2.49 0.477
Sex (male) 4.491 0.213
Site of index event (proximal DVT) 0.658 0.883
Site of index event (PE) 2.495 0.476
Log-D-dimer 9.68 0.022
Log-lag time 3.98 0.264
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FIGURE 39 Comparison of observed and imputed data for log-lag time (the post D-dimer model).
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To check that the imputation results were reproducible, such that similar conclusions could be drawn from
an identical imputation approach, the MC error of each estimated HR and standard error was checked. The
MC error was measured as a percentage of the standard error of the estimated HR, where an MC error
lower than 10% of the standard error was considered appropriate. The MC errors observed from the
imputation procedure used were all lower than 10%, with the greatest being 5.74% for D-dimer, meaning
that it is highly likely that the results of multiple imputation procedure would lead to consistent conclusions
across the imputed data sets (Table 33).
Summary of sensitivity analysis
Compared with the complete data model, the multiple imputation approach suggests similar conclusions
about the predictors to include and their magnitude of effect. As the complete data model was already
validated during the IECV approach, and it performed well in terms of calibration and discrimination,
it was decided by the team to retain the post D-dimer model as derived using complete data as the final
model. Furthermore, the multiple imputation approach makes the additional assumption about MAR,
which may not hold.
External validation in RIETE and MEGA data sets
Two independent databases (RIETE and MEGA) were available for potential external validation of the
proposed post D-dimer model (see Identifying, obtaining and cleaning individual patient data).
Unfortunately neither included D-dimer or lag time predictors, meaning that the post D-dimer model could
not be externally validated in these databases. However, it should be emphasised that through the IECV
approach external validation has been conducted already as discussed above (see Internal–external
cross-validation).
Summary
Compared with the pre D-dimer model, the performance of the post D-dimer model was substantially
improved in terms of discrimination and it retained good calibration up to at least 2 years post cessation of
therapy. Thus including D-dimer and lag time appears beneficial for improved prediction of recurrence risk
following cessation of therapy for a first unprovoked VTE. Performance may be improved by the inclusion
of further predictors not available in the RVTEC database, but – given the good discrimination and
calibration identified through the IECV external validations – the model appears robust and potentially
useful for informing clinical decisions.
TABLE 32 The post D-dimer model specification following imputation of missing variable data
Predictor Beta coefficient (95% CI) HR (SE) p-value FMIa
Age –0.017 (–0.026 to –0.007) 0.983 (0.974 to 0.993) 0.001 0.032
Sex
Male 0.666 (0.352 to 0.98) 1.946 (1.434 to 2.640) < 0.001 0.007
Site of index event
Proximal DVT 1.662 (0.627 to 2.697) 5.27 (1.933 to 14.368) 0.001 0.001
PE 1.639 (0.596 to 2.683) 5.151 (1.875 to 14.153) 0.002 0.002
Log-D-dimer 0.657 (0.485 to 0.829) 1.93 (1.607 to 2.317) < 0.001 0.169
Log-lag time –0.298 (–0.572 to –0.025) 0.742 (0.555 to 0.992) 0.044 0.167
FMI, fraction of missing information; SE, standard error.
a B/(W+ B); where B is the between-imputations variance and W is the within imputation variance.
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Using the post D-dimer model to make predictions for new
individuals: a detailed illustration of the model in practice
The post D-dimer model has the potential to stratify the largely heterogeneous population of unprovoked
patients, allowing for better decision-making on duration of treatment for these high-risk patients.
Although Final model: post D-dimer model discussed development, assumption checking and external
validation, this section now explains the practical application of the final post D-dimer model.
In order to predict an individual’s risk of recurrence the beta coefficients must be combined with the
baseline risk corresponding to the time that prediction is required for. The equation to combine these
parameters is given below (Equation 4), along with the beta values from the post D-dimer model (see
Equation 5, risk score equation for the post D-dimer model). In Equation 4, S0(t) represents the average




βχ = (−0:0105 × Age) + (0:545 × Sex : Male) + (1:735 × Site: Proximal DVT ) + (1:756 × Site: PE)
+ (0:701 × (Log)D dimer) + (−0:291 × (Log)Lag time).
(5)
TABLE 33 Monte Carlo error acceptability for analysis based on 50 imputed data sets
Predictor HR SE p-value Lower 95% CI Upper 95% CI FMIa
Age 0.98 0.005 0.001 0.97 0.99 0.03
MC error 0.00 6.90 × 10–7 0.000 1.26 × 10–7 1.21 × 10–7 0.01
% of SE 2.50 0.01
Sex (male) 1.95 0.302 0.000 1.43 2.64 0.01
MC error 0.00 0.0003 0.000 0.003 0.005 0.00
% of SE 1.16 0.12
Site (proximal DVT) 5.27 2.694 0.001 1.93 14.37 0.00
MC error 0.01 0.003 0.000 0.01 0.04 0.00
% of SE 0.54 0.12
Site (PE) 5.15 2.653 0.002 1.87 14.15 0.00
MC error 0.01 0.003 0.000 0.01 0.04 0.00
% of SE 0.56 0.13
Log-D-dimer 1.93 0.180 0.000 1.61 2.32 0.17
MC error 0.01 0.001 0.000 0.01 0.02 0.03
% of SE 5.74 0.78
Log-lag time 0.74 0.110 0.044 0.56 0.99 0.17
MC error 0.01 0.002 0.006 0.006 0.009 0.03
% of SE 5.70 1.37
FMI, fraction of missing information; SE, standard error.
a B/(W+ B); where B is the between-imputations variance, and W is the within imputation variance.
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Equation 4 allows the prediction of a recurrence-free survival probability at a particular time point after
cessation of therapy, meaning that the probability of recurrence by a specific time point, R(t), can also be
predicted and is equal to Equation 6.
R(t) = 1−S(t). (6)
The average baseline risk at time t, S0(t), can be estimated for any time t (post cessation of therapy) by
reading off its value from the Kaplan–Meier presented in Figure 40 and provided for specific time points
(6 months, 1 year, 2 years and 3 years) within Table 34.
Example application of the model
As an example of the potential application of the post D-dimer model, three example patients were
created using varying predictor information to illustrate patients at different risk of recurrence (Table 35).
For each of the continuous predictors (age, log-D-dimer and log-lag time), the 25th, 50th and 75th
percentile of the predictors distribution was used for patients A, B and C, respectively, to reflect the RVTEC
database (see Table 22). All three patients were selected as male, and the site of index event was selected
as distal DVT, proximal DVT and PE for patients A, B and C respectively. An example of the risk score
created using these patient characteristics is presented for patient A in Equation 7 (risk score equation for
patient A using the post D-dimer model). Both recurrence-free survival probability and probability of
recurrence were predicted at 1, 2 and 3 years post cessation of therapy for patients A, B and C,
respectively, to show a range of predictions (see Table 35).
βχ = (−0:0105 × Age ( = 51)) + (0:545 × Sex: Male ( = 1)) + (1:735 × Site : Proximal DVT ( = 0))
+ (1:756 × Site : PE ( = 0)) + (0:701 × (Log)D dimer ( = 5:55))
+ (−0:291 × (Log)Lag time ( = 3:14)).
(7)
TABLE 34 Baseline (recurrence-free) survival at particular time points to combine with patient-specific predictor
values for individual risk prediction (post D-dimer model)
Model predictor
Time from cessation of therapy
6 months 1 year 2 years 3 years
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FIGURE 40 Average baseline (recurrence-free) survival function for the post D-dimer model.
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The post D-dimer model predictions are presented in Table 35, with recurrence-free survival probability
and probability of recurrence calculated using Equations 4 and 6 respectively. Predicted recurrence-free
survival probability can be seen to decrease over time for all three example patients (Figure 41). The
predicted S0(t) is markedly different between patient A and the other two patients, this is likely due to
lower values of continuous predictors such as D-dimer and also the low-risk site of index event (distal DVT)
contributing little within the post D-dimer model (see Equation 4) to patient A’s risk of recurrence. Smaller
differences were observed between patients B and C, reflecting the similar effect seen for proximal DVT
and PE index events (see Specification and parameter estimates).
The predicted probabilities of recurrence-free survival can be seen in Figure 41 at points on the predicted
curves corresponding to time from the cessation of therapy. For example, at 1 year from cessation of
therapy, patient A has a predicted probability of recurrence-free survival of 0.985, from Equation 4,
using patient A’s risk score (see Equation 7 and Table 35).
Similarly, the predicted probability of recurrence over time from cessation of therapy can be predicted
using the post D-dimer model (see Equation 6). The probability of recurrence is opposite to the probability
of recurrence-free survival, increasing over time from cessation of therapy (Figure 42). The same trends
seen in Figure 41 between patients A, B and C can be seen in Figure 42 as expected.
TABLE 35 Model parameters for three example patients and recurrence-free survival/recurrence risk predictions
using post D-dimer model
Model predictor Patient A Patient B Patient C
Years from cessation of therapy 1 year 2 years 3 years
S0(t) 0.9993 0.9988 0.9983
Age (years) 51 64 74
Sex
Male 1 1 1
Female 0 0 0
Site of index
Distal DVT 1 0 0
Proximal DVT 0 1 0
PE 0 0 1
D-dimer (ng/ml) 275 417.5 747
Log-D-dimer 5.55 6.03 6.62
Lag time (days) 22 29 33
Log-lag time 3.14 3.4 3.53
Individual prediction 1 year 2 years 3 years
S(t)a 0.985 0.858 0.755
R(t)b 0.015 0.142 0.245
a Probability of recurrence free survival at time t.
b Cumulative probability of recurrence at time t.
DOI: 10.3310/hta20120 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 12
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Ensor et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
87
Comparison with existing prognostic models
It was hoped that the performance of any existing prognostic models or decision rules identified by the
systematic review (see Chapter 3) could be examined within the RIETE, MEGA and RVTEC databases, to
allow comparison across the existing models and in relation to the post D-dimer model, in terms of their
performance. However, the predictors included within the existing models identified through the
systematic review (see Chapter 3), were not all available within any individual database, making validation
and comparison of the existing models impossible.
Discussion
The aim of this chapter was to develop and validate two prognostic models for recurrence of VTE
following cessation of therapy for a first unprovoked VTE: one model for use at the exact time of cessation
of therapy (called the pre D-dimer model) and one model for use after some ‘lag time’ following cessation
of therapy at which D-dimer could be measured (called the post D-dimer model). The key findings of this
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FIGURE 41 Predicted recurrence-free survival for three example patients using the post D-dimer model.
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A detailed and transparent strategy was used for developing the two models using a set of candidate
predictors available in the RVTEC database, a large database containing data from patients enrolled across
seven trials.11 The candidate predictors included a set of potentially important clinical and laboratory
predictors, as evidenced in previous research identified within the systematic review of existing models
(see Chapter 3). A novel IECV approach was used in the development of the model so as to maximise the
benefits of having IPD from several trials. The IECV approach allowed external validation of each developed
model through exclusion of a single trial in cycles (see Development of prognostic model). Therefore,
compared with previous prognostic models in this field (see Chapter 3),2,9,41 external validation was possible
and on multiple occasions. Patients who died without any recurrence were censored, therefore our
predictions relate to a hypothetical world where patients cannot die before a recurrence occurs. The
proportion of deaths before a recurrence is likely to be very small (especially up to 2–3 years follow-up
where the model calibrates well), and therefore the model predictions would not change importantly if a
competing risks model had been used.
Model performance was measured in the validation trials by both discrimination and calibration of the
model. Discrimination was assessed using Harrell’s c-statisitc,82,83 and was far greater for the post D-dimer
model, with the average c-statistic 0.69 in the external validation of this model compared with 0.56 in the
external validation of the pre D-dimer model. The post D-dimer model (see Results III: development and
validation of post D-dimer model), additionally included D-dimer and lag time (see Aims: develop and
validate two models, based on different start points). This suggests that D-dimer and its associated lag
time are important and strong predictors, which add significantly to the discriminatory ability of the model.
The predictive ability of D-dimer has also been evidenced widely by others.2,11,58,60,61,67–70
The calibration of both the post D-dimer model and the pre D-dimer model was, on average across all
external validation trials, very good with close agreement between observed and predicted risk of
recurrence up to at least 2 years. Given that external validation was performed within the IECV and the
average calibration was excellent across trials, it was considered unnecessary to adjust for optimism in
performance (e.g. using bootstrapping). There was heterogeneity in calibration performance across
BOX 1 Key findings of Chapter 4: prognostic model development
l The RVTEC database, containing patients from seven trials, was used to develop and externally validate two
prognostic models for the risk of VTE recurrence following cessation of therapy.
l The first model, the pre D-dimer model, is applicable at the exact time of cessation of therapy. The second
model, the post D-dimer model, is applicable when D-dimer is measured at a particular lag time following
cessation of therapy.
l Both models allowed for heterogeneity in the baseline hazard across trials and the average hazard was
used in the final models.
l IECV allowed each model to be developed and externally validated on multiple occasions.
l The final pre D-dimer model contained three predictors: site of index, sex and age, with the latter retained
on clinical grounds rather than statistical significance.
l The final post D-dimer model contained five predictors: site of index, sex, age, D-dimer and lag time, all of
which were statistically significant.
l The pre D-dimer model had good calibration on average across the external validation trials; however,
discrimination was poor with an average c-statistic of 0.56.
l The pre D dimer model is not suitable for use and requires additional predictors to be included in future research.
l The post D-dimer model had excellent calibration up to at least 2 years on average across the validation
trials; discrimination was also moderately good, with an average c-statistic of 0.69.
l The post D-dimer model is useful for patient counselling and informing clinical decisions, but requires
patients to be off therapy for a lag time, at which D-dimer can be measured.
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different trial populations, likely due to the heterogeneity in the baseline risk across populations; however,
with only five or six validation trials in the IECV approach, it was not possible to estimate heterogeneity
reliably here. Interrogation of the model fit in regard to multiple imputation of missing data, interaction
terms, non-linear trends, outliers and other advanced aspects did not suggest the final models produced
should be modified.
The pre D-dimer model is clearly inadequate, given its poor discrimination. This is not surprising given it
only contained two factors of statistical significance, sex and site of index event. However, in terms of
recurrent VTE events within the standard lag time of around 30 days, there were 20 additional recurrences
which could have been accounted for in the pre D-dimer model, due to the earlier start point, highlighting
the need for a model applicable at cessation of therapy. Therefore further research should build on this
model, by looking to include additional predictors. This is considered further in Chapter 6.
In contrast, given the good discrimination and excellent average calibration, the post D-dimer model would
seem useful for clinical practice. In particular, it could inform patient counselling, and help patients and
their clinicians make decisions about remaining off treatment and continued monitoring. An individual’s
risk predicted using the post D-dimer model should be seen as an additional tool in an evidence-based
approach to patient care, both clinical judgement and patient preference should also be considered
alongside the predicted risk of recurrence. A caveat is that the model can only be applied in patients who
have been off therapy for a certain lag time, at which D-dimer is then measured. In the database, a large
majority of lag times were around 30 days from cessation of therapy11 and so the model is likely to be
most reliable when D-dimer is measured at that time.
Finally it should be noted that a limitation of the developed post D-dimer model is that external validation
within non-trial populations was not possible due to some of the model predictors not being recorded in
these data sets (e.g. D-dimer). Despite performing external validation through the IECV approach, it is clear
that further external validation in non-trial data sets from different sources would be advantageous, and
therefore the post D-dimer model could also be considered at moderate risk of bias (based on the
definition used within the systematic review undertaken in Chapter 3), until such external validation
is undertaken.
The following chapter evaluates the cost-effectiveness of a clinical decision rule to decide on extension of
OAC therapy, with the rule based on an individual’s risk prediction estimates from the post D-dimer model.
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Chapter 5 Economic evaluation
The previous chapter developed two prognostic models, the latter of which (the post D-dimer model) wasconsidered to have good external validity in terms of calibration and discrimination performance.
Therefore, the post D-dimer model is potentially useful for informing clinical practice. When any prognostic
model is used to inform decisions for clinical practice, it should be evaluated like any other health technology;
that is, there should be evidence that the use of the model to inform therapy decisions is cost-effective for
the NHS when evaluated in the context of relevant populations and health outcomes. One mechanism for
implementing a prognostic model is to use it to inform a decision rule, for whether individuals do or do not
receive a particular therapy. In the context of this report, the post D-dimer model could therefore be used to
obtain a predicted probability of VTE recurrence (e.g. by 2 years) for individuals, and if this is at or above a
particular threshold (e.g. 5%) then the individual could be put back onto therapy, but if not (< 5%) the
individual remains off therapy. In this chapter we undertake extensive health economic modelling to
ascertain, under a variety of assumptions, the cost-effectiveness of such a decision rule that uses predictions
from the post D-dimer model to make a decision about continued cessation of therapy or not.
This chapter is in two main parts. The first part describes the methods and results of a systematic review of
cost-effectiveness studies evaluating the use of a decision rule for patients with a first unprovoked VTE. The
second and substantive part of the chapter reports the de novo decision model-based cost-effectiveness
analysis of the use of a decision rule in this patient group.
Systematic review of cost-effectiveness studies
Methods
Search strategy
A comprehensive literature search was conducted to identify papers reporting the costs or cost-effectiveness
of the use of a clinical decision rule compared with the absence of a clinical decision rule for a first
unprovoked VTE. The searches, performed in December 2013, aimed to identify all costing studies,
trial-based economic evaluations and economic models from three electronic databases (EMBASE, MEDLINE
and NHS Economic Evaluation Database). The search strategy used the same terms applied in the clinical
effectiveness review (see Chapter 3), supplemented with relevant economic search terms. Examples of these
search strategies can be found in Appendix 1. The search results were supplemented with any further
economic evaluations and cost studies identified during screening of the literature identified in the
systematic review of prognostic models (see Chapter 3).
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Study selection and data extraction
Two reviewers independently screened titles and abstracts for relevance, using all of the pre-specified
selection criteria (Box 2). Full texts were obtained in any of the following situations: if the article appeared
to fulfil the selection criteria, if it was unclear whether the paper was relevant, or in the case of
disagreement between reviewers. Full-text articles were then independently assessed against the full
criteria (see Box 2) by the two reviewers. Articles not meeting all the criteria were excluded from
subsequent review and the reason for exclusion noted. Articles meeting all the criteria had relevant
information extracted and methodological quality assessed by one reviewer with checking by a second
reviewer. Information extracted included study characteristics, data or parameter estimates, methods of
analysis and results. Studies were quality assessed using the Philips checklist90 for model-based analyses.
Studies that did not meet the inclusion criteria but included potentially useful data for the economic model
were coded for further review at the model building stage.
Results
A total of 1045 records were identified from the searches. Duplicates were removed both automatically
using reference management software and manually. Once duplicates were removed, there were 775
unique records. An initial screening of title and abstracts excluded 734 records, leaving 41 full-text articles
to be accessed for assessment against the full screening criteria. No studies fulfilled the criteria for inclusion
out of the 41 full-text articles assessed for eligibility. The excluded articles are listed in Appendix 6 with
reasons for exclusion. The main reasons for exclusion were an inappropriate study design, the study
population did not fulfil the selection criteria, or the intervention did not include a decision rule. A flow
diagram presenting the process of selecting studies can be found in Figure 43.
Summary
The review demonstrates there is currently no evidence on the costs or cost-effectiveness of using a
decision rule in patients with a first unprovoked VTE, thus highlighting the need for this analysis to be
undertaken. The next section describes an economic model developed to consider a decision rule for
resumption of therapy in this patient population.
BOX 2 Selection criteria for the systematic review of economic studies
l Study design: cost–consequence analysis, cost-effectiveness analysis, cost–benefit analysis, cost–utility
analysis, cost studies.
l Population: patients aged ≥ 18 years. Patients with a first unprovoked VTE who had received at least
3 months oral anticoagulation therapy. Studies with mixed populations were to be included as long as data
for relevant patients could be extracted.
l Intervention: clinical decision rule for the resumption of anticoagulation.
l Outcomes: cost-effectiveness, cost estimates, quality-of-life estimates.
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FIGURE 43 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of selection process
for cost-effectiveness review.
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This section provides a detailed description of the economic model developed to evaluate the cost-
effectiveness of using a clinical decision rule in patients with a first unprovoked VTE. The model calculates
a predicted 1-year risk of a VTE using the post D-dimer model and compares this risk with a decision rule
(with a specified threshold risk of recurrence, e.g. 5%) to determine whether or not cessation of therapy is
continued or therapy is restarted. The model compares a strategy of no therapy (usual care) with a number
of decision rule strategies, where therapy is restarted if the predicted risk of a VTE is equal to or greater
than the given threshold risk. In the model, a total of five decision rule strategies were compared with
usual care, each one using a different threshold risk (1%, 3%, 5%, 10% and 15%). A further strategy
was evaluated where all patients recommenced therapy (a ‘treat all’ strategy, with a 0% threshold),
meaning six strategies were compared with no therapy in the model. The specific thresholds were chosen
to reflect the recurrence thresholds reported previously in Chapter 4, Validation of final post D-dimer
model in risk groups (1%, 3%, 5%), with the addition of two higher thresholds (10%, 15%) to estimate
the cost-effectiveness of only resuming therapy in those individuals with a considerable risk of suffering a
VTE in 1 year.
The model describes possible clinical pathways that a patient can move through once they have suffered a
first unprovoked VTE. These pathways include remaining event free, having another VTE (either a DVT or a
PE), having a major bleed and dying from a clinical event or other causes. The model takes into account
whether or not a patient is on therapy and the risks of further clinical events are determined by their
therapy status. In addition, events within the model can change the therapy status of a patient; for
example, if someone is not on therapy and has a further VTE they are put on therapy for life, and if
someone has a major bleed on therapy, therapy is stopped. The key feature of the model is that it can
weigh up the risk of a further VTE off therapy with the risk of bleeding on therapy, by attaching costs,
impact on quality of life and survival to both therapy and clinical events. These costs and outcomes, in
quality-adjusted life-years (QALYs), can be compared between strategies to determine the most
cost-effective strategy. The following sections will give a detailed description of the model structure, data
inputs and methods of analysis, and will then provide base case results and sensitivity analyses and




A Markov patient-level simulation was developed in TreeAge version 2014 (TreeAge Software, Inc.,
Williamstown, MA, USA) to estimate the cost-effectiveness of the use of a decision rule compared with
treating no-one (usual care) in patients with a first unprovoked VTE event. In patients no longer receiving
therapy, the clinical decision rule used a threshold risk of recurrent VTE in 1 year to make a decision about
return to therapy as follows:
l If the post D-dimer model gives a predicted probability of recurrence equal to or above the threshold,
an individual should have their therapy resumed.
l If the post D-dimer model gives a predicted probability of recurrence less than the threshold, an
individual should remain off therapy
The comparators for the treat no-one strategy were decision rules using threshold risks of 1%, 3%, 5%,
10%, 15% and a strategy where everyone restarts therapy (0% threshold). The decision rule used the risk
of recurrent VTE at 1 year provided by the post D-dimer model described in detail in Chapter 4, Final
model: post D-dimer model.
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A Markov model is the most appropriate model type for this decision problem as the model can represent a
clinical situation where patients change health states or experience recurrent events over a long period of
time. A patient-level simulation was chosen instead of a cohort model. This allowed individual patients to be
created, using data on existing patients where a number of characteristics could vary, with the model
predicting individual VTE risks. Model results represent the mean costs and QALYs for a realistic patient
population. This is in contrast to running the model for a hypothetical cohort of patients. The model was run
for 50,000 simulated patients and had a time cycle of 1 month. The number of simulated patients was
determined to be sufficiently large to reduce the variability in the model results. A time cycle of 1 month was
chosen as it was agreed through clinical consensus that it is a short enough period of time to allow an
assumption of only one clinical event occurring within a time cycle. The base-case analysis used a lifetime
time horizon and the evaluation was conducted from a UK NHS/Personal Social Services perspective, to take
into account health-care costs and longer-term care costs of recurrent VTE and major bleeds. Costs, utilities
and clinical probabilities were converted into monthly equivalents in accordance with the time cycle length.
Model population
Individuals were created from the patient-level data previously used to develop the post D-dimer model
(RVTEC database). The patient population consisted of patients aged ≥ 18 years with a first unprovoked
VTE, having completed at least 3 months of anticoagulation for the unprovoked VTE. The patient-level
data contained information on age, sex, type of index VTE event (distal DVT, proximal DVT and PE) and
post-warfarin D-dimer level. Further details on this data set can be found in Chapter 4, Results I: summary
characteristics of available data sets.
In order to align the economic model with the post D-dimer model developed in Chapter 4, Results III:
development and validation of post D-dimer model, the starting point of the economic model is defined as
the point where a patient had received at least three months of anticoagulation therapy after suffering
their first unprovoked VTE. The model assumed all individuals entered the model with their D-dimer
measured 30 days after stopping their anticoagulation (known as the ‘lag time’ in the post D-dimer
model). At model entry, the characteristics of an individual patient were determined by randomly sampling
from the patient-level data11 using a uniform distribution. Sex was sampled first, and once this was
determined, age was sampled from a sex-specific age distribution, again from the patient level data.
D-dimer and site of index VTE were sampled independently of age and sex as no clear relationship was
observed in the data set (see Table 9 and Figure 63). After an individual’s characteristics were determined,
the risk of a recurrent VTE in 1 year was estimated by entering these characteristics into the risk equation
taken from the post D-dimer model. Table 36 contains summary statistics of the patient-level data, which
contained information on 1200 patients. Graphical representations of the distributions used for age and
D-dimer can be found in Figures 48 and 54 in Appendix 4.
TABLE 36 Summary statistics for the patient-level data used to determine patient characteristics
Predictor Summary statistics
Continuous Mean (SD) Median
Age 61.70 (15.21) 63.59




Site of index event
Distal DVT 9.2 (110)
Proximal DVT 58.5 (702)
PE 32.3 (388)
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Model pathways and clinical events
In the clinical decision rule strategy, a specific threshold risk was chosen (1%, 3%, 5%, 10% or 15%),
then the decision rule was applied. If the patient had a first year risk of a VTE event equal to or higher
than the specified threshold risk, it was assumed they resume therapy, otherwise they continued without
further therapy. The clinical decision rule was only assumed to be applied at this point in the model. In the
comparator with no decision rule, individuals remained off therapy. Once the clinical decision rule was
applied, all individuals had the same potential patient pathways, with probabilities of events, costs and
utilities determined by their characteristics.
Figure 44 shows the potential patient pathways each simulated individual could progress along,
irrespective of whether the clinical decision rule dictated they resumed therapy or remained off therapy.
Given the very low probability of more than one clinical event occurring in a month, it was assumed
that only one clinical event could occur per time cycle. In 1 month, an individual has a probability of
experiencing a clinical event: death from other causes, recurrent VTE (distal or proximal DVT, fatal or
non-fatal PE), or fatal or non-fatal major bleed [intracranial bleed, gastrointestinal (GI) bleed, other bleed].
The following describes the details for each possible event.
An individual patient could die from other causes, with other-cause mortality dependent on the current
age and sex of the patient. Patients had a risk of a recurrent VTE, with risk determined by the patient’s
characteristics, whether or not they had already suffered a recurrent event, length of time since entering
the model and whether or not the patient was on anticoagulant therapy. If the patient had a recurrent
VTE, this could be a PE, proximal DVT or distal DVT. It was assumed that the type of recurrent VTE was
influenced by the patient’s index VTE location. For example, a patient with an index PE had a higher
probability of having a further PE that a patient who had index DVT. If the patient suffered a PE, there was
a risk the PE was fatal, whereas a DVT alone was assumed not to be fatal. Once a recurrent VTE occurred,
an individual was put on lifelong therapy if they were not already on therapy. All VTE events incurred an
acute cost of therapy. Surviving patients were assumed to suffer a one-off reduction of quality of life, and
a proportion of patients were also assumed to suffer from PTS and had quality of life reduced for life.
FIGURE 44 Model patient pathways.
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An individual was also at risk of a major bleed. The risk of a major bleed depended on age and whether or
not the patient was on therapy, and bleeds were split into GI bleeds, intracranial bleeds and other major
bleeds. Each of the major bleeds had a risk of death and was associated with acute costs and a short-term
reduction in quality of life. An intracranial bleed was assumed to have ongoing health-care costs and a
permanent reduction in quality of life. For the purposes of the model and in order to assign costs and
utilities, an ‘other major bleed’ was assumed to have the same cost and quality-of-life reduction as a GI
bleed. If the patient was on anticoagulation therapy, any bleed led to immediate cessation of therapy.
If they suffered a recurrent VTE in a subsequent cycle, they were put back on therapy.
Model parameters
Clinical parameters
This section outlines the sources used to populate the base-case parameters in the model and any related
assumptions. Parameter estimates are presented in Table 37. The model assumes the base-case anticoagulation
therapy is warfarin. The base-case analysis considers warfarin as the therapy of choice, with newer anticoagulant
therapies [dabigatran (Pradaxa®, Boehringer Ingelheim), rivaroxaban] explored in the sensitivity analysis.
The initial off-therapy risk of a recurrent VTE was calculated using the information on simulated patient
characteristics which were then entered into the post D-dimer model. Risks were estimated for 6 months,
1 year, 2 years and 3 years post D-dimer measurement 30 days after initial therapy cessation. Beyond
3 years, the post D-dimer model was considered to have weak calibration statistics and therefore was not
used; rather an annual risk of 5% for recurrent VTE off therapy was assumed for all patients after 3 years.
This value was taken from a cohort study of patients who had discontinued anticoagulation, using
incidence data from patients who had stopped therapy for more than a year.66 The risk of a VTE on
therapy was assumed to be 1.3%, taken from a trial of long-term therapy with rivaroxaban after VTE.43
For those individuals who had a recurrent VTE event within the model, the risk of a further VTE was
taken from the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial, which considered
low-intensity warfarin and placebo, and reported recurrence rates with normal and elevated D-dimer in
those with two or more prior VTE.62 The risk of VTE recurrence was estimated as 12% if off therapy and 5%
if on therapy, with risks assumed to be between those values for patients with normal and elevated D-dimer.
On-therapy VTE risks were assumed to be applicable for warfarin, dabigatran and rivaroxaban. The RVTEC
data set11 provided the probabilities on the type of recurrent VTE event by index event, with a probability of
0.4828 for a PE after an index PE and a probability of 0.1456 for a PE after an index DVT. The risk of death
from a PE was estimated by clinical consensus and was assumed to be 20% for the base case, with a higher
estimate of 30% to be used in the sensitivity analysis. It was assumed that a proportion (1.1%) of patients
who suffered a recurrent VTE would develop severe PTS and have a reduced quality of life, and these data
were obtained from a study of patients on subtherapeutic warfarin after a first idiopathic VTE.91
The model assumes that all patients have an age-related risk of major bleeding on and off therapy, with a
greater risk on anticoagulation therapy which increases with age. The bleeding risk for patients with a first
unprovoked VTE not receiving anticoagulant therapy (0.45%) was taken from a systematic review and
meta-analysis of patients who had completed anticoagulant therapy for secondary prevention of VTE.92
The bleeding risk for those on warfarin by age category is taken from the warfarin arm of the Randomized
Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial which compares warfarin with dabigatran
for atrial fibrillation.93 Bleeding was assumed to increase with age from 2.43% if aged < 65 years to
3.25% for those aged 65–74 years and 4.37% if aged ≥ 75 years. Major bleeds were split into GI bleeds,
intracranial bleeds and other major bleeds, with the split between types of bleed 36.5%, 17.9% and
45.6% respectively. All bleeds had a risk of being fatal and the risk of death from each type of bleed in
the first month after the bleed was 18.4%, 32.2% and 10.5% respectively. Data on bleeds were obtained
from a Spanish registry of patients who have suffered a first VTE.94 Once an individual suffered a non-fatal
intracranial bleed, it was assumed that they had an increased risk of death for the rest of their life, and a
standardised mortality ratio of 2.2 was applied, taken from a study looking at long-term survival after an
intracerebral haemorrhage.95 All clinical parameter estimates and their sources are presented in Table 37.
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TABLE 37 Estimates for clinical parameters used in the economic model
Clinical parameter (distribution type) Estimate (distribution) Source
Annual risk of recurrent VTE off therapy Calculated using the post
D-dimer model
See Chapter 4, Final model:
post D-dimer model
Annual risk of recurrent VTE on therapy (anticoagulation)
(beta)
1.3% (α= 8, β= 594) Romualdi 201143
Long-term annual risk of VTE recurrence beyond 3 years (beta)
Off therapy 5.0% (α= 5, β= 95) Palareti 200266
On therapy 1.3% (α= 8, β= 594) Romualdi 201143
Annual risk of further VTE off therapy after previous recurrent VTE (beta)
Off therapy 12.0% (α= 11, β= 81) Shrivastava 200662
On therapy 5.0% (α= 5, β= 95)
Probability a recurrent VTE is a PE by index event (beta)
Index event DVT 0.15 (α= 15, β= 88) RVTEC data set11
Index event PE 0.48 (α= 28, β= 30)
Probability of death from PE (first month) (beta) 0.2 (α= 2, β= 8) Clinical consensus
Proportion of recurrent VTE resulting in severe PTS (beta) 1.1% (α= 4, β= 345) Chitsike 201291
Annual risk of major bleed by age group (beta)
Not on therapy 0.45% (α= 25, β= 5593) Castellucci 201492
On therapy aged Eikelboom 201193
< 65 years 2.43% (α= 23, β= 929)
65–74 years 3.25% (α= 86, β= 2554)
75+ years 4.37% (α= 106, β= 2324)
Split of major bleeds by bleed type (Dirichlet)
GI 36.5% RIETE database94
Intracranial haemorrhage 17.9%
Other major bleed 45.6%
(α1; α2; α3)= (499; 245; 622)
Risk of death from major bleed (first month) (beta)
GI 18.4% (α= 92, β= 407) RIETE database94
Intracranial haemorrhage 32.2% (α= 79, β= 166)
Other major bleeds 10.5% (α= 65, β= 557)
Standardised mortality ratio for after an intracranial bleed
(log-normal)a
2.2 (95% CI 2.0 to 2.4) Fogelholm 200595
a A 95% CI is assumed to be ± 0.2 of the mean.
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Resource use and costs
The model included costs of therapy (drugs and monitoring) and acute costs for clinical events and
long-term costs for intracerebral haemorrhage. Base-case anticoagulation costs included warfarin tablets,
assuming an average dose of 4mg of warfarin per day and INR monitoring. In the sensitivity analysis,
dabigatran and rivaroxaban were explored as therapy options. All drug costs were obtained from the
British National Formulary.96 Monitoring was only assumed for warfarin and annual INR test costs were
obtained from the economic modelling in a National Institute for Health and Care Excellence (NICE)
technology appraisal for dabigatran in the treatment of VTE.97
One-off acute care costs for DVT and PE, GI bleeds and other major bleeds were obtained from NHS
reference costs,98 with costs for DVT and PE calculated as a weighted cost taking into account all
Healthcare Resource Group categories for these events. The cost for other bleeds was assumed to be the
same as the cost of a GI bleed, due to the huge amount of heterogeneity in the other bleeds category.
This assumption was agreed through clinical consensus. Intracranial bleeds were assigned an acute cost
and it was assumed that a non-fatal intracranial bleed would lead to lifelong health-care costs. The source
of both costs was a study reporting costs of all types of stroke.99 All unit costs were updated to 2012/13
prices using the Hospital and Community Health Services index100 and are presented in Table 38.
Estimation of quality-adjusted life-years
Utility values were required for all possible health states and clinical events, and were combined with
information on survival in order to calculate QALYs. The initial post-index VTE health state was assumed to
have a utility value related to the age of each individual as they enter the model using European Quality of
Life-5 Dimensions UK normative values.101 As individuals age within the model, their utility score changes
to reflect the score for that age range (Table 39).
Therapy with warfarin was associated with a very small disutility of 0.997102 (applied multiplicatively). DVTs
and non-fatal PEs were assumed to reduce quality of life for a month then patients returned to their
previous utility level. Non-fatal intracranial bleeds and PTS were assumed to reduce quality of life for the
rest of the patient’s lifetime. GI bleeds and other major bleeds reduced quality of life for 2 weeks after the
event and the same level of disutility was assumed. Median utility values and their interquartile range for a
DVT, PE, GI bleed, intracranial bleeds and PTS are taken from Locadia et al.,103 who used the time trade-off
TABLE 38 Unit costs
Parameter Value (£) Source
PE 1519 NHS Reference Costs 2012–201398
Distal DVT 732 NHS Reference Costs 2012–201398
Proximal DVT 732 NHS Reference Costs 2012–201398
Warfarin monitoring (12 months) 337 NICE 201497
Warfarin (4mg per day, 12 months) 22.29 BNF 201496
Rivaroxaban (20mg per day, 12 months) 767 BNF 201496
Dabigatran (150mg twice daily, 12 months) 803 BNF 201496
GI bleed 1092 NHS Reference Costs 2012–201398
Other major bleed 1092 Assumed same as GI bleed
Intracranial bleed: acute cost 8350 Luengo-Fernandez 201299
(Gamma distribution) (α= 30.99, λ= 0.0037)
Intracranial bleed: annual cost 1300 Luengo-Fernandez 201299
BNF, British National Formulary.
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method to elicit utility weights from a 124 participants who had been affected by a VTE, major bleeding
event or PTS. All utility values were applied to the age-related utility multiplicatively. For example, for an
individual aged between 55 and 64 years (utility value 0.80), PTS would reduce their utility to a value
of 0.66 (0.80 × 0.82= 0.66). Utility values and their sources can be found in Table 40. In addition to
event-specific mortality, other-cause mortality was also included in the model, dependent on the current
age and sex of the patient, and the risk of death was taken from UK life tables.104
Assessment of cost-effectiveness
The incremental analysis was designed to generate the cost per additional QALY gained for opting to use
the clinical decision rule versus using treat no-one (usual care). The comparators for the treat no-one
strategy were decision rules using threshold risks of 1%, 3%, 5%, 10%, 15% and a strategy where
everyone restarts therapy. In addition, a range of values for the threshold VTE risk was applied in order
to determine the lowest risk at which using a decision rule to determine resumption of therapy was
cost-effective. The standard approach of ordering strategies from lowest to highest cost and comparing
each strategy to the next best strategy (rather than no therapy) is not appropriate in this context. Here, the
analysis seeks to estimate the cost-effectiveness of different possible decision rules when compared with
no therapy rather than compare each strategy incrementally. Cost-effectiveness was assessed in relation to
the NICE lower threshold of £20,000 per QALY gained, where a value of £20,000 per QALY is deemed to
be cost-effective.105 All costs and outcomes are discounted by 3.5%.
TABLE 39 Starting health state utility weights by age101














DVT 0.84 (0.64–0.98) α= 2.00, β= 0.60 1 month Locadia 2004103
PE 0.63 (0.36–0.86) α= 1.15, β= 0.79 1 month Locadia 2004103
Non-fatal intracranial bleed 0.33 (0.14–0.53) α= 1.17, β= 2.06 Permanent Locadia 2004103
GI bleed 0.65 (0.49–0.86) α= 1.22, β= 0.78 2 weeks Locadia 2004103
Other bleeds 0.65 (0.49–0.86) α= 1.22, β= 0.78 2 weeks Assumed same
as GI bleeds
PTS 0.82 (0.66–0.97) α= 3.03, β= 0.89 Permanent Locadia 2004103
Warfarina 0.997 (0.95–1.0)a α= 16.43, β= 0.26 Treatment length Gage 1996102
Dead 0 Permanent Assumption
IQR, interquartile range.
a 10th and 90th percentile reported instead of IQR.
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Sensitivity analysis
Additional model runs were undertaken to determine the impact of changing key parameters on the
model results. The parameters where the incremental cost-effectiveness ratio (ICER) was demonstrated to
be particularly sensitive to change were explored in more detail. The following analyses were undertaken:
l The time horizon was restricted to 3 years, 5 years and 10 years.
l The cost of warfarin monitoring was reduced by 50% and increased by 100%. The rationale behind
this analysis was that the costs of monitoring vary widely, depending on the model of care, with
secondary care monitoring having a lower cost than the primary care near-patient testing model.
l The disutility from warfarin therapy was changed from 0.997 to 0.95, representing greater disutility.
The model was also run with an assumption of no disutility. These alternative values were used to
reflect the variability in patient disutility from being on warfarin.
l The cost-effectiveness of the decision rule strategies assuming the use of newer anticoagulants,
dabigatran and rivaroxaban were explored. They were assumed to have the same effectiveness and
same impact on bleeds as warfarin, but the cost of the drug was changed and the cost of monitoring
was removed. In addition, there was assumed to be no disutility on these newer anticoagulants due to
no requirements for regular monitoring.
l Alternative values for utility losses due to VTE and bleeding events were used, obtained from an
alternative source.106 These values were from a cohort study measuring quality of life in acute DVT,
acute PE and with bleeding complications using standard gamble methods. The alternative values were
0.81 for a DVT for 1 month, 0.75 for a PE for 1 month, 0.65 for a GI bleed for 1 week and 0.15 for a
major intracranial bleed for patient lifetime.
l The disutility from PTS was changed from 0.82 to 0.93107 to reflect the uncertainty around this value in
the literature.
l The proportion of patients who could suffer from severe PTS after a recurrent VTE was increased from
1.1% to 10%, again to reflect uncertainty around this parameter.
l As there was uncertainty within the group of clinical experts on the study concerning the assumption
of the probability of death from a PE, this was increased from 20% to 30%.
l As the base-case model was concerned with a broad patient population, across a wide age range, a
subgroup analysis was undertaken to consider the cost-effectiveness of using a decision rule in those
aged ≥ 60 years, where risk of bleeding on therapy would be higher.
l Subgroup analyses were undertaken for index PE patients and index DVT patients, to determine
whether a lower or higher threshold risk may be more appropriate for these patient groups.
Where available, data were entered into the model as distributions in order to fully incorporate the
uncertainty around parameter values in order that a probabilistic sensitivity analysis (PSA) could be
undertaken. Risks and probabilities were entered as beta distributions. A log-normal distribution was used
for the standardised mortality ratio for an intracranial bleed and a gamma distribution was used for the
cost of an acute intracranial bleed. The split between different types of major bleed was represented as a
Dirichlet distribution. The PSA was run with 10,000 simulations for each trial of 1000 simulated patients
and cost-effectiveness planes and acceptability curves were produced for the base-case analysis.
Summary of economic modelling assumptions
The following assumptions were made during the economic evaluation:
l Patients have received at least 3 months anticoagulation and had their D-dimer measured 1 month
after stopping therapy before their risk of recurrent VTE is assessed at the starting point of the model.
l An individual VTE risk can be correctly predicted for the first 3 years, using the post D-dimer model.
Beyond 3 years, a constant risk of recurrent VTE is assumed.
l Patients are put on lifelong therapy if they suffer a further VTE event.
l The type of recurrent event is influenced by their first event, with a PE more likely to be followed by
another PE.
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l A proportion of those suffering a recurrent VTE will develop PTS and their quality of life will
be reduced.
l Recurrent DVT is not fatal; however, a PE can be fatal.
l All bleeds result in a loss of quality of life, with short-term disutility for PE, DVT, GI bleeds and other
bleeds, and permanent disutility for intracranial bleeds.
l Other bleeds are assigned the same cost as GI bleeds and have the same acute cost.
l If a patient has a major bleed, they cease anticoagulation until they have a current VTE.
l Only one clinical event can occur in a 1-month time cycle.
l Newer anticoagulants, explored in the sensitivity analysis, were assumed to be effective as warfarin in
preventing recurrence of VTE and the same risk of major bleeding, but had no disutility due to the
absence of regular monitoring.
Results
This section presents the results of the base-case analyses and a series of sensitivity analyses for the use of
a clinical decision rule for resumption of anticoagulation in patients with first unprovoked VTE. The
sensitivity analyses explored the impact of changing parameter values and assumptions within the model.
Base-case analysis (warfarin)
The base-case analyses considered the use of a clinical decision rule for resuming therapy, assuming the
use of warfarin, using different possible thresholds for risk of recurrence compared with a baseline strategy
of treating no-one, over a lifetime time horizon. Table 41 shows the results for recurrence thresholds of
1%, 3%, 5%, 10% and 15%, plus treat all (0% threshold). All options with a threshold of 3% or higher
resulted in greater QALYs and increased costs compared with treating no-one. A threshold of 1% and the
treat all strategy had higher costs and lower QALYs, and were therefore dominated by the treat no-one
strategy. Comparing thresholds of 3% and 5% with no therapy resulted in ICERs > £20,000 per QALY
gained, indicating that using these risk thresholds in a decision rule would not be cost-effective if the
health service was not willing to pay more than £20,000 per QALY. Using either a 10% or 15% risk
threshold in a decision rule could be considered cost-effective, with ICERs of £11,624 and £4616 per
QALY gained respectively. The 10% threshold results in the greatest QALY gain of all the options (0.0525);
however, the 15% threshold has the lower ICER due to the smallest incremental cost of £228.
Table 42 presents the results for risk thresholds between 5% and 10%. This is to determine, compared
only to no therapy, what is the lowest threshold risk for the decision rule to be considered cost-effective at
£20,000 per QALY gained. The lowest threshold appears to be about 8%, with an ICER of £18,514 per
QALY gained.
TABLE 41 Cost-effectiveness of using each decision rule compared with treat no-one (lifetime time horizon)
Strategy Mean cost (£) Mean QALYs Cost difference (£) QALY difference
ICER
(cost/QALY)(£)
Treat no-one 3228 10.4751
Decision rule: 15% 3456 10.5244 228 0.0493 4616
Decision rule: 10% 3838 10.5276 610 0.0525 11,624
Decision rule: 5% 4818 10.4947 1590 0.0195 81,340
Decision rule: 3% 5303 10.4612 2075 –0.0139 Dominated
Decision rule: 1% 5644 10.4323 2416 –0.0428 Dominated
Treat all 5738 10.4223 2510 –0.0528 Dominated
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The results of the PSA for decision rules with 8%, 10% and 15% thresholds are shown in the
cost-effectiveness plane in Figure 45 and cost-effectiveness acceptability curve in Figure 46. The
cost-effectiveness plane shows the large amount of uncertainty in the QALY differences for all strategies.
Most of the cost–QALY difference points show all strategies to be more costly than treating no-one;
however, many of the points on the plane are in the area which indicates that a strategy is more expensive
and less effective. At a willingness-to-pay threshold of £20,000 per QALY gained, the 15% threshold
strategy has a 58% probability of being cost-effective. This drops to 40% for the 10% threshold and 31%
for the 8% threshold. These results demonstrate that the model is very sensitive and there is a large
amount of uncertainty around the ICERs. Therefore, although the calculated ICERs for all three strategies
appear to suggest cost-effectiveness, there should be caution in adopting any of the strategies, due to the
uncertainty around the results.
Sensitivity analysis
This section presents the results of the sensitivity analysis conducted on the base-case parameter estimates
and assumptions. All analyses were run for the same threshold risk estimates as the base case.
TABLE 42 Analysis of alternative decision rules compared with treat no-one to determine the most
cost-effective threshold
Strategy Mean cost (£) Mean QALYs
ICER (cost/QALY) (£) compared
with treat no-one
Treat no-one 3228 10.4751
Decision rule: 15% 3456 10.5244 4616
Decision rule: 10% 3838 10.5276 11,624
Decision rule: 9% 3971 10.5241 15,175
Decision rule: 8% 4143 10.5246 18,514
Decision rule: 7% 4351 10.5156 27,755
Decision rule: 6% 4575 10.5012 51,585




































FIGURE 45 Cost-effectiveness plane of cost–QALY difference pairs for 15%, 10% and 8% threshold strategies vs.
treat no-one.
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Time horizon restricted to 3, 5 and 10 years
In order to determine the impact of a decision rule over a shorter time horizon, the model was run for time
horizons of 3, 5 and 10 years. In particular, 3 years was the length of time the post D-dimer model could
provide predicted recurrence estimates with good calibration statistics (see Model validation in the
internal–external cross-validation cycles). The results, shown in Tables 43–45, show all ICERs were larger
for the shorter time horizons than the lifetime time horizon. The 15% threshold strategy could be
considered be cost-effective within 3 years; however, the 10% threshold strategy is no longer
cost-effective, although is close to the £20,000 per QALY threshold by 10 years.
Cost of warfarin monitoring
The model was run with scenarios where the cost of warfarin monitoring was doubled and where the cost
was halved. For the a higher cost of monitoring, the 15% threshold strategy remained potentially
cost-effective at £9830 per QALY gained, but the ICER for the 10% threshold strategy increased to
£23,597 per QALY gained, above the threshold for cost-effectiveness (Table 46). Lowering the cost of
monitoring resulted in lower ICERs for the 15% and 10% threshold strategies, thus becoming more
cost-effective. However, the 5% threshold strategy, with an ICER of £42,066 per QALY, was still not a
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FIGURE 46 Cost-effectiveness acceptability curve of 15%, 10% and 8% threshold strategies vs. treat no-one.
TABLE 43 Cost-effectiveness of different decision rules vs. treat no-one over a 3-year time horizon
Strategy Mean cost (£) Mean QALYs
ICER (cost/QALY) (£) compared
with treat no-one
Treat no-one 366 2.2027
Decision rule: 15% 423 2.2074 12,162
Decision rule: 10% 544 2.2082 32,504
Decision rule: 5% 877 2.2055 180,357
Decision rule: 3% 1053 2.2024 Dominated
Decision rule: 1% 1175 2.2001 Dominated
Treat all 1211 2.1992 Dominated
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
104
TABLE 44 Cost-effectiveness of different decision rules vs. treat no-one over a 5-year time horizon
Strategy Mean cost (£) Mean QALYs
ICER (cost/QALY) (£) compared
with treat no-one
Treat no-one 620 3.4538
Decision rule: 15% 712 3.4615 11,919
Decision rule: 10% 897 3.4620 33,574
Decision rule: 5% 1398 3.4548 772,271
Decision rule: 3% 1660 3.4509 Dominated
Decision rule: 1% 1834 3.4462 Dominated
Treat all 1883 3.4448 Dominated
TABLE 45 Cost-effectiveness of different decision rules vs. treat no-one over a 10-year time horizon
Strategy Mean cost (£) Mean QALYs
ICER (cost/QALY) (£) compared
with treat no-one
Treat no-one 1278 5.9348
Decision rule: 15% 1441 5.9523 9307
Decision rule: 10% 1721 5.9555 21,451
Decision rule: 5% 2485 5.9401 227,988
Decision rule: 3% 2872 5.9245 Dominated
Decision rule: 1% 3138 5.9131 Dominated
Treat all 3207 5.9098 Dominated
TABLE 46 Cost-effectiveness of using a decision rule vs. treat no-one, using a higher warfarin monitoring cost
Strategy Mean cost (£) Mean QALYs
ICER (cost/QALY) (£) compared
with treat no-one
Treat no-one 5009 10.4751
Decision rule: 15% 5493 10.5244 9830
Decision rule: 10% 6247 10.5276 23,597
Decision rule: 5% 8134 10.4947 159,887
Decision rule: 3% 9045 10.4612 Dominated
Decision rule: 1% 9674 10.4323 Dominated
Treat all 9844 10.4223 Dominated
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Tables 48 and 49 present the results of changing the disutility on warfarin. It is evident the model is
sensitive to this variable, with only the 15% threshold decision rule that could be considered cost-effective
if there is a greater disutility of 0.95, with all other options dominated by no therapy. However, if there is
no disutility, then all ICERs decrease; however, the 15% and 10% threshold strategies still remain the only
potentially cost-effective options at the £20,000 per QALY willingness-to-pay threshold.
TABLE 47 Cost-effectiveness of using a decision rule vs. treat no-one, using a lower warfarin monitoring cost
Strategy Mean cost (£) Mean QALYs
ICER (cost/QALY) (£) compared
with treat no-one
Treat no-one 2338 10.4751
Decision rule: 15% 2437 10.5244 2009
Decision rule: 10% 2634 10.5276 5637
Decision rule: 5% 3160 10.4947 42,066
Decision rule: 3% 3432 10.4612 Dominated
Decision rule: 1% 3629 10.4323 Dominated
Treat all 3685 10.4223 Dominated
TABLE 49 Cost-effectiveness of using a decision rule vs. treat no-one, assuming no disutility with warfarin
Strategy Mean cost (£) Mean QALYs
ICER (cost/QALY) (£) compared
with treat no-one
Treat no-one 3228 10.4867
Decision rule: 15% 3456 10.5378 4458
Decision rule: 10% 3838 10.5434 10,752
Decision rule: 5% 4818 10.5165 53,340
Decision rule: 3% 5303 10.4858 Dominated
Decision rule: 1% 5644 10.4588 Dominated
Treat all 5738 10.4493 Dominated
TABLE 48 Cost-effectiveness of using a decision rule vs. treat no-one, assuming greater disutility with warfarin
Strategy Mean cost (£) Mean QALYs
ICER (cost/QALY) (£) compared
with treat no-one
Treat no-one 3228 10.2937
Decision rule: 15% 3456 10.3155 10,425
Decision rule: 10% 3838 10.2795 Dominated
Decision rule: 5% 4818 10.1525 Dominated
Decision rule: 3% 5303 10.0757 Dominated
Decision rule: 1% 5644 10.0174 Dominated
Treat all 5738 9.9996 Dominated
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Newer anticoagulants
The model was run for the newer anticoagulants rivaroxaban and dabigatran, using their higher drug
costs, but assuming the same effectiveness and impact on bleeds, and also assuming they resulted in no
disutility for individuals. If patients are treated with either therapy, only a strategy with a threshold of 15%
could be considered cost-effective, with all ICERs higher than those for warfarin (Tables 50 and 51).
The 10% threshold strategy is no longer cost-effective, with ICERs above the £20,000 per QALY
willingness-to-pay threshold.
Alternative values for utility losses: all clinical events
Alternative values for utility losses due to VTE and bleeding events were used, as an alternative source for
values was available.106 Results in Table 52 demonstrate that changing values for all types of event does
not change the overall result a great deal, rather than just changing values related to therapy.
Alternative values for utility loss: post-thrombotic syndrome
By lessening the quality-of-life impact of one condition (PTS) the values on mean QALYs for different
decision rules all increase; however, the overall results do not differ greatly from the base case (Table 53).
This is due to only a small proportion of patients in the model being affected by severe PTS.
Alternative value for risk of severe post-thrombotic syndrome after recurrent
venous thromboembolism
Increasing the risk of severe PTS after a recurrent VTE decreases all ICERs, with no strategies dominated.
This demonstrates the positive impact of avoiding VTE and therefore PTS by treating more patients.
However, the 15% and 10% threshold strategies still remain the only cost-effective options (Table 54).
TABLE 51 Cost-effectiveness of using a decision rule vs. treat no-one, assuming therapy with dabigatran
Strategy Mean cost (£) Mean QALYs
ICER (cost/QALY) (£) compared
with treat no-one
Treat no-one 5423 10.4751
Decision rule: 15% 5967 10.5244 11,043
Decision rule: 10% 6807 10.5276 26,382
Decision rule: 5% 8906 10.4947 178,158
Decision rule: 3% 9916 10.4612 Dominated
Decision rule: 1% 10,611 10.4323 Dominated
Treat all 10,800 10.4223 Dominated
TABLE 50 Cost-effectiveness of using a decision rule vs. treat no-one, assuming therapy with rivaroxaban
Strategy Mean cost (£) Mean QALYs
ICER (cost/QALY) (£) compared
with treat no-one
Treat no-one 5242 10.4751
Decision rule: 15% 5761 10.5244 10,514
Decision rule: 10% 6563 10.5276 25,167
Decision rule: 5% 8569 10.4947 170,187
Decision rule: 3% 9536 10.4612 Dominated
Decision rule: 1% 10,202 10.4323 Dominated
Treat all 10,383 10.4223 Dominated
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TABLE 52 Cost-effectiveness of using a decision rule vs. treat no-one, using alternative utility values for
clinical events
Strategy Mean cost (£) Mean QALYs
ICER (cost/QALY) (£) compared
with treat no-one
Treat no-one 3228 10.4757
Decision rule: 15% 3456 10.5250 4615
Decision rule: 10% 3838 10.5282 11,610
Decision rule: 5% 4818 10.4955 80,114
Decision rule: 3% 5303 10.4621 Dominated
Decision rule: 1% 5644 10.4334 Dominated
Treat all 5738 10.4234 Dominated
TABLE 53 Cost-effectiveness of using a decision rule vs. treat no-one, using an alternative utility values for PTS
Strategy Mean cost (£) Mean QALYs
ICER (cost/QALY) (£) compared
with treat no-one
Treat no-one 3228 10.4828
Decision rule: 15% 3456 10.5309 4732
Decision rule: 10% 3838 10.5331 12,125
Decision rule: 5% 4818 10.4983 102,520
Decision rule: 3% 5303 10.4642 Dominated
Decision rule: 1% 5644 10.4353 Dominated
Treat all 5738 10.4252 Dominated
TABLE 54 Cost-effectiveness of using a decision rule vs. treat no-one, using an alternative value for risk of
severe PTS
Strategy Mean cost (£) Mean QALYs
ICER (cost/QALY) (£) compared
with treat no-one
Treat no-one 3228 10.3580
Decision rule: 15% 3456 10.4270 3296
Decision rule: 10% 3838 10.4469 6863
Decision rule: 5% 4819 10.4362 20,357
Decision rule: 3% 5304 10.4099 40,052
Decision rule: 1% 5644 10.3846 90,888
Treat all 5738 10.3752 146,019
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
108
Alternative value for risk of death from pulmonary embolism
The model appears to be very sensitive to the risk of death from PE, with the 5% threshold strategy now
potentially cost-effective compared with no therapy, with an ICER of £13,979 per QALY gained (Table 55).
This demonstrates how sensitive the model is to small changes in risk of death and a greater risk of PE
being fatal makes continuing therapy appear to be worthwhile even at a relatively low 1-year risk of VTE.
Subgroup analysis: patients aged ≥ 60 years
A subgroup analysis was undertaken to determine the cost-effectiveness of alternative strategies when
considering only a patient population over the age of 60 years, where risks of bleeding are higher. Only
data for those aged ≥ 60 years were used from the patient-level data set for simulating individuals for the
model. The 15% threshold strategy could still be considered cost-effective, albeit at a higher ICER of
£7337 per QALY (Table 56). The 10% threshold strategy was no longer cost-effective and all other
strategies were dominated by treating no-one. This highlights the impact of higher bleeding risks which
outweigh the risk of recurrent VTE.
Subgroup analysis: modelling index pulmonary embolism and index deep-vein
thrombosis patients separately
The model was run for two separate subgroups, to determine whether the cost-effectiveness of the
decision rules strategies were different for different index VTE types. If the model is only run for individuals
who have an index PE, all strategies are cost-effective compared with treat no-one, even the treat all
option (Table 57). This suggests that the risk of further VTE in this subgroup, which has a higher
probability of being a PE (with the risk of being fatal), far outweighs any risk of bleeding on therapy. When
the model is run for index DVT patients, the only cost-effective strategy is the 15% threshold strategy, with
all other options dominated (Table 58). This suggests that the impact of bleeds and the small disutility on
warfarin outweighs the short-term impact of a recurrent VTE in most patients.
TABLE 55 Cost-effectiveness of using a decision rule vs. treat no-one, using an alternative value for risk of death
from PE
Strategy Mean cost (£) Mean QALYs
ICER (cost/QALY) (£) compared
with treat no-one
Treat no-one 3115 10.2948
Decision rule: 15% 3365 10.3762 3074
Decision rule: 10% 3765 10.4082 5742
Decision rule: 5% 4758 10.4124 13,979
Decision rule: 3% 5252 10.3905 22,349
Decision rule: 1% 5598 10.3661 34,843
Treat all 5691 10.3566 41,721
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TABLE 56 Cost-effectiveness of using a decision rule vs. treat no-one in patients aged ≥ 60 years
Strategy Mean cost (£) Mean QALYs
ICER (cost/QALY) (£) compared
with treat no-one
Treat no-one 2334 8.2497
Decision rule: 15% 2506 8.2714 7337
Decision rule: 10% 2817 8.2682 20,958
Decision rule: 5% 3745 8.2090 Dominated
Decision rule: 3% 4256 8.1777 Dominated
Decision rule: 1% 4591 8.1550 Dominated
Treat all 4678 8.1469 Dominated
TABLE 57 Cost-effectiveness of using a decision rule vs. treat no-one in patients with an index PE
Strategy Mean cost (£) Mean QALYs
ICER (cost/QALY) (£) compared
with treat no-one
Treat no-one 3247 10.1270
Decision rule: 15% 3523 10.2379 2486
Decision rule: 10% 3959 10.2887 4403
Decision rule: 5% 5031 10.3153 9479
Decision rule: 3% 5538 10.3058 12,819
Decision rule: 1% 5720 10.2954 14,685
Treat all 5720 10.2954 14,685
TABLE 58 Cost-effectiveness of using a decision rule vs. treat no-one in patients with an index DVT
Strategy Mean cost (£) Mean QALYs
ICER (cost/QALY) (£) compared
with treat no-one
Treat no-one 3248 10.6534
Decision rule: 15% 3459 10.6674 15,114
Decision rule: 10% 3834 10.6477 Dominated
Decision rule: 5% 4822 10.5743 Dominated
Decision rule: 3% 5312 10.5293 Dominated
Decision rule: 1% 5658 10.4982 Dominated
Treat all 5750 10.4875 Dominated
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Discussion
Economic modelling was conducted to determine the cost-effectiveness of using a clinical decision rule for
resumption of therapy in patients with first unprovoked VTE, using warfarin as the base-case therapy. This
is the first economic model to consider the use of a clinical decision rule for extending therapy in this
patient group, with the systematic review of economic evidence yielding no previous studies. The results
demonstrate that the use of a decision rule with a threshold risk of VTE recurrence, where individuals with
a 1-year risk equal to or above approximately 8% are treated, could be considered a cost-effective strategy
over the lifetime of a patient. This result holds if this strategy is compared with no therapy and not
compared incrementally with other strategies with a higher threshold. It is appropriate for the purpose of
this analysis is to look at each strategy individually. The key findings of this chapter are summarised below
and in Box 3.
Sensitivity analyses which only consider the strategies of 1%, 3%, 5%, 10% and 15% threshold risk
demonstrate that only a decision rule using a 15% threshold could be considered cost-effective with a
much shorter time horizon of 3 years. Again, only a decision rule with a threshold of 15% was potentially
cost-effective for both newer anticoagulants, although the 10% threshold strategy was between the
£20,000 and £30,000 per QALY willingness-to-pay thresholds. This suggests that using a decision rule
could still be cost-effective even if a more expensive treatment option is used; however, it is important to
note a number of assumptions regarding the newer drugs were included in the model. The base-case
results were particularly sensitive to changes in mortality risk or disutility that affect one side of the benefit/
risk balance of therapy. If a greater risk of death from PE is assumed, then lower threshold decision rules
become cost-effective. Conversely, if there is greater disutility from being on warfarin, only the 15%
threshold is likely to be cost-effective, with all other options dominated by treat no-one.
Subgroup analysis demonstrated how sensitive the model was when considering a specific group of
patients. When only those aged ≥ 60 years were considered, only the 15% threshold strategy remained
potentially cost-effective, demonstrating the impact of increased risk of bleeding on therapy in older
people. The impact was even more marked when index DVT and index PE patients were considered
separately. This analysis suggested that all PE patients should receive therapy, but only those DVT patients
with a predicted 1-year risk of recurrence of 15% or over should be considered for therapy. The PSA
results demonstrated the large amount of uncertainty around the model results, with even the 15%
threshold strategy only having a 58% probability of being cost-effective at a £20,000 per QALY
willingness-to-pay threshold. This uncertainty was primarily due to about half of the cost–QALY difference
points on the cost-effectiveness plane showing strategies to be less effective. This result is in line with the
results of the deterministic sensitivity analysis, where changes in disutility on therapy and risk of death
from PE had the greatest impact.
BOX 3 Key findings of Chapter 5: economic evaluation
l Economic modelling can be used to apply a clinical decision rule using a threshold risk of recurrence for
lifelong therapy.
l Results from the economic modelling suggest that a base-case threshold risk of 8% or higher for therapy
with warfarin could be considered cost-effective if decision-makers are willing to pay up to £20,000 per
QALY gained, if compared with no therapy. However, the results of the PSA show the model is highly
sensitive to overall parameter uncertainty.
l The model is sensitive to changes in utility and mortality estimates that either solely favour the no therapy
comparator or a decision rule strategy.
l Better data are required to predict long-term bleeding risks on therapy in this patient group.
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There are a number of key strengths of this modelling work. First, as stated above, this is the first model to
consider this decision problem, so therefore represents a step forward in providing a tool for decision-making,
weighing up the risks of recurrent VTE and bleeding in order to determine the optimal therapy strategy.
Furthermore, the model is an individual-level simulation, using real patient data, which allows the calculation
of risk of recurrence using the post D-dimer model for each hypothetical individual entering the model. This is
a more intuitive way of considering this decision problem of this type where risk of recurrence will vary from
patient to patient, and is dependent on their baseline characteristics and subsequent clinical events.
The main limitation of this economic modelling is the number of clinical and data assumptions that
underpin this model. Key simplifying assumptions are the use of constant risks of recurrent VTE after
3 years, after a further VTE and with therapy. In reality this risk of a recurrent event will vary from
individual to individual, and be influenced by age, whether the VTE is unprovoked or provoked and
whether or not the individual has an INR within a therapeutic range on warfarin. There is also uncertainty
around the outcome of intracranial bleeds in this patient group, with a wide range of possible outcomes,
from a mild bleed with a good outcome to a more severe event which leads to a poor quality of life and
ongoing care costs. In this model, a more severe bleed has been assumed, thus favouring fewer individuals
to be treated with anticoagulation and suggesting a higher threshold risk for the decision rule. The model
also required assumptions regarding the use and discontinuation of anticoagulation when a major bleed
occurred. In the model it was assumed that a major bleed stopped therapy, which was restarted only if a
further VTE occurred. In reality, some patients will have a bleed and continue with their anticoagulation
and others will go on to suffer a VTE but not resume therapy as their bleeding risk is too high.
It is evident from the sensitivity analysis that many of these assumptions and data inputs will have a large
impact on the direction of the results. Therefore, this work has highlighted that good-quality long-term
data are required from patient cohorts with first unprovoked VTE and recurrent VTE, to estimate individual
VTE risk beyond 3 years, and also to provide data to predict major bleeds in this patient group, possibly
using a prognostic model as utilised here for recurrent VTE. Furthermore, more research is required to
determine the short- and long-term impact of VTE, PTS and major bleeds on quality of life.
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Chapter 6 Overall discussion
This report has conducted research into the risk of VTE recurrence following cessation of therapy in thosepatients with a first, unprovoked VTE. Three research strands were undertaken. First, in Chapter 3,
a systematic review of existing prognostic models was performed, to examine the quality, content and
performance of models currently proposed for identifying those at high recurrence risk. Second, in Chapter 4,
a large IPD meta-analysis database was used to develop and externally validate two new prognostic models:
a pre D-dimer model (applicable at the exact time when cessation of therapy may begin) and a post D-dimer
model (applicable at a particular lag time after cessation of therapy, typically 30 days, at which D-dimer is
measured). The post D-dimer model showed good discrimination and calibration performance across trial
populations, and so Chapter 5 evaluated the cost-effectiveness of a decision rule based on individual
predictions from this model. The key conclusions and limitations of these three research strands are now
discussed, followed by clinical recommendations based on our findings and further research requirements.
Systematic review of prognostic models
The extensive systematic review identified three published articles that proposed a prognostic model for
risk of VTE recurrence following cessation of therapy in patients with a first unprovoked VTE. These were
referred to as the HER DOO 2 model, the DASH score, and the Vienna model. We chose the term
‘unprovoked’ rather than ‘idiopathic’ as this aligns with Baglin et al.45 who identified low recurrence
rates for patients with first provoked VTE rather than including underlying hereditary thrombophilia.
Furthermore, after evaluation of the models’ development and validation criteria, all models were labelled
with at least a moderate risk of bias. This was mainly due to a lack of any external validation, which is
essential as prognostic model performance is known to be optimistic when evaluated on the same data
used to develop the model. The HER DOO 2 model development was classed at high risk of bias, as –
alongside no external validation – it had methodological concerns, including the choice of analysis model,
substantially underpowered analyses, data-driven categorisation of predictors, lack of adjustment for
optimism and the presentation of the model for use. The Vienna model and DASH score were more
methodologically sound, as they had adequate statistical power to investigate their candidate predictors,
accounted for optimism in their selection procedures, assessed continuous predictors without
categorisation and loss of information, and presented their proposed models clearly. However, until
external validation is performed, the true performance in new populations cannot be ascertained. This is
especially important for the Vienna model, which presented internal validation results adjusted for
optimism, but it was not clear if the evaluation related to the fitted model, or the nomogram (a potentially
simplified version of the model). External validation of the Vienna model is under way.26
Development and validation of a new prognostic model
As the systematic review identified that existing prognostic models were inconsistent in their definition of
an unprovoked VTE, and were at a moderate to high risk of bias due to a lack of external validation, it was
important to address this in new research. This project therefore used the IPD meta-analysis database
supplied by the RVTEC group to develop and externally validate two new models: a pre D-dimer model
and a post D-dimer model.
The RVTEC database contained seven trials57–63 and therefore allowed the novel framework of Debray
et al.65 to be utilised for model development and external validation. This approach adapts the IECV
procedure first described by Royston et al.64 whereby N-1 trials are iteratively selected from the N total
trials in the IPD meta-analysis, and the prognostic model is developed within this subset of trials, leaving
the remaining trial for validation of the model. In this manner, it was possible to investigate (across all
permutations of the excluded trial) whether or not model performance remains consistent when applied in
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another trial’s population that was not included during model development. In other words, external
validation was possible on multiple occasions. The database also contained adequate sample size, with at
least 23 events per candidate predictor available, giving ample power to consider non-linear relationships
and interaction terms. Although a complete-case analysis was primarily performed, a sensitivity analysis
using multiple imputation led to the same set of predictors being included and gave similar parameter
estimates in the models.
In all models, the Royston and Parmar72,73 approach was used to flexibly model the baseline hazard using
restricted cubic splines. The baseline hazard is essential for individualised predictions from a survival model,
and the use of splines allowed the shape to be modelled flexibly, without forcing a particular parametric
form. This is likely to improve the performance and generalisability of the developed prognostic models,
especially as the shape of the baseline hazard was observed to be very similar across the set of trials in the
RVTEC database.
The development of the pre D-dimer model was considered as, in contrast to the post D-dimer scenario,
it allows individual risk predictions at the exact time therapy might cease. However, it contained only
two predictors: sex and site of index event. On external validation (in the IECV approach using the
RVTEC database and also additionally in the MEGA database) the model had poor discrimination with
an average c-statistic of 0.58 across the trials. Although calibration appeared good on average, there was
heterogeneity in calibration performance across trials and in some it was rather poor (as evident in MEGA).
The pre D-dimer model is thus clearly inadequate, which is not surprising given only two predictors were
identified as important. Further research is needed to extend the set of included predictors. In particular,
it may be that D-dimer measured without a lag time is also a prognostic factor and therefore data sets
need to be collected to examine whether or not this adds prognostic value in terms of calibration and
discrimination. There are currently three studies known to be ongoing in UK [extended anticoagulation
treatment for VTE (ExACT)], Holland (VISTA) and Canada [D-dimer Optimal Duration Study (DODS)], which
may provide further information regarding D-dimer testing while still on OAC therapy.
The development of the post D-dimer model allowed the inclusion of D-dimer measured at a particular
lag time, along with age, sex and site of index. This model had substantially improved discrimination
performance compared to the pre D-dimer model. c-statistics ranged from 0.64 to 0.81 in the IECV cycles,
with the average c-statistic of 0.69; other published clinical prediction models have similar discriminatory
ability.87 Calibration of the model again appeared excellent on average across the external validation trials,
although there remained heterogeneity. Ideally, further external validation studies would be helpful to
examine this heterogeneity further, as it was estimated with large uncertainty in the IECV approach (due to
only five external validation trials). Furthermore, the patients included in the RVTEC database were enrolled
in clinical trials and thus may not be representative of all populations of interest.
Examining heterogeneity of prognostic model performance across studies and populations is a novel idea;
most prognostic models are just considered in one external validation study, or just report the average
performance across multiple clusters (e.g. practices, studies). Ideally there would be no heterogeneity, but
this is a very high standard to attain and this issue is not even evaluated for other well-used prediction
models (such as QRISK®), and was never considered for the DASH, Vienna or HER DOO 2 models for VTE
recurrence. The IECV showed that calibration of the post D-dimer model was excellent up to 2 years, on
average across the trials. This means that across applicable populations, it is expected the final D-dimer
model would perform well on average up to 2 years. Heterogeneity in calibration performance at the
individual population level would be reduced if a population-specific baseline hazard were used, rather
than our average baseline hazard (or equivalently a population-specific S0(t) rather than our average S0(t)
currently in the model). Identifying population-specific baseline survival functions is difficult, however.
Heterogeneity might also be reduced by including additional predictors. These areas could be the subject
of further work.
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One particular area for potential heterogeneity is in the use of various D-dimer assays across the studies
in the RVTEC database. There is inherent variability in the different assays used, particularly in the
recommended cut-offs used to decide on a normal or abnormal D-dimer result. In the RVTEC database
there were five D-dimer assays used, with each study using one assay exclusively (Table 59). This is a
potential limitation of the post D-dimer model in that the model was built on data using these five assays
to measure patient D-dimer, and therefore predictions from the model in practice may only be valid in
cases where one of these assays was used. However, it may also be considered a strength to have used
data based on multiple assays, as this enhances the generalisability of the model, making applicable to a
wider population. Previous research has investigated the link between variability in D-dimer assays and
recurrent VTE and found that various assays do not differ in ability to predict recurrence.11 It is also not
possible to differentiate the study-level assay effect from other study-level covariates, such as location of
study or year of study. It is therefore difficult to discern if any assay effect is genuine, as it may be
confounded by other study-level covariates. Furthermore, if one included assay in the model, then external
validation of the model in the excluded trials would not be possible as most trials used a unique assay.
The discrimination of the post D-dimer model was shown to be reasonably consistent, with moderate to
good discrimination regardless of the D-dimer assay used in the validation study. Similarly, the calibration
performance up to 2 years appears very good in all trials, with generally tiny miscalibration on average and
small heterogeneity in calibration across studies. Therefore, by developing a model using all assays, the HR
obtained for D-dimer appears to provide reasonably robust predictions in external validation, regardless of
the assay available. Finally, a small sensitivity analysis was conducted to crudely assess the impact of
differences in the continuous scale of D-dimer assays on the predicted risk of recurrent VTE from the post
D-dimer model. Assuming that there could be a potential discrepancy of up to 10% in D-dimer values
across assays, the change in predicted risk of recurrence was assessed using example patients with true
D-dimer values at the 25th, 50th and 75th percentiles of the distribution of D-dimer values within the
RVTEC population. These were varied by 10% either greater or lower and the resulting predicted survival
probabilities were plotted over time (see Appendix 7). The results showed very little change in the
predictions, certainly not enough to alter a clinical decision on choice of therapy.
An interesting area for discussion is the observed effect of D-dimer and lag time in the final post D-dimer
model. The effect of a patient’s D-dimer score appears to indicate an increase in recurrence rate of
around 70% for every 1 ng/ml increase in D-dimer score, with a HR of 1.716 (95% CI 1.43 to 2.06).
Conversely, the lag time between cessation of therapy and measurement of patient’s D-dimer appears to
decrease recurrence rate by around 20% for every day increase in lag time. This effect appears to be
counterintuitive as it may be expected that recurrence rate would increase the longer it takes to measure
patients D-dimer and identify those with high D-dimer at greater risk of recurrence. However, the observed
effect of lag time may be acting as a proxy for time from cessation of therapy itself, in that the more time
which elapses from cessation of therapy the greater chance that patients at higher risk of recurrence will
have already had a recurrence, leaving a population of healthier patients.
Given the good discrimination and the excellent average calibration performance demonstrated through
external validation, the post D-dimer model would appear suitable for informing patient counselling and
clinical decision making at a particular lag time post cessation of therapy. Chapter 4, Using the post
D-dimer model to make predictions for new individuals: a detailed illustration of the model in practice
detailed how to apply the model in practice, to obtain individual risk predictions for new patients.
TABLE 59 Different D-dimer assays used within the RVTEC database

















ELISA, enzyme-linked immunosorbent assay; LIA, latex immunoassay.
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In terms of usefulness in clinical practice, it should be noted that the post D-dimer model has important
limitations. As anticoagulation significantly lowers D-dimer, measurement of D-dimer in the data set was
always performed after some lag time (or wash-out period), to allow the effects of therapy to subside.
Therefore the post D-dimer model is only applicable at a set lag time post cessation of therapy, meaning it
can be used only after a delay in making the decision on a patient’s therapy. Although this is current practice,
with D-dimer recommended to be measured around 30 days after cessation of therapy, there has been some
evidence towards the predictive ability of D-dimer on therapy108 and there are several ongoing studies
investigating the predictive ability of D-dimer on-therapy. Evidence from the RVTEC database suggests that
approximately 58.7% of recurrent events occurred within the 30-day lag time before D-dimer measurement
(for the pre D-dimer model data set). Thus, as mentioned above, more clinically useful models might to be
derived by extending the pre D-dimer model with other predictors measured without any lag time.
It should be discussed that many may consider an initial distal DVT as a low-risk group of patients, in whom
many would not favour prolonged OAC therapy, and that some would chose not to include such a low-risk
group within the model development (e.g. the DASH model did not consider such patients). However, this
tendency to cease therapy in patients with initial distal DVT has, in this case, been captured within the post
D-dimer model through the inclusion of such patients. This means that predictions from the model indicate
that in the majority of cases these patients have low predicted risk of recurrence. Subsequently, in practice
post D-dimer model predictions would lead to the same decision not to prolong OAC therapy.
A potential limitation of the study is the exclusion of BMI as a candidate predictor due to complete
missingness in four of the included studies. Although it was the intention of the study to consider BMI as a
potential predictor, it would be inappropriate to impute across studies (due to complete missingness within
studies). Selection of the BMI predictor within the model was also not assumed certain, because while
there is evidence to suggest that BMI is an important predictor for a first VTE event, there is conflicting
evidence for the effect of BMI on VTE recurrence. The systematic review undertaken here (see Chapter 3),
identified three models which assessed the impact of predictors in combination on VTE recurrence and
could therefore be considered the strongest evidence to date of which predictors affect recurrence risk. Of
these three, the Vienna model found BMI to be a weak predictor (1.19 HR per 5 kg/m2 change in BMI) and
to be non-significant when adjusted for optimism.2 The DASH model found BMI to be non-significant at
univariate analysis, as did the HER DOO 2 model.9,41 The HER DOO 2 then went on to split their analysis by
sex and only then found BMI to be important in women alone (p-value= 0.02).9 Eichinger et al.109 and
Heit et al.110 also provide conflicting evidence suggesting that BMI is a weak risk factor in the order of
around 1.2 HR, with borderline 95% CIs. This evidence suggests that BMI may not be a strong consistent
predictor of VTE recurrence risk when adjusted for other important predictors including site of index event.
Further limitations concern the use of new/novel oral anticoagulants (NOACs). The studies included in the
RVTEC database used primarily warfarin to treat patients first VTE, none of the studies used any of the
NOACs. In this regard the model is built on and therefore applicable to patients treated with warfarin. This
was a limitation of the available study data, as no studies used NOACs, the effect of these drugs could not
be accounted for in the modelling process. However, the economic evaluation did investigate the effect of
using NOACs in the economic modelling as a sensitivity analysis which is further discussed below (see also
Chapter 5, Sensitivity analysis). In the economic evaluation the effectiveness of the NOACs was assumed to
be equal to that of warfarin, whereas the detriments of treatment with NOACs were assumed to be lesser
than those associated with warfarin (such as monitoring). If the NOACs can be considered equivalent in
efficacy to warfarin then inferences from the model are valid and there would be no requirement for a
separate model for patients undergoing NOAC therapy. However, though no new model would be required,
the post D-dimer model would need to be further validated in patient populations where NOACs were used.
It must also be noted that while external validation was possible using the IECV approach, it would also be
beneficial to undertake external validation in non-trial data sets, and therefore the post D-dimer model
could also be considered at moderate risk of bias (see quality assessment defined within Chapter 3), until
such external validation is undertaken.
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There are also potentially broader uses of the post D-dimer model, as prognostic models are useful at
many stages of the translational pathway towards improved patient outcomes.18 For example, it might be
used to improve the design and analysis of randomised therapeutic trials in patients with a first
unprovoked VTE, as a stratification factor in the randomisation process (to ensure treatment groups are
balanced in the predicted risk of recurrence) or as an adjustment factor to increase statistical power.
Inclusion criteria for trials may also be restricted to individuals with a high risk of recurrence based on the
model. It could also be used to adjust for case-mix variation (confounding) in health services research and
observational studies.
Recurrent venous thromboembolism collaborative database
One of the key findings of the systematic review was that the existing prognostic models had not received
external validation. Therefore, when presented with the available data sets for use in this new research,
it was deemed a high priority to ensure that the new research allowed external validation. Given that
different sets of predictors (variables) were recorded in the three different data sets, it was decided to
focus primarily on the RVTEC database by Douketis et al.11 as it contained seven trials. This allowed
enhanced research in this area by implementing the novel IECV approach to develop a new model and,
crucially, also externally validate this model. Furthermore, the database contained D-dimer, which was
deemed likely to be a crucial prognostic factor based on earlier research conducted by others. A slight
tension with the choice of this database was that parts of it had already been used to develop the DASH
score and Vienna model. However, the new research conducted within this report can be seen to enhance
current research which uses the RVTEC database, and research in this field in general, by:
i. using the novel IECV approach to externally validate the model multiple times, unlike existing scores
ii. the identification of additional predictors not previously picked up (e.g. age, lag time)
iii. directly modelling the baseline hazard; this allows predictions over all follow-up times up to 5 years or
more (rather than at just a few time points as in previous models)
iv. not requiring simplification of the model to make predictions; this report provides an equation to
predict recurrence using the values at hand (i.e. no need for a simplified score) and the baseline survival
v. identify the distribution of population characteristics for use in the subsequent health economics model
vi. evaluating the cost-effectiveness of our prognostic model which has not been done for previous scores.
Furthermore, the DASH score developed by Tosetto et al.41 using the RVTEC database is fundamentally
different from the proposed post D-dimer model developed within this research report. The DASH score is
only applicable in a distinctly different population of patients, one which uses a different definition of an
unprovoked first VTE. Indeed the DASH score includes predictors for hormone intake, where any patients
provoked by hormone intake were excluded from the post D-dimer model development as per the
pre-defined definition of unprovoked VTE (see Chapter 1). As such, the DASH score could not be
compared with the post D-dimer model, as they include different predictors and are applicable in different
populations, despite both being developed within the RVTEC database.
Cost-effectiveness of a decision rule based on the post
D-dimer model
Prognostic models aim to assist clinicians with their prediction of a patient’s future outcome and to
enhance informed decision-making with the patient. Indeed, a prognostic model can only influence
patient outcome (or the cost-effectiveness of care) when changes in clinical management are based on
the prognostic information provided by the model.18 Prognostic models also have a cost in their
implementation (e.g. measurement of D-dimer levels) and might even have adverse consequences on
clinical outcomes if they lead to decisions that withhold beneficial treatments. Therefore it is important to
formally evaluate the impact of a prognostic model when used to make clinical decisions: as for any health
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technology, it should only be used if it can be shown to improve patient outcomes and/or reduce costs
whilst ensuring acceptable patient outcomes. This can perhaps best be achieved in a randomised trial,
where individuals are randomised to two groups, those that utilise the prognostic model and those that do
not, and their subsequent outcomes (and costs) compared. However, such trials are rare, as they are
expensive and time-consuming. Therefore, health economic models are important to ascertain – under a
variety of assumptions – the cost-effectiveness of using a prognostic model to make decisions in the
context of current care and expenditure, for relevant populations and outcomes of interest. For this
purpose, Chapter 5 performed a cost-effectiveness analysis of using the post D-dimer model as a decision
rule regarding continued cessation of therapy or not.
It was assumed that the post D-dimer model would inform clinical decision-making by using it to establish
if an individual was above a pre-defined threshold of recurrence risk. If they were above the threshold,
then they would be returned to therapy, if they were below the threshold, they would remain off therapy.
This strategy therefore defined a decision rule for cessation of therapy. A range of recurrence risk
thresholds were considered (1%, 3%, 5%, 10% and 15%). The 5% threshold was selected to reflect the
recommendations of Kearon et al.111 based on consensus that an annual risk of recurrence up to 5% may
be deemed acceptable.
The aim of the economic modelling was to determine the cost-effectiveness of using a clinical decision rule
for resumption of therapy in this patient group, using warfarin as the base-case therapy. The modelling
allows the risk of recurrence of VTE and risk of bleeding on therapy, plus the associated costs, impact on
quality of life and mortality to be taken into account simultaneously. The results demonstrated that the
use of a decision rule with a threshold risk of VTE recurrence of about 8% could be a cost-effective
strategy over the lifetime of a patient, with any threshold risk higher than this also a cost-effective strategy.
However, the economic model appeared to be very sensitive to changes in a number of variables including
disutility on warfarin and death from PE. The subgroup analyses gave very different results for patients
aged ≥ 60 years, where the thresholds for treatment appeared to be higher and the difference in results
was even more marked when considering index DVT and index PE patients separately. The PSA results
were in line with the deterministic sensitivity analyses, suggesting there is still a great deal of uncertainty
around which thresholds are cost-effective.
This is the first economic model to estimate the cost-effectiveness of using a clinical decision rule for
extending treatment with anticoagulation in this patient group. This represents a step forward in providing
a tool for decision making, to weighing up the risk of recurrent VTE and bleeding, in order to determine
the optimal treatment strategy. However, this modelling assumes the prognostic model can reliably predict
risk of recurrence, as risks and the decision rule are based on these risk calculations. Further assumptions
were required, regarding the use of constant risks of recurrent VTE after 3 years, after a further VTE and
with treatment, and the use and discontinuation of therapy when a major bleed occurs. Therefore, caution
should be applied when interpreting the results of the economic analysis; however, this should be
regarded as evidence that economic modelling has potential in this clinical area. This work has highlighted
that good longitudinal data are required from patient cohorts with first unprovoked VTE and recurrent
VTE, to estimate individual VTE risk beyond 3 years and also to provide data to predict major bleeds. The
latter could be utilised to develop a prognostic model for major bleeds, which in turn could be used by the
decision model to get better estimates of bleeding.
Implications of research for clinical practice
The systematic reviews and model development within this study provide us with a new prognostic tool to
aid clinical decision-making for patients who sustain a first unprovoked VTE. The clinical paradigm has
shifted while this project has been undertaken with a view now to identify those patients at sufficiently
low risk of recurrence that they can safely stop OAC therapy after a relatively short period of time (usually
3–6 months). The post D-dimer model developed within this project performs better in terms of identifying
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this group than previously reported models. Currently available models are not routinely used within UK
practice and have not been included within NICE guidelines. The utility of the post D-dimer model may be
improved by including D-dimer measured before potential cessation of therapy, but it can certainly be
introduced into clinical practice immediately. This will enable, with a high degree of certainty, identification
of patients in whom it is safe to stop therapy while continuing therapy for those with a relatively high risk
of recurrence.
Further research recommendations
A number of further research recommendations arise from this work, which are now outlined.
l Develop and externally validate a prognostic model that can be used at the point of considering
cessation of therapy. This should build on the pre D-dimer model and thus include sex and site of index
event. Evaluation of the prognostic ability of D-dimer levels measured at the exact time of cessation of
therapy is needed (i.e. measured at a lag time of 0).
l Further external validation of the post D-dimer model, especially in non-trial populations. Trial
populations available within the RVTEC database may be a select groups of individuals and thus the
post D-dimer model requires validation in other populations (e.g. from cohort studies or large
databases). Such data sets may not currently be available that contain D-dimer values and so further
observational studies are needed that enrol new patients, measure their predictors following cessation
of therapy (including D-dimer measurements and lag time) and recording of VTE outcomes.
l Further research to examine if between-study heterogeneity in the calibration performance of post
D-dimer model can be reduced. Though the post D-dimer model performed excellently on average
across all trial populations, there was between-trial heterogeneity in the calibration. Further research
should seek to reduce this heterogeneity, by potentially updating the model with additional predictors
(requiring further external validation of course) and/or by identifying revised S0(t) functions for
populations that differ importantly from the average S0(t) currently used in the model (this is sometimes
referred to as model recalibration).
l Further research to develop and validate a prognostic model for bleeding on therapy. There is an
immediate need to develop a prognostic model to predict individuals’ risk of bleeding while on therapy.
This would allow the balance between risk of recurrence and risk bleeding to be accounted for in the
decision of treatment strategy and also a more effective economic evaluation to be undertaken.
l Further research to investigate the prognostic importance of D-dimer over time. Sensitivity analyses
considered the inclusion of time-dependent effects within the post D-dimer model, and although
the inclusion of such effects was not warranted within this study, evidence suggests a potential
time-dependent effect of log-D-dimer. Future research could aim to investigate the potential prognostic
value of D-dimer over time to predict VTE recurrence risk.
l Further research to reduce the uncertainty of conclusions drawn from any economic evaluation.
Research should aim to incorporate more robust estimates of key economic parameters which have
large uncertainty such as bleeding risk and long-term risk of VTE.
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We have developed a prognostic model which can be used in clinical practice to aid decision-makingwith regard to the duration of OAC therapy for patients sustaining a first unprovoked VTE.
This has been robustly evaluated within a trials database using novel methodology. We have demonstrated
improved performance of the prognostic model in comparison with previously reported models.
A speculative health economic model has suggested that the prognostic model would be cost-effective
for patients with predicted risk of recurrence of over 5–10% over the next 3 years. Although the health
economic model relies on many assumptions due to lack of routinely collected data, it will provide a
platform for evaluating further prognostic models once these data are available. This will be useful also for
evaluating cost-effectiveness of treatment strategies based on the new generation of OACs. Further work
is required in this area in terms of evaluating this prognostic model in routine clinical practice and
improving our ability to predict severe bleeding events for patients taking long-term OACs.
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Appendix 1 Search strategies
Prognostic model searches
MEDLINE
Ovid MEDLINE(R) 1946 to June week 3 2014.
Search strategy
1. exp Venous Thromboembolism/
2. Pulmonary Embolism/
3. exp Venous Thrombosis/
4. (vte or dvt or pe).ti,ab.




9. (recurr$ or re-occur$).ti,ab.
10. Recurrence/
11. exp Death/





17. post thrombotic syndrome.ti,ab.
18. PTS.ti,ab.
19. or/9-18







27. (anti-coagul$ or anticoagul$ or warfarin or acenocoumarol or coumadin or coumarin or
phenprocoumon or sintrom or sinthrome or jantoven or marevan or waran or nicoumalone or
dicoumarol or dicumarol).ti,ab.
28. (phenindione or dabigatran or ximelagatran or apixaban or rivaroxaban or edoxaban or azd0837 or
ly517717 or ym150 or betrixaban or idraparinux).ti,ab.
29. or/26-28
30. 8 and 19 and 25 and 29
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MEDLINE In-Process & Other Non-Indexed Citations
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 30 June 2014.
Searched: inception to 2014.
Search strategy
1. (vte or dvt or pe).ti,ab.




6. (recurr$ or re-occur$).ti,ab.
7. (death$ or mortality).ti,ab.
8. clot$.ti,ab.
9. pulmonary hypertension.ti,ab.







17. (anti-coagul$ or anticoagul$ or warfarin or acenocoumarol or coumadin or coumarin or
phenprocoumon or sintrom or sinthrome or jantoven or marevan or waran or nicoumalone or
dicoumarol or dicumarol).ti,ab.
18. (phenindione or dabigatran or ximelagatran or apixaban or rivaroxaban or edoxaban or azd0837 or
ly517717 or ym150 or betrixaban or idraparinux).ti,ab.
19. or/17-18
20. 5 and 12 and 16 and 19
EMBASE
EMBASE 1980 to 2014 week 26.
Search strategy
1. exp venous thromboembolism/
2. lung embolism/
3. exp vein thrombosis/
4. deep vein thrombosis.ti,ab.




9. (recurrence or recurr or re-occur$).ti,ab.
10. recurrent disease/
11. death/





17. post thrombotic syndrome.ti,ab.
APPENDIX 1










26. exp anticoagulant agent/
27. (anti-coagul$ or anticoagul$ or warfarin or acenocoumarol or coumadin or coumarin or
phenprocoumon or sintrom or sinthrome or jantoven or marevan or waran or nicoumalone or
dicoumarol or dicumarol).ti,ab.
28. phenindione or dabigatran or ximelagatran or apixaban or rivaroxaban or edoxaban or azd0837 or
ly517717 or ym150 or betrixaban or idraparinux).ti,ab.
29. or/26-28
30. 8 and 19 and 25 and 29
The Cochrane Library
The Cochrane Library (Wiley) 2014.
Searched: inception to 2014.
Search strategy
#1 MeSH descriptor: [Venous Thromboembolism] explode all trees
#2 MeSH descriptor: [Pulmonary Embolism] this term only
#3 MeSH descriptor: [Venous Thrombosis] explode all trees
#4 vte or dvt or pe
#5 deep next vein next thrombosis
#6 pulmonary next embolism*
#7 venous next thrombo*
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
#9 recurrence or recurr* or re-occur*
#10 MeSH descriptor: [Recurrence] this term only
#11 MeSH descriptor: [Death] explode all trees
#12 death* or mortality
#13 MeSH descriptor: [Mortality] this term only
#14 clot*
#15 MeSH descriptor: [Hypertension, Pulmonary] this term only
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#16 pulmonary next hypertension
#17 post next thrombotic next syndrome
#18 PTS
#19 #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
#20 MeSH descriptor: [Predictive Value of Tests] this term only
#21 predict*
#22 MeSH descriptor: [Risk] explode all trees
#23 risk*
#24 prognos*
#25 #20 or #21 or #22 or #23 or #24
#26 MeSH descriptor: [Anticoagulants] explode all trees
#27 anti-coagul* or anticoagul* or warfarin or acenocoumarol or coumadin or coumarin or
phenprocoumon or sintrom or sinthrome or jantoven or marevan or waran or nicoumalone or dicoumarol
or dicumarol
#28 phenindione or dabigatran or ximelagatran or apixaban or rivaroxaban or edoxaban or azd0837 or
ly517717 or ym150 or betrixaban or idraparinux
#29 #26 or #27 or #28
#30 #8 and #19 and #25 and #29
Cost-effectiveness searches
MEDLINE
Ovid MEDLINE (Ovid) 1946 to November week 3 2013.
Search strategy
1. exp Venous Thromboembolism/
2. Pulmonary Embolism/
3. exp Venous Thrombosis/
4. (vte or dvt or pe).ti,ab.




9. (recurr$ or re-occur$).ti,ab.
10. Recurrence/
11. exp Death/
12. (death$ or mortality).ti,ab.
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17. post thrombotic syndrome.ti,ab.
18. PTS.ti,ab.
19. or/9-18







27. (anti-coagul$ or anticoagul$ or warfarin or acenocoumarol or coumadin or coumarin or
phenprocoumon or sintrom or sinthrome or jantoven or marevan or waran or nicoumalone or
dicoumarol or dicumarol).ti,ab.
28. (phenindione or dabigatran or ximelagatran or apixaban or rivaroxaban or edoxaban or azd0837 or
ly517717 or ym150 or betrixaban or idraparinux).ti,ab.
29. or/26-28
30. 8 and 19 and 25 and 29
31. economics/
32. exp “costs and cost analysis”/
33. cost of illness/
34. exp health care costs/
35. economic value of life/
36. exp economics medical/
37. exp economics hospital/
38. economics pharmaceutical/
39. exp “fees and charges”/
40. econom$ or cost or costs or costly or costing or price or pricing or pharmacoeconomic$).tw.
41. expenditure$ not energy).tw.
42. value adj1 money).tw.
43. budget$.tw.
44. or/31-43
45. 30 and 44
EMBASE
EMBASE (Ovid) 1980 to 2013 week 49.
Search strategy
1. exp venous thromboembolism/
2. lung embolism/
3. exp vein thrombosis/
4. deep vein thrombosis.ti,ab.




9. (recurr$ or re-occur$.ti,ab.
10. recurrent disease/
11. death/
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26. exp anticoagulant agent/
27. (anti-coagul$ or anticoagul$ or warfarin or acenocoumarol or coumadin or coumarin or
phenprocoumon or sintrom or sinthrome or jantoven or marevan or waran or nicoumalone or
dicoumarol or dicumarol).ti,ab.
28. (phenindione or dabigatran or ximelagatran or apixaban or rivaroxaban or edoxaban or azd0837 or
ly517717 or ym150 or betrixaban or idraparinux).ti,ab.
29. or/26-28
30. 8 and 19 and 25 and 29
31. cost benefit analysis/
32. cost effectiveness analysis/
33. cost minimization analysis/
34. cost utility analysis/
35. economic evaluation/
36. (cost or costs or costed or costly or costing).tw.
37. (economic$ or pharmacoeconomic$ or price$ or pricing).tw.
38. (technology adj assessment$).tw.
39. or/31-38
40. 30 and 39
The Cochrane Library
The Cochrane Library (Wiley) NHS Economic Evaluation Database 2012 Issue 4 of 4.
Search strategy
#1 MeSH descriptor: [Venous Thromboembolism] explode all trees
#2 MeSH descriptor: [Pulmonary Embolism] this term only
#3 MeSH descriptor: [Venous Thrombosis] explode all trees
#4 vte or dvt or pe
#5 deep next vein next thrombosis
#6 pulmonary next embolism*
#7 venous next thrombo*
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
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#9 recurrence or recurr* or re-occur*
#10 MeSH descriptor: [Recurrence] this term only
#11 MeSH descriptor: [Death] explode all trees
#12 death* or mortality
#13 MeSH descriptor: [Mortality] this term only
#14 clot*
#15 MeSH descriptor: [Hypertension, Pulmonary] this term only
#16 pulmonary next hypertension
#17 post next thrombotic next syndrome
#18 PTS
#19 #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
#20 MeSH descriptor: [Predictive Value of Tests] this term only
#21 predict*
#22 MeSH descriptor: [Risk] explode all trees
#23 risk*
#24 prognos*
#25 #20 or #21 or #22 or #23 or #24
#26 MeSH descriptor: [Anticoagulants] explode all trees
#27 anti-coagul* or anticoagul* or warfarin or acenocoumarol or coumadin or coumarin or
phenprocoumon or sintrom or sinthrome or jantoven or marevan or waran or nicoumalone or dicoumarol
or dicumarol
#28 phenindione or dabigatran or ximelagatran or apixaban or rivaroxaban or edoxaban or azd0837 or
ly517717 or ym150 or betrixaban or idraparinux
#29 #26 or #27 or #28
#30 #8 and #19 and #25 and #29
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Appendix 2 Inclusion/exclusion forms
Titles and abstracts inclusion/exclusions form
Title and/or abstract
Include Exclude
Prognostic models Prognostic models
Study design RCTs Non-human studies
Cohort Commentaries
Case–control Case reports (single case reports)
Case series Study design papers
Letters Non-systematic reviews
Systematic reviews (at least one database used) Cross-sectional




‘model’ (e.g. prediction model) No mention of a ‘model’/’rule’/’score’/
’prediction’/’index’/’algorithm’, etc.
‘rule’






‘factors contribution to risk’
‘adjusted odds ratio/hazard ratio/relative risk’, etc.
Population Majority of patients aged ≥ 18 years Patients aged < 18 years
Patients with a first unprovoked VTE
(unprovoked= no history of major surgery; lower
limb trauma, e.g. fracture, cast, limping for
3 days; use of the combined OC pill or HRT;
pregnancy; significant immobility, e.g. confined
to bed for 3 days; cancer)
Patients with a first provoked VTE
(provoked= history of major surgery; lower limb
trauma, e.g. fracture, cast, limping for 3 days;
use of the combined OC pill or HRT; pregnancy;
significant immobility, e.g. confined to bed for
3 days; cancer)
Patients must have received at least 3 months
oral anticoagulation treatment
Patients not treated with OACs, or treated for
less than 3 months
Mixed populations; only where data extractable
for patients meeting above criteria
Healthy individuals, or with conditions other than
those described under inclusion criteria (e.g.
portal, mesenteric, cerebral vein thrombosis, etc.)
Prognostic model Prognostic models utilising multiple prognostic
variables
Does not report prognostic models
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Prognostic models Prognostic models
Outcome Recurrence of VTE Outcomes other than those mentioned in the
inclusion criteria
Adverse outcomes including mortality and
bleeding
Quality of life/cost-effectiveness
Link Appears to (or could possibly) utilise model to
predict risk of VTE recurrence or adverse outcome
Clearly does not link prognostic models to VTE
recurrence or adverse outcomes
Full-text inclusion/exclusion form
Criteria Yes C/T No Prognostic model
Reviews and discussions Does the study do more than just discuss a model
Population Are patients at least 18 years old
Could the population or a defined subpopulation
be considered as unprovoked (if not why not)
Can we identify results specifically for the
unprovoked population
Did patients receive at least 3 months treatment
with either a vitamin K antagonist or an OAC
Outcome Does the model predict least one of: recurrence/
mortality/bleeding/quality of life
Models Does the model aim to do more than assess a
single factor adjusted for other things
Is the model used to predict individuals risk of one
of the above outcomes
Decision
Exclude with reason
Does the study include an economic
evaluation of a model?
Comments
If included Yes C/T No Factors








Thrombophillia (e.g. antiphosphlipid syndrome,
factor V leiden, etc.)
C/T, can’t tell.
Notes
Unprovoked= no history (within 3 months) of major surgery; lower limb trauma, e.g. fracture, cast; use of the combined
OC pill or HRT; pregnancy; significant immobility, e.g. confined to bed for 3 days; cancer.
A ‘yes’ in all categories under criteria indicates to include a study, any ‘no’ responses indicate exclusion.
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systematic review
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A
Stiegler H. [Venous thrombosis–diagnosis and treatment.] MMW Fortschr Med 1969;153:65–7 A
Prandoni P, Mannucci PM. Deep-vein thrombosis of the lower limbs: diagnosis and management.
Baillieres Clinical Haematology 1994;7:693–712
A
Chesterman CN. After a first episode of venous thromboembolism. BMJ 1995;311:700–1 A
Hirsh J. The optimal duration of anticoagulant therapy for venous thrombosis. N Engl J Med
1995;332:1710–11
A
Hirsh J, Kearon C, Ginsberg J. Duration of anticoagulant therapy after first episode of venous
thrombosis in patients with inherited thrombophilia. Arch Intern Med 1997;157:2174–7
A
Solymoss S. Optimising the duration of anticoagulation therapy for venous thrombosis. CMAJ
1999;160:1317–18
A
van der Heijden JF, Kraaijenhagen RA, Buller HR. The risk of recurrent venous thrombosis. N Engl J
Med 2000;342:214–15
A
Schulman S. Duration of anticoagulants in acute or recurrent venous thromboembolism. Curr Opin
Pulm Med 2000;6:321–5
A
Schulman S. Optimal duration of anticoagulation therapy after venous thromboembolism. Arch
Hellenic Med 2000;17:A71–4
A
Diet F. [Optimum duration of anticoagulation for deep-vein thrombosis – How long?] Herz Kreislauf
2000;32:16–18
A
Dickey TL. Can thrombophilia testing help to prevent recurrent VTE? Part 2. JAAPA 2002;15:23–4 A
Bounameaux H. [Venous thromboembolism recurrence: is there a place for D-dimer?] Rev Med Interne
2002;23:810–12
A
Levesque H. [Risk of haemorrhage with oral anticoagulants for deep-vein thrombosis.] J Mal Vasc
2002;27:129–36
A
D’Angelo A, Piovella F. Optimal duration of oral anticoagulant therapy after a first episode of venous
thromboembolism: where to go? Haematologica 2002;87:1009–13
A
Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous
thromboembolism recurrence: high negative predictive value of D-dimer performed after oral
anticoagulation is stopped. Thromb Haemost 2002;87:7–12
A
Douketis JD, Crowther MA. Identifying patients at increased risk for recurrent venous
thromboembolism: clinical, biochemical, and radiologic risk factors. Cardiovasc Rev Rep
2002;23:280–5
A
Chodri TA, Groth ML. Optimal duration of anticoagulation therapy for idiopathic deep-vein
thrombosis. Clin Pulm Med 2002;9:131–2
A
Brotman DJ. Identifying patients at risk of recurrent venous thromboembolism. JAMA 2003;290:3192 A
van Dongen CJ, Vink R, Hutten BA, Buller HR, Prins MH. Recurrent thromboembolism after treatment
with vitamin K antagonists. Arch Intern Med 2003;163:2793–822
A
Kyrle PA, Eichinger S. The risk of recurrent venous thromboembolism: the Austrian study on recurrent
venous thromboembolism. Wien Klin Wochenschr 2003;115:471–4
A
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Hyers TM. Duration of anticoagulation in venous thromboembolism. Arch Intern Med
2003;163:1265–6
A
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A
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N Engl J Med 2004;350:618–19
A
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FIGURE 48 Patient age (years). (a) Histogram; and (b) normal plot.
DOI: 10.3310/hta20120 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 12
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Ensor et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR











5.0 × 10– 5
1.0 × 10– 4
1.5 × 10– 4


























FIGURE 50 Box plot for patient BMI.
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FIGURE 52 Patient BMI (BMI > 45 kg/m2 removed). (a) Histogram; and (b) normal plot.
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FIGURE 54 Patient D-dimer score (ng/ml). (a) Histogram; and (b) normal plot.
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FIGURE 56 Box plot for patient lag time (days).
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FIGURE 58 Patient log-lag time (days). (a) Histogram; (b) box plot; and (c) normal plot.
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FIGURE 61 Box plot for patient log-treatment duration (months).
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FIGURE 62 Patient log-treatment duration (months) (treatment durations > 1000 months removed).
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FIGURE 63 Scatterplots of continuous candidate factors.
APPENDIX 4




































































FIGURE 64 Box plots for patient age (years) by sex. (a) Female; and (b) male.
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FIGURE 67 Box plots of patients BMI by site of index event. (a) Proximal DVT; (b) PE; and (c) distal DVT.
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FIGURE 69 Box plots of patients log-D-dimer score (ng/ml) by site of index event. (a) Proximal DVT; (b) PE; and
(c) distal DVT.
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FIGURE 71 Box plots of patient log-lag time (days) by site of index event. (a) Proximal DVT; (b) PE; and
(c) distal DVT.
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FIGURE 73 Box plots of patient log-treatment duration (months) by site of index event. (a) Proximal DVT;
(b) PE; and (c) distal DVT.
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FIGURE 75 Box plots of patient age × log-D-dimer interaction by site of index event. (a) Proximal DVT; (b) PE;
and (c) distal DVT.
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Appendix 5 Model checking results
The pre D-dimer model
Proportional hazards assumption
For the pre D-dimer model a Royston and Parmar model72,73 was fitted on the proportional hazards scale,
which assumes that the effect of factors in the model are not associated with time, so that any two rates
predicted from the model are proportional. To test whether or not the proportional hazards assumption is
valid for the pre D-dimer model, a plot of the scaled Schoenfeld residuals against the natural logarithm of
time from cessation of therapy was examined for each factor in the model (Figures 76 and 77). Horizontal
reference lines in Figure 76 indicate zero and the log-HR for the factor, a smoother is applied and should
follow the log-HR reference line over log-time when the proportional hazards assumption is valid. It is clear
from Figures 76 and 77 for site of index event that the proportional hazards assumption is met, and similar














































FIGURE 77 Scaled Schoenfeld residuals vs. log-time from cessation of therapy for PE (the pre D-dimer model)
(HR –0.053).
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The functional form of continuous covariates within the model can be checked using Martingale residuals.
A scatterplot of the Martingale residuals against the continuous covariate of interest with a smoother
applied can reveal whether linearity is appropriate, or if non-linear forms should be considered.
As patient age was the only continuous covariate within the pre D-dimer model the functional form within
the model was checked using Martingale residuals. Figure 80 shows the lowess smoother applied to a
scatter of Martingale residuals against age appears to follow a linear trend over age, indicating that
inclusion of age as linear within the model was appropriate.
Outliers
Deviance residuals can be used to investigate potential outliers in whom the model will perform poorly.
A scatterplot of the deviance residuals against a simple patient indicator enables us to assess the normality
of the deviance residuals and identify outliers which fall outside of the critical z-values associated with a
95% CI. Figure 81 illustrates a scatter of the deviance residuals for the pre D-dimer model, the deviance
residuals do not appear to follow a normal distribution and this may be due to heavy censoring in the data







































FIGURE 79 Scaled Schoenfeld residuals vs. log-time from cessation of therapy for sex (the pre D-dimer model)
(sex: male HR –0.6).
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A plot of the deviance residuals against years from cessation of therapy allows investigation of any trend in
the deviance residuals. In Figure 82, for the pre D-dimer model there is a clear trend in the deviance
residuals over time, this is to be expected because deviance residuals are based on the cumulative hazard
at the event time (or censoring time). The deviance residuals which lie in the top left of the plot are likely
to be those individuals who had a recurrence early and therefore did not accumulate much hazard.
Leverage
To check the influence of individuals on the parameter estimates, leverage can be assessed using
delta–beta changes for each covariate. A scatterplot of the delta–beta change for the covariate of interest
against time allows inspection of the largest change with respect to the log-HR of the covariate.
Scatterplots of delta–betas for age (Figure 83) and sex (Figure 84) show that even individuals with the
greatest leverage on these parameter estimates, have very small effects on the log-HR. Similarly, small







































FIGURE 81 Scatterplot of deviance residuals vs. patient ID (the pre D-dimer model). ID, identification.
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FIGURE 84 Scatterplot of delta–beta for sex vs. years from cessation of therapy (log-HR 0.573)
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Interaction effects
Interaction effects quantify a differential effect in a specific subgroup of the population. An interaction
effect can be either an increased risk or decreased risk beyond that associated with a single characteristic.
For example, within the pre D-dimer model, both sex (being male) and site of index event (having a first
PE) are associated with significant increases in recurrence rate, an interaction between sex and site of index
event would imply that patients who are both male and have a PE are at increased risk beyond that
associated with being male or having a PE alone.
The pre D-dimer model includes factors for patient age, sex and site of index event (distal DVT, proximal
DVT or PE). Given this set of factors no interactions were considered plausible, either biologically or as
evidenced within previous research. As there were no plausible effect-modifying interactions, testing for
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FIGURE 86 Scatterplot of delta–beta for site (PE) vs. years from cessation of therapy (log-HR 1.659).
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Often time-fixed covariates may have time-dependent effects, where the effect (e.g. HR) varies with time.75
Allowing for time-dependent effects could improve the performance of the prognostic model by better
fitting the underlying data.
Non-proportional hazards can be a sign of a time-dependent effect and, as such, including time-dependent
effects can account for departures from the proportional hazards assumption. The validity of the proportional
hazards assumption for the pre D-dimer model was assessed in Appendix 5, and the assumption was met for
all factors included in the models. It was therefore not expected that any time-dependent effects would be
found to significantly improve the performance of either final model.
A procedure proposed by Royston and Lambert75 was used to identify potential time-dependent effects
within the final model. The procedure first identifies the p-value associated with including each covariate in
the model as a time-dependent effect using a likelihood ratio test. A time-dependent effect is included for
the factor with the smallest p-value, providing the p-value is less than a pre-defined alpha significance
level. The process is repeated until no time-dependent effects are significant at the chosen alpha level.
Following the procedure described above, an alpha of 0.01 was selected so as to allow for multiple testing
of time-dependent effects. The same level of df was used to assess time-dependent effects as was selected
for the model, therefore allowing complex forms of time dependency.75 The procedure completed one
cycle through the potential covariates and found none of the covariates to be significantly time dependent
at the 1% level as expected (Table 62).
TABLE 62 First cycle of stepwise forward selection of time-dependent effects (the pre D-dimer model)
Predictors Deviance difference p-value vs. null
Age 2.208 0.530
Sex (male) 9.323 0.025
Site of index event (proximal DVT) 1.321 0.724
Site of index event (PE) 3.421 0.331
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The post D-dimer model additional plots
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cost-effectiveness review
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Appendix 7 Sensitivity analysis on D-dimer assays
A sensitivity analysis was performed to assess the impact of variability in D-dimer measurements, whichcould be due to different D-dimer assays. The effect of a 10% change in D-dimer values on the predicted
probabilities from the post D-dimer model was calculated and plotted (Table 64 and Figures 87–89). To give
a broad picture the median and upper and lower quartile values of D-dimer were selected from the RVTEC
database. All other predictor values were forced to be constant in the model for the predictions. The figures
show very little difference in predicted recurrence-free survival, indicating that in practice a similar treatment
decision would be made regardless of such a discrepancy in D-dimer measurements.
TABLE 64 Values of log-D-dimer used in post D-dimer model to assess 10% change in D-dimer value
Values of log-D-dimer used in the post D-dimer model
Percentile of the data set
25th 50th 75th
D-dimer 10% lower 247.5 375.75 672.3
Log-D-dimer 10% lower 5.51 5.93 6.51
D-dimer 275 417.5 747
Log-D-dimer 5.55 6.03 6.62
D-dimer 10% higher 302.5 459.25 821.7
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D-dimer level at 25th percentile of data
D-dimer 10% higher
FIGURE 87 Predicted recurrence-free survival for the 25th percentile of D-dimer values and 10% change in
D-dimer values.
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D-dimer 10% higher
FIGURE 88 Predicted recurrence-free survival for the 50th percentile of D-dimer values and 10% change in
D-dimer values.
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FIGURE 89 Predicted recurrence-free survival for the 75th percentile of D-dimer values and 10% change in
D-dimer values.
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